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V17β-Hydroxysteroid dehydrogenase type 14 (17β-HSD14) is the latest identified subtype of
17β-HSDs. In vivo this enzyme oxidizes the hydroxyl group at position 17 of estradiol (E2)
and 5-androstenediol (5-diol) in the presence of NAD+ as cofactor. Two isoforms of this
cytosolic protein exist that differ only in sequence position 205: S205 and T205. So far, the
protein has not been thoroughly investigated in detail and its physiological role remains
unknown. Prior to this thesis, the 17β-HSD14 apoenzyme (S205) had already been
crystallized. The determined structure revealed a very broad and open active site and the
conserved catalytic triad and the Rossmann-fold motif. However, all C-terminal tails and for
some chains also amino acids in the flexible loop (189-212) were not defined in the electron
density. Moreover, it is impossible to derive information regarding a potential substrate from
this apo structure. Therefore, the renewed structural determination of the 17β-HSD14 apo
protein as well as in complex with its cofactor and substrate was of utmost importance.
After successful establishment of the expression and purification protocols for 17β-HSD14
protein, the two enzyme isoforms (S205 and T205) were characterized biochemically. The
structures of the S205 apoenzyme and the binary complexes with NAD+ of both isoforms
were determined. In these complex structures the flexible loop adopts a unique closed
conformation differing from the apo structure. Binding of the cofactor is accompanied by a
shift of the flexible loop and of the C-terminal Tyr253’ of the adjacent monomer, thereby
reducing the size of the active site. The ternary complex of the enzyme with estrone (E1) and
NAD+ was also determined. E1 binds to the active site in an atypical fashion, in so far as its
A-ring and not the enzymatically modified position 17 close to the nicotinamide moiety of
NAD+.
Enzyme inhibitors are useful tools to study the consequences of enzyme inhibition in vivo.
This allows to clarify whether this enzyme may be interesting as a new drug target for a
certain disease. In addition, potent and selective 17β-HSD14 inhibitors may help understand
the selectivity issue with other 17β-HSDs. As no 17β-HSD14 inhibitor was known prior to
this study, the goal was to identify and optimize nonsteroidal 17β-HSD14 inhibitors. To that,
a library of 17β-HSD1 and 17β-HSD2 inhibitors was screened against 17β-HSD14. The most
promising hit was taken as the starting point for further chemical modification applying a
ligand-based approach. Newly designed compounds were synthesized and subsequently
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tested for their 17β-HSD14 inhibitory activity. Prior to this thesis, no human 17β-HSD
structure in complex with a nonsteroidal ligand was published. The crystal structures
confirmed that the inhibitors bind to the substrate binding site and allowed to rationalize the
strong affinity of these inhibitors.
Subsequently, two different structure-based strategies were pursued for inhibitor design. The
first structure-based modifications of the initial pyridine-based scaffold led to a ten-fold
more potent inhibitor. The goal of the second structure-based optimization strategy was to
extend the central pyridine core to interact with the empty binding pocket adjacent to the
steroid A and B-ring. The predicted binding mode was verified by co-crystal structures and
the low nanomolar potency was confirmed by biophysical characterization. The new crystal
structures revealed how small changes of the inhibitors affect the adopted binding mode. The
characterization of the most promising 17β-HSD14 inhibitors against 17β-HSD1, 17β-HSD2,
and 17β-HSD10 revealed varying degrees of selectivity. In addition, some of these inhibitors
showed very low cytotoxicity and did not interact with the multi-drug resistance protein Pgp,
indicating these compounds might not be effluxed from the brain and that the risk of
potential side effects is reduced. This suggests these inhibitors as tool compounds for further
investigation in vivo.
To explain the selectivity profiles of the ligands towards 17β-HSD14 and other 17β-HSDs we
conducted a structural comparison. The typical V-like shape of the binding pocket of
17β-HSD14 is determined by His93 and Gln148, which are not present in 17β-HSD1,
17β-HSD8 and 17β-HSD10. In addition, the latter three enzymes have a rather flat binding
pocket. This suggests that matching the characteristic three-dimensional requirements of
17β-HSD14 and optionally addressing His93 and/or Gln148 will increase the selectivity
toward this target. Such inhibitors were predicted by docking a library of about 400 17β-
HSD1 and 17β-HSD2 inhibitors with GOLD followed by in vitro screening of docking hits
and related compounds. Remarkably, predicted binding modes were in poor agreement with
the subsequently determined crystal structures due to the adaptability of the binding pocket
caused by the flexible loop.
Finally, a large fragment screening campaign by X-ray crystallography with the aim to
discover new inhibitor scaffolds bound to 17β-HSD14 was performed. This resulted in two
fragments that could be clearly identified in the electron density. However, these fragments
did not significantly inhibit 17β-HSD14. In order to enhance affinity, fragment growing and
fragment linking strategies were applied, resulting in two new inhibitors with better affinity
than the starting fragments.
In summary, both isoforms of 17β-HSD14, S205 and T205, were characterized biochemically
and structurally resulting in four new crystal structures. The first two classes of inhibitor for
this enzyme were discovered and the ligands were thoroughly profiled. In addition, the
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structures of 12 nonsteroidal inhibitors in complex with the protein were elucidated for the
first time for this protein family. The fragment screening by determining 96 fragment-soaked
structures, resulted in two fragment hits that were successfully optimize culminating in two
inhibitors more active than their precursor fragments.

IX
Die 17β-Hydroxysteroid Dehydrogenase Typ 14 (17β-HSD14) ist der zuletzt identifizierte
Subtyp der 17β-HSDs. In vivo oxidiert dieses Enzym die Hydroxyl-Gruppe von Estradiol (E2)
und 5-Androstendiol (5-Diol) an Position 17 in Gegenwart des Kofaktors NAD+. Es
existieren zwei Isoformen dieses zytosolischen Proteins, die sich ausschließlich in
Sequenzposition 205 unterscheiden: S205 und T205. Bis jetzt wurde das Protein noch nicht
gründlich und im Detail untersucht und seine physiologische Rolle bleibt unbekannt. Vor der
Durchführung dieser Doktorarbeit war das 17β-HSD14 Apoenzym (S205) bereits
kristallisiert worden. Die gelöste Struktur zeigte ein sehr weites und offenes aktives Zentrum
sowie die konservierte katalytische Triade und das Rossmann-Faltmotiv. Jedoch waren alle
C-terminalen Enden und bei einigen Ketten auch Aminosäuren der flexiblen Schleife (189-
212) nicht in der Elektronendichte definiert. Darüber hinaus ist es unmöglich, Informationen
bezüglich eines potentiellen Substrats von dieser Apostruktur abzuleiten. Deshalb war die
erneute Strukturbestimmung des 17β-HSD14 Apoproteins sowie seiner Komplexe mit
Kofaktor und Substrat von größter Wichtigkeit.
Nach erfolgreicher Etablierung der Expressions- und Aufreinigungsprotokolle für 17β-
HSD14 wurden die beiden Isoformen (S205 und T205) biochemisch charakterisiert. Die
Strukturen des S205 Apoenzyms und der binären Komplexe beider Isoformen mit NAD+
wurden aufgeklärt. In diesen Strukturen nimmt die flexible Schleife eine einzigartige
geschlossene Konformation ein, die sich von der Apostruktur unterscheidet. Die Bindung des
Kofaktors geht einher mit einer Verschiebung der flexiblen Schleife und des C-terminalen
Tyr253’ des benachbarten Monomers, wodurch die Größe des aktiven Zentrums vermindert
wird. Der ternäre Komplex des Enzyms mit Estron (E1) und NAD+ wurde ebenfalls
aufgeklärt. E1 bindet auf untypische Weise in das aktive Zentrum, insofern als sein A-Ring
und nicht die enzymatisch modifizierte Position 17 nahe dem Nikotinamid-Baustein des
NAD+ positioniert ist.
Enzyminhibitoren sind nützliche Werkzeuge, um die Konsequenzen einer Enzymhemmung
in vivo zu studieren. Dies erlaubt zu klären, ob dieses Enzym als neues Arzneistofftarget für
bestimmte Krankheiten interessant sein könnte. Außerdem könnten potente und selektive
17β-HSD14 Inhibitoren auch helfen, das Selektivitätsproblem anderen 17β-HSDs zu
verstehen. Da vor dieser Studie kein 17β-HSD14 Inhibitor bekannt war, war das Ziel die
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Identifizierung und Optimierung nicht-steroidaler 17β-HSD14 Inhibitoren. Dafür wurden
17β-HSD1 und 17β-HSD2 Inhibitorbibliotheken gegen 17β-HSD14 gescreent. Der
vielversprechendste Treffer wurde als Startpunkt für weitere chemische Modifizierung unter
Anwendung eines ligandbasierten Ansatzes verwendet. Neu designte Verbindungen wurden
synthetisiert und anschließend auf ihre inhibitorische Aktivität gegen 17β-HSD14 getestet.
Vor dieser Doktorarbeit waren keine Strukturen einer humanen 17β-HSD im Komplex mit
einem nicht-steroidalen Liganden veröffentlicht. Die Kristallstrukturen bestätigten, dass die
Inhibitoren an die Substratbindestelle binden und ermöglichten die hohe Affinität dieser
Inhibitoren zu erklären.
Anschließen wurden zwei unterschiedliche Strategien zum Inhibitordesign verfolgt. Die
ersten struktur-basierten Modifikationen des ursprünglichen Pyridin-Grundgerüstes führten
zu 10-fach potenteren Inhibitoren. Das Ziel der zweiten struktur-basierten
Optimierungsstrategie war die Erweiterung des zentralen Pyridin Kerns, um eine Interaktion
mit der leeren Tasche neben den Steroid-Ringen A und B zu gewährleisten. Der
vorhergesagte Bindungsmodus wurde durch Kokristallstrukturen verifiziert und die niedrig-
nanomolare Affinität durch biophysikalische Charakterisierung bestätigt. Die neuen
Kristallstrukturen offenbarten, wie kleine Änderungen der Inhibitoren den eingenommenen
Bindungsmodus beeinflussen. Die Charakterisierung der vielversprechendsten 17β-HSD14
Inhibitoren bezüglich 17β-HSD1, 17β-HSD2 und 17β-HSD10 offenbarte unterschiedliche
Grade an Selektivität. Zusätzlich zeigten einige dieser Inhibitoren eine sehr niedrige
Zytotoxizität und keine Wechselwirkung mit dem Multidrug-Resistance-Protein Pgp, was
darauf hindeutet, dass diese Verbindungen nicht aus dem Gehirn ausgeschleust werden und
dass das Risiko möglicher Nebenwirkungen erniedrigt ist. Dies legt die Nutzung dieser
Inhibitoren als Werkzeuge für weitere in vivo Untersuchungen nahe.
Um die Selektivitätsprofile dieser Liganden hinsichtlich 17β-HSD14 und anderen 17β-HSDs
zu erklären, führten wir einen strukturellen Vergleich durch. Die typische V-ähnliche Form
der Bindetasche von 17β-HSD14 wird durch His93 und Gln148 bestimmt, welche in
17β-HSD1, 17β-HSD8 and 17β-HSD10 fehlen. Zusätzlich haben diese drei Enzyme eine eher
flache Bindetasche. Dies legt nahe, dass eine Anpassung an die charakteristischen
dreidimensionalen Anforderungen von 17β-HSD14 und wahlweise die Adressierung von
His93 und/oder Gln148 die Selektivität für dieses Target erhöhen werden. Solche Inhibitoren
wurden durch Docking einer Bibliothek von 400 17β-HSD1 und 17β-HSD2 Inhibitoren mit
GOLD vorhergesagt, gefolgt von einem in vitro Screening der Docking Hits und verwandter
Verbindungen. Bemerkenswerterweise waren die vorhergesagten Bindemoden in schlechter
Übereinstimmung mit den nachfolgend ermittelten Kristallstrukturen, bedingt durch die
Anpassungsfähigkeit der Bindetasche welche durch die flexible Schleife verursacht wird.
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Schließlich wurde eine großangelegte röntgenkristallographische Fragment-Screening
Kampagne durchgeführt, mit dem Ziel neue Inhibitor-Grundgerüste die an 17β-HSD14
binden zu entdecken. Dies führte zu zwei Fragmenten die deutlich in der Elektronendichte
identifiziert werden konnten. Jedoch zeigten diese Fragmente keine signifikante Inhibition
von 17β-HSD14. Um die Affinität zu erhöhen, wurden Strategien zum Fragment-Wachstum
und zur Fragment-Kopplung (growing und linking) angewendet, was zu zwei neuen
Inhibitoren mit gegenüber den Start-Fragmenten erhöhter Affinität führte.
Zusammengefasst wurden beide Isoformen von 17β-HSD14, S205 und T205, biochemisch
und strukturell charakterisiert, was zu vier neuen Kristallstrukturen führte. Die ersten zwei
Klassen von Inhibitoren dieser Enzyme wurden entdeckt und gründlich charakterisiert.
Zusätzlich wurden zum ersten Mal für diese Familie die Strukturen von 12 nicht-steroidalen
Inhibitoren im Komplex mit dem Protein ermittelt. Das Fragment-Screening durch die
Bestimmung der Struktur von 96 mit Fragmenten getränkten Kristallen führte zu zwei
Fragment Hits, die erfolgreich optimiert und zu zwei Inhibitoren mit gegenüber den
Vorgänger-Fragmenten erhöhter Aktivität entwickelt werden konnten.
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1.1 Sex steroid hormones
Hormones are signaling molecules that are produced and subsequently released by an
endocrine gland into the circulatory system. Thereby, they are able to address distant organs
and thus regulate physiology and behavior. Hormones can be categorized into four main
chemical classes: amino acid derivatives, polypeptides, eicosanoids, and steroids [1]. Sex
hormones are lipophilic compounds derived from cholesterol that belong to the chemical
class of steroids [1]. They can be divided into two main classes: Androgens, considered as
“male sex hormones” mainly constituted by 4-androstene-3,17-dione (4-dione), as well as
testosterone (T) and dihydrotestosterone (DHT). Furthermore, the most important
representatives of the estrogens (or so-called “female sex hormones”) are estradiol (E2) and
estrone (E1). One crucial role of androgens and estrogens is the induction of body changes,
known as primary and secondary sex characteristics. However, both, androgens as well as
estrogens, have a variety of effects on various organs and tissues. In fact, estrogens play an
important role in maintaining the bone mass by keeping the equilibrium between bone
formation and resorption, in vasoprotection and in the immune system [2–5]. In addition,
several studies have proven that estrogens are fundamental for the development and
maintenance of the brain function. Furthermore, they have shown that an increase in the
concentration of E2 is beneficial for the treatment of neuronal diseases [6, 7]. Estrogens and
androgens can also be produced by the intracrine system that activates the steroids directly in
the local tissue from their inactive precursors, without being released into the blood stream
[8, 9].
Due to the many different enzymes that are involved in the biosynthesis of androgen and
estrogen starting from cholesterol (Figure1.1), the cholesterol metabolism pathway is a very
attractive but also challenging pathway for the discovery of new potential targets for the
treatment of different diseases [10].
1.2 17β-hydroxysteroid dehydrogenases family
The interest in 17β-hydroxysteroid dehydrogenases (17β-HSDs) enzymes started over 40
years ago when their function in eukaryotic and prokaryotic species was characterized [8, 11,
12]. At present, 14 different mammalian 17β-HSDs have been characterized. Of these, 12
occur in humans, whereas 17β-HSD6 and 17β-HSD9 were only identified in rodents [11].
With the exception of 17β-HSD5, that belongs to the aldo-keto reductase (AKR) superfamily,
they all belong to the short-chain dehydrogenase/reductase (SDR) super family [12, 13]. SDR
constitutes a large protein family of oxidoreductases (over 160,000 members in the Uniprot
database), mainly present as oligomeric enzymes. The SDR enzymes share an overall residue
identity of 15-30%, mainly resulting from the conserved cofactor binding site and the
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Figure 1.1: Schematic summary of the biosynthesis pathway of the sex steroid hormones (Taken
from Gargano M. [14]).
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catalytic residues. All members of this family have a conserved Rossman-fold domain
established by an α/β sandwich folding pattern that is arranged in 6 to 7 central β-sheets, and
flanked by 3 α-helices at both sides (Figure 1.2) [15–17]. The sequence of the SDR enzymes
typically comprises about 250-350 amino acids. The SDR enzymes are NAD(H)/NADP(H)
dependent and the cofactor-binding site is located at the N-terminal region [17, 18]. A
further characteristic is that they contain a highly conserved Tyr-X-X-X-Lys motif that
functions as catalytic domain [19]. The catalytic Tyr residue functions as general acid/base
catalyst. The pKa value of the OH group of the Tyr group is lowered by a neighboring
conserved Lys residue, and the substrate binding is achieved through the sidechain of a
conserved serine (Figure 1.3) [20, 21]. In many SDRs, a proton relay system appears to
involve the 2’ OH of the nicotinamide ribose in addition to a conserved water molecule,
whereas no metal ion is required for catalysis [16, 17, 21–24].
17β-HSDs are characterized by the ability to activate or inactivate the sex steroid hormones
by stereospecific reduction or oxidation of the keto/alcohol group in position 17 (Figure 1.4).
Besides, these enzymes are also involved in the metabolism of different nonsteroidal
compounds like retinoid acid, fatty acid and hydroxyacyl CoAs [11, 25–32]. The 17β-HSD
enzymes are bidirectional in vitro, whereas in vivo they show a preference for the oxidative or
Figure 1.2: (A) Ribbon representation of the 17β-HSD14 apoenzyme. The conserved Rossmann-
fold domain is established by α-helices (white) and β-sheets (beige). The loops giving special
shape to the binding pocket and the variable C-terminal tail are colored in green. (B) Close-up
view of the substrate binding pocket. The catalytic amino acids are shown as stick model. All
structural representations were prepared with PyMOL [33].
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Figure 1.3 Scheme of the postulated reduction mechanism of E1 to E2 by the 17β-HSD1 enzyme
[20, 21, 24]. The cofactor NADPH is colored in red and the substrate E1 in blue. The involved amino
acids are displayed in black. Hydrogen bonds are represented as dashed lines, the proton transfer
reactions are indicated by arrows (Figure taken and modified from Negri M. et al. [24]).
reductive reaction, which is mainly associated by the enzyme localization, the cofactor
preference and the availability of substrate [11]. The large substrate variability observed in
this protein family is dictated by the C-terminal tail that equips the different enzymes with a
special substrate/inhibitor binding site [15, 16]. This back portion is usually folded into three
large loops that capture the substrate and undergo a structural rearrangement after binding
of cofactor and substrate [26]. The nomenclature of 17β-HSD enzymes is following the
historical description order established by the Human Genome Organization (HUGO).
Homology model studies are difficult to perform due to the low similarity of the substrate
binding sites between these enzymes. A further reason is the structural flexibility of the C-
terminal tail. Thus, it is necessary to structurally characterize every single subtype member of
this family in order to understand its function. The following seven human enzymes have
Figure 1.4 Schematic representation of the general catalytic reaction of 17β-HSDs.
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already been structurally characterized: 17β-HSD1, 17β-HSD4, 17β-HSD5, 17β-HSD8, 17β-
HSD10, 17β-HSD11 and 17β-HSD14 [27, 34].
The 17β-hydroxysteroid dehydrogenases (17β-HSDs) are essential for the last step of the
formation and degradation of steroid hormones.  They regulate the intracellular availability
of steroid hormones and their potential activation of the  nuclear receptors [11, 34]. In
addition, these enzymes are specifically expressed in certain tissues. Consequently, this
enzyme family is of high interest as therapeutic targets for several steroid hormone
dependent diseases [34], and for several types of 17β-HSDs a correlation with some human
diseases has already been found. In addition, the expression level of some of these enzymes
can be used as prognostic marker in breast and prostate cancer [35, 36].
Cofactor preference
As mentioned above, 17β-HSDs drive the redox reactions unidirectional in vivo. Inside the
cells, the concentration of NADPH is about 500 times higher than of its oxidized form
NADP+. The NAD+ form is about 700 times higher than its reduced NADH form [37–39].
Beside the concentration difference, kinetic studies revealed that 17β-HSDs are able to
discriminate between the non-phosphorylated and the phosphorylated form of the cofactor
[40]. These results are in accordance with the crystal structures: an arginine is present in the
Rossmann-fold motif of the reductive HSD enzymes that stabilizes the 2’-phosphate moiety
of NADPH via a salt bridge. In contrast, in the oxidative enzyme a negative charged amino
acid, often aspartate, is present in the same region repulsing the 2’-phosphate group and
stabilizing instead the ribose (Figure 1.5) [41–44]. Furthermore, these observations have been
confirmed by mutagenesis studies [45, 46].
Figure 1.5 Scheme of the binding preferences for NADPH vs. NAD+ for reductive/oxidative HSDs.
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Reducing 17β-HSDs enzymes
Six reductive 17β-HSDs enzymes are described in the literature [11, 24, 34]. They are
activating enzymes and responsible for the high level of active sex steroids in target tissues.
17β-HSD1 was the first enzyme in this family to be cloned and structurally characterized.
This enzyme, which is active as a homodimer [47], is one of the most important enzymes
involved in the last step of the activation of estradiol starting from estrone, resulting in a high
concentration of the sex hormone in the target tissue. This enzyme is estrogen specific. A
minor effect on the reduction of androgen was also identified [48–50]. 17β-HSD1 is a
cytosolic enzyme that is mainly expressed in breast, endometrium, ovary and placenta. In
minor concentration it is expressed in adipose tissue and skin. During the last decades, an
increasing number of inhibitors targeting 17β-HSD1 were discovered. The first inhibitors are
based on a steroidal scaffold, some are mixed inhibitors combining both, cofactor and
steroid, whereas the latter inhibitors show a nonsteroidal core [34, 51–54]. At present, several
crystal structures of the apoenzyme, the cofactor-enzyme complex and the ternary complexes
with substrate or steroidal inhibitors are already resolved. However, no crystal structure of
the enzyme in complex with a nonsteroidal inhibitor has been reported so far. 17β-HSD1 has
been proven to play a crucial role in several estrogen-dependent diseases such as breast
cancer, ovarian tumor, endometriosis, and uterine leiomyoma [55–63] and it is a validated
drug target for estrogen dependent breast cancer.
17β-HSD3 is a microsomal membrane-bound enzyme that is mainly present in the testis that
it is bound to the endoplasmic reticulum through its N-terminal domain [11, 64]. 17β-HSD3
has 310 amino acids and it catalyzes the reductive reaction of 4-dione and 5α-
androstenedione to testosterone (T) and dihydrotestosterone (DHT), respectively [65, 66].
This enzyme is overexpress in prostate cancer and, due its catalytic action, its inhibitions
would reduce the concentration of T and therefore it could be beneficial against tumor
growth [67, 68]. The determination of the structure of this enzyme was unsuccessful due its
hydrophobic nature.
17β-HSD5 is located in the cytosol. This enzyme is prevalently expressed in breast, liver and
prostate. 17β-HSD5 shows a broad substrate specificity [69, 70]. As it is member of the aldo-
ketoreductase (AKR) protein superfamily, it will not be further discussion.
17β-HSD7 is a microsomal enzyme bound to the endoplasmic reticulum. It is present in
breast, liver, testis, ovary, kidney, placenta as well as in neuronal tissue and lung [11, 71, 72].
The enzyme is involved in the production of E2. Furthermore, it has been proven that it
fulfills a main role in the synthesis of cholesterol [73]. No crystal structure is available so far.
17β-HSD12 is present in microsomes of especially kidney, liver, heart and skeletal muscle
and in minor level in placenta, breast and ovary. This enzyme is involved mainly in the
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regulation of the lipid biosynthesis and plays only a marginal role in the metabolism of E2
[74–76].
17β-HSD13 is present in the liver but is also detected in ovary, bone marrow, kidney, brain,
lung, skeletal muscle, bladder and testis. It is a cytosolic enzyme and it may be involved in the
lipid metabolic pathways [77, 78].
Oxidizing 17β-HSDs enzymes
Characteristic for these enzymes is that they catalyze oxidation reactions and that they are
found ubiquitously in the body also in non-steroidogenic tissues. As they inactivate the sex
hormones (oxidation of the potent estradiol and testosterone in estrone and 4-dione,
respectively) and thus lower the concentration of the latter in the target tissues, it is assumed
that these enzymes play a protective role in vivo [11].
17β-HSD2 is widely expressed in tissues such as placenta, uterus, liver, bone, gastrointestinal
and urinary tracts [79–82]. This enzyme is found to be bound to membranes of the
microsomal fraction. It catalyzes the conversion of E2, T and DHT to their less potent forms
E1, 4-dione and 5α-androstenedione, respectively [29]. Due to the unspecific localization of
17β-HSD2 and its physiological role in inactivating the sex hormones, it has been suggested
that it plays a role in protecting tissues from excessive steroid concentrations [12]. Several
steroidal and non-steroidal inhibitors have already been identified for this enzyme [34, 83,
84]. The estrogen replacement therapy for the treatment of osteoporosis is proven to be
beneficial; however, this therapy is no longer recommended due the many side effects [34, 85,
86]. 17β-HSD2 oxidizes E2 into E1, resulting in a decreased concentration of E2 in bone cells.
Therefore, inhibition of this enzyme is a promising approach for the treatment of
osteoporosis [34, 87–92]. Unfortunately, the three-dimensional structure of this enzyme is
still unknown due to its hydrophobic nature that has proven to be a huge obstacle for the
structural elucidation.
17β-HSD4 is ubiquitously distributed and it is mainly involved in the inactivation of sex
steroids. The enzyme 17β-HSD4 is a much larger enzyme compared to the other 17β-HSDs
and its tertiary structure can be divided into three domains [11, 18, 34].
17β-HSD8 is located in liver, placenta, gonads and kidney. 17β-HSD8 can catalyzes a wide
range of substrates including estrogen, androgen and fatty acids and its three-dimensional
structure is known [11, 34].
17β-HSD10 is a mitochondrial enzyme that is located in the central nervous system (CNS). It
is overexpressed in the amyloid plaques of patients suffering of Alzheimer’s disease. The
enzyme is involved in several substrate pathways, for instance in the inactivation of sex
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steroids and the catabolism of short hydroxyacyl CoAs [93–97]. One class of inhibitors
described for this enzyme forms a covalent bond to the cofactor (NAD+) and typically has a
peculiar chemical structure [94]. Few crystal structures of this protein are available as
apoenzyme or in inhibitor-enzyme complexes.
17β-HSD11 is expressed in liver, lung, placenta and kidney. Its physiological role is not
disclosed yet; however, recent studies suggest that the enzyme might be involved in the
metabolism of fatty acids rather than in the metabolism of  sex steroids [98, 99].
17β-HSD14
Human 17β-hydroxysteroid dehydrogenase type 14 (17β-HSD14) — also called retSDR3,
DHRS10 or SDR47C19 — is the latest enzyme identified that belongs to the 17β-HSD family
[11, 16, 32, 34]. Initially, its gene was isolated from the retina by Haeseleer and Palczewski
[100]. Subsequently, a second version of the gene was isolated from a melanotic melanoma
cell in the framework of a genome sequencing campaign [101, 102]. Both genes are identical
with the exception of a single point mutation of the amino acid at position 205: The gene
isolated from the retina encodes at this position for a serine (17β-HSD14 S205), whereas the
gene isolated from a melanotic melanoma encodes for a threonine (17β-HSD14 T205). Since
only the S205 variant was characterized so far, the reason for this protein polymorphism is
not yet clear. However, it is hard to believe that the single point mutation could give rise to a
significant difference in activity, as the structural difference is limited to a single methyl
group. Furthermore, it cannot be excluded that a spontaneous mutation occurred during the
isolation of the second gene from the cancer tissue. Nevertheless, it would be of high interest
to characterize also the T205 protein variant.
As the gene was first isolated from a retina cDNA library, it was hypothesized that this
enzyme would be involved in the retinoid metabolism. However, this function could not be
proven [100]. Northern blot analyses has revealed that the S205 hHSD17B14 gene is mainly
expressed in brain, liver, placenta [32], and in the kidneys [100]. However, Sivik et al [103]
applied immunochemical based methods to demonstrate that the protein is also expressed in
adrenals and testis as well as in the eyes, heart, kidney, esophagus, liver, rectum, salivary
glands, skeletal muscles and in breast cancer tissue [35]. The striking discrepancy between the
enzyme-containing tissues reported in the two studies can be explained by the differences in
the specificity of the applied antibodies. Thus, further investigation is required before a
conclusion can be drawn [104].
Although the in vitro reaction of 17β-HSD14 was investigated, its physiological role in vivo is
still unclear. About 50 ligands binding to SDR enzymes were tested on 17β-HSD14, but only
some sex steroids showed significant affinity to the enzyme. These results suggest that the
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enzyme is potentially involved in the sex steroid metabolic pathway [32]. 17β-HSD14
catalyzes the oxidation of the alcohol function at position 17 of E2, 5-androstene-3β, 17β-diol
(5-diol), and T — using NAD+ as a cofactor — and transforms them into their less active
forms E1, dihydroepiandrostenedione (DHEA), and 4-dione, respectively [32]. However, the
low turnover rate for these steroids and the not saturatable kinetics of T suggest the
hypothesis that in vivo the enzyme might play a role also in other metabolic pathways (Km=
5.6 µM ± 1.7 for E2; Km= 13.6 µM ± 1.6 for 5-diol) [32].
Prior to the studies conducted in the framework of this thesis, only a single crystal structure
of the 17β-HSD14 apoenzyme exhibiting a resolution of 2.4 Å was available (PDB ID 1YDE)
[32]. The assembly of the enzyme is homotetrameric, and the asymmetric unit of the crystal
structure contains four tetramers giving rise to a total of 16 monomers (Figure 1.6). The
protein comprises 270 amino acids, whereas only 250 of them could be clearly assigned to the
electron density. Beside the typical, conserved Rossmann-fold region (consisting of seven
parallel β-sheets and an array of α-helices at both ends) and the catalytic triad — consisting of
Ser141, Tyr154 and Lys158 — the structure shows the distinctive flexible loops formed by the
segments αFG1 and αFG2 (Figure 1.2). Unfortunately, several pieces of the flexible loops are
not visible in the electron density of some of the chains, and none of the chains’ C-termini
are detectable. The binding cleft of 17β-HSD14 appears widely open and rather lipophilic. No
information about a potential substrate can be derived from this crystal structure and due the
scatter over various conformations of the flexible loops, it is difficult to use the structure for
docking studies.
Figure 1.6 (A) Ribbon representation of the four homotetramers in in the asymmetric unit of
17β-HSD14 (PDB ID: 1YDE). (B) Single homotetramer. The conserved Rossmann-fold domain is
colored in white and beige. The flexible parts are colored in green.
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1.3 Tools for the characterization of enzymes and their planned
application in the current study
Different techniques are available for the characterization of enzymes and for studying
ligand-protein interactions. The different methods are often complementary to each other,
resulting in a more complete and reliable picture of the studied effects in operation. However,
during the planning of the experiment to characterize the enzyme structure it is important to
take the limitations especially into account. For example, for well-characterized enzymes in
silico approaches can successfully identify compounds during drug development [104];
however, as mention earlier, it can be rather challenging to identify binders based on
homology models derived from of sequence data showing low identity and for proteins
exhibiting highly flexible parts. Several attempts to dock ligands into 17β-HSD14 were
performed in the course of some preliminary studies of this project. However, the
subsequntly determined crystal structures revealed that the predicted binding modes were
incorrect.
One of the techniques on which the current thesis is strongly based is macromolecular X-ray
crystallography. This technique is a diffraction method for the determination of structural
information up to the atomic level [105–108]. Since the 17β-HSD enzyme family does not
share a high sequence homology, especially across the binding-site region, crystal structures
can provide important insights into the peculiarities of the binding sites. As mention above,
one crystals structure for 17β-HSD14 had already been described in literature prior to this
study [32]. Even though this crystal structure already revealed some details about the
architecture of this protein, there still remained many open questions. The electron density of
highly variable regions of the protein were ill-defined (flexible loops and the C-terminal tail),
however they are of utmost importance because they contribute to ligand binding. This
deficiency could resulted from several effects, for instance the relative low resolution of the
dataset (2.4 Å) could have prevented to properly resolve these mobile regions. Another aspect
that makes this structure not ideal as a starting point for a rational drug discovery endeavor is
that 16 monomeric units (four tetramers) form the asymmetric unit. These chains of the 16
units all differ in the arrangement of the flexible loops resulting in binding pockets of
deviating shape and volume. It is therefore difficult to predict which of the chains represents
the relevant conformation of the active binding site competent to accommodate a ligand.
Furthermore, the question remains whether the observed flexibility of the protein also occurs
while the protein is in complex with a ligand and/or the cofactor. It is obvious that a higher
quality of the apoenzyme crystal structure and the availability of multiple crystal structures of
the protein in complex with cofactor and ligand would be tremendously beneficial for the
intended drug design studies.
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Even though the X-ray diffraction technology underwent an immense improvement within
the last decades, for instance the development of more powerful light sources at synchrotrons
that are equipped with faster detectors, one important factor limiting the quality of the crystal
structure is the quality of the protein crystal itself [106, 108]. In this study, in order to
produce well-diffracting three dimensional crystals, extensive crystallization screenings were
performed.
Crystal structures are also essential for the rational design of ligands. Crystals of
protein-ligand complexes can be prepared following two different strategies: Soaking or
cocrystallization [109, 110]. The strength of the crystal soaking approach is that it can be
performed very fast, since protein-ligand complexes are simply prepared by exposing
premanufactured crystals with known diffraction quality to the ligand of interest. Usually
soaking of fragments or small ligands is unproblematic; however, more bulky ligands can be
incompatible with the crystal packing. Due to their high affinity, they can forcibly squeeze
into the pre-shaped active site and thereby adopting themselves unrealistic conformation or
inducing conformational changes of protein sidechains/loops, or even interfere with the
packing in the crystal. This frequently results in a decrease in crystal quality (increased
mosaicity) or even a complete destruction of the exposed crystal. Furthermore, cases have
been reported where soaking seemingly results in a different binding mode than
cocrystallization [106, 110, 111]. This observation suggests that conformational changes of
the protein upon ligand binding are already established in solution prior crystallization — as
reflected by the co-crystallized structures — will prevented false conclusions that might occur
if premanufactured  crystals are subjected to soaking experiments [110, 111].
Cocrystallization is a viable alternative to soaking protocols. In this case, a solution of protein
and ligand is prepared that is subsequently used to grow crystals. Thereby, crystals are
formed in periodic arrangements of the pre-assembled protein-ligand complexes of interest.
Since the ligands bind to the protein already in solution, this induces protein rearrangements
and thus reflects better the conformation of the protein-ligand complex in solution and
hopefully the biologically relevant conditions — and thus will be less biased by putative
imposed crystal packing effects of the apoenzyme. In addition, co-crystallization could even
result in a qualitatively better crystal structure. The downside of this technique is that it is
more demanding with respect to protein material and can potentially result in a new crystal
form that requires new crystallization conditions [109–111].
Through an extensice examination of the protein-ligand complex crystal structure ligand
portions that do not achieve interactions to the protein can be identified. This knowledge can
be used to rationally improve the chemical structure of the ligand in the next design cycle
[112].
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If it is intended to study especially the function of the protein, one limitation of
macromolecular X-ray crystallography is that hydrogen atoms are usually not detected.
Consequently, it is not possible to directly determine the protonation state of ligands and
amino acids. Thus, the protonation state can only be rationalized on the basis of consensus
interaction patterns and distance and angle between atoms.
Another technique used in this work is the thermal shift assay (TSA) also called differential
scanning fluorimetry (DSF). The stability of a protein is temperature-dependent [113, 114],
and this method detects the differences of the melting temperature of a protein under various
conditions. Stable, correctly folded protein tends to have the hydrophilic amino acids
exposed to the surface and the hydrophobic ones are buried within the core. At a defined
temperature — specific for each macromolecule and dependent on the buffer composition —
the protein will partially or completely unfold and, as a consequence, the hydrophobic amino
acids will get exposed to the solvent. This assay detects at which temperature this unfolding
event occurs. It is usually performed using a real-time PCR devise [115], and is dependent on
a special dye (SYPRO orange) that begins to fluorescent upon binding to exposed
hydrophobic portions of the protein. No or very low florescence is detected while the
globular protein is correctly folded. However, with increasing temperature the protein will
start to unfold and thus expose hydrophobic residues to the solvent phase, thereby getting in
contact with the dye, that in consequence starts to fluorescent. Recording the intensity of the
fluorescence signal over a temperature range results in a sigmoidal curve, where the melting
temperature Tm of the protein is described by the inflection point (Figure 1.7). When the
protein is surrounded by molecules that help to stabilize its tertiary structure, a shift to a
higher melting point will occur. The TSA is extremely useful for the screening of different
additives, for instance different salts and buffers at different pH values, in order to find a
buffer composition that shows an optimal stabilizing effect on the protein. The application of
buffers that optimally stabilize the protein has the advantage that the yield during protein
expression as well as the success rate during crystallization screenings can drastically increase
[116]. This assay also allows fast and efficient screening for binding ligands. The principle is
that upon binding of a ligand to the protein, the ligand stabilizes or destabilizes through
binding the protein architecture and the observed shift of the melting temperature is
proportional to the strength of the formed complex (i.e. in close series even to the affinity of
the ligand) as well as proportional to the concentration of the ligand. The amount of
stabilization due to the complexation with different ligands results in shifts of varying extend
of the melting temperature Tm compared to the melting point of the uncomplexed enzyme
[116–119]. However, the magnitude of the shift is not reflecting the affinity of the ligand but
it is primarily proportional to the change in the entropy of binding upon formation of the
complex [119]. Thus, the TSA can be used to discriminate binders from non-binders, but not
for the determination and comparison of compound affinities.
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Figure 1.7 Example of TSA curves obtained in the presence of different buffers (taken and
modified from [120, 121]).
Biochemical assays are necessary for the characterization of the enzyme activity. As we had
no access to a radio-detector for the analysis of the conversion of radiolabeled E2 into E1 as
described by Lukacik et al. [32], we used instead two different enzymatic assays that were
established in our laboratory at different stages of the project. The thin-layer
chromatography (TLC) assay was only used during the establishment of the protein
purification procedure for the detection of the enzyme in the different fractions after column
chromatography. The selective transformation of E2 into E1 was visualized by UV light,
indicating the presence of the active protein in the studied fractions. However, the assay does
not allow the quantification of the conversion of E1 into E2.
For the kinetic characterization, the quantification of the enzymatic turnover of E2 into E1
was determined using a fluorescence-based assay. The 96-well plate format used in our
fluorescence assay is rather convenient, as it requires only low quantities of the protein, it is
fast and can easily be adapted for the evaluation of the inhibitors. The fluorescence-based
assay is monitoring the increase of NADH formed by the catalytic reaction by measuring the
increase in fluorescence (excitation at 340 nm and emission at 496 nm). As the catalytic
reaction has a stoichiometry of one — one molecule of NAD+ is converted into one molecule
of NADH for each E2 that is converted into E1 — it is trivial to derive the E2 turnover from
the NADH formation. However, it has to be considered that if the concentration of the total
molecules in the well is too high, the fluorescence signal will get partially quenched and the
detected fluorescence will report a lower concentration than actually present (inner filter
effect). Furthermore, also other molecules than E2, acting as substrate of the enzyme, could
principally participate in the catalytic reaction leading to the formation of NADH. In this
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case, the increasing florescence would not exclusively represent the formation of E1.
Therefore, it is important to perform a negative control of the reaction in parallel, for
example containing the enzyme and NAD+, but without the substrate E2. One of the largest
limitations of this assay are intrinsically self-fluorescent inhibitors. If an inhibitor is
fluorescent at a similar wavelength (λ) as NADH, the read out of the florescence signal
becomes inaccurate and the interpretation of the results is rather difficult or even impossible.
1.4 Aim of the research project and thesis outline
Although the sequencing of the human genome has been solved and all genes are accessible,
the physiological role of more than half of all SDR members remains unknown or poorly
examined. It is of utmost importance to deorphanize and characterize these enzymes as a
basis to explore their physiological functions and thereby identify new potential drug targets
for the treatment of human diseases [122].
17β-HSD14 has been suggested to play a role in neuromodulation [32] and in inflammation
processes [123]. The availability of a potent and selective enzyme inhibitor would foster
research in this direction and potentially support the collection of data to proof the
involvement of this enzyme in neuronal diseases. Furthermore, such an inhibitor is also
prerequisite for the conduction of proteomic or metabolic studies in vivo. In addition, potent
and selective enzyme inhibitors are also useful tool compounds to study the consequence of
full enzyme inhibition, comparable to the change of the phenotype of a knockout mouse.
Having access to such a potent inhibitor allowing the detailed characterization in vivo, this
protein could prove to be an attractive drug target as it is already the case for 17β-HSD1 [34,
124, 125] and 17β-HSD2 [87, 90–92]. Potent and selective enzyme inhibitors are also needed
to address the selectivity issues of inhibitors with respect to other 17β-HSDs.
Taking all these considerations into account, the main research objective of this thesis is to
structurally characterize the active site of 17β-HSD14 in order to facilitate the development
of highly active inhibitors. Newly discovered and optimized inhibitors can then be applied as
tools to further elucidate the structure and function of the enzyme, and to gain insights into
the possible functional roles of this enzyme in vivo.
Chapter 2 of this thesis (publication [126]) describes the chemical and biological
characterization of both S205 and T205 isoforms of 17β-HSD14. To obtain both variants of
the recombinant protein in high yield, an expression and purification protocol had to be
established. As it turned out that the protein was quite challenging to handle, special
attention was attributed to on the different approaches followed to overcome issues during
the purification procedure to obtain the protein in crystallization and assay-pure quality, in
particular protein stability. An extensive crystallization screening enabled the determination
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of four novel crystal structures of the human 17β-HSD14, as apoenzyme, in binary complex
with NAD+ and in ternary complex with NAD+ and the catalytic product of the enzyme
reaction (E1). These crystal structures were the basis to obtain new insights into the enzyme’s
properties. Since we had access to the S205 as well as to the T205 isoform of the protein, we
performed the biochemical characterization of both.
Chapter 3 (publications [126] and [127]) describes our first ligand-based drug discovery
approach. The goal of this chapter was to identify and to optimize the first class of 17β-
HSD14 inhibitors. In a preliminary study a library of 17β-HSD1 and 17β-HSD2 inhibitors —
selected to guarantee scaffold diversity — was tested on potential inhibitory activity for
17β-HSD14. The most interesting hit was taken as a starting point for further chemical
optimization. As matter of fact, this investigation was performed before the first structure of
the ternary complex (protein-cofactor-ligand) could be determined. Therefore, the
optimization of the inhibitor was performed at the beginning following a ligand-based
approach. The newly designed compounds were synthesized and tested for 17β-HSD14
inhibitory activity. The best inhibitors identified in this study showed a very high affinity
toward the enzyme with a Ki of about 10 nM. In this chapter, the first five crystal structures of
the protein in its ternary complex with the cofactor and highly potent nonsteroidal inhibitors
were further elucidated. It is striking that until now no human SDR 17β-HSD enzyme
structure has ever been reported in complex with a nonsteroidal compound. It is known that
several attempts have been conducted with 17β-HSD1; however, they all failed, possibly
owing to the lipophilicity of the active site or the flexibility of the compounds.
Chapter 4 (manuscript in preparation) describes our strategies to optimize the previously
reported class of 2,6-pyridine ketone inhibitors (Chapter 3). The availability of the crystal
structures of the enzyme in complex with an inhibitor enabled us to pursue a rational
structure-based approach. A special focus was placed on scaffold diversity with the aim to
further characterize the binding pocket of the target protein and thereby to create inhibitors
with different pharmacokinetic properties. Seven new crystal structures of inhibitors in
complex with the protein were determined. This was necessary to understand the inhibitors’
structure-activity relationship (SAR) as a basis for their further optimization. In fact, these
systematic studies revealed how small structural changes of the substituents on the inhibitors
can lead to surprising variation of their binding mode. Furthermore, this chapter describes
considerations regarding the selectivity profile of the inhibitors toward the different closely
related 17β-HSD enzymes as well as in silico determined physicochemical properties of the
new inhibitors.
In Chapter 5 the structural differences between different HSD enzymes are address. X-ray
crystal structure models of proteins provide unvaluable structural information about binding
sites and therefore enable to chemically tailor ligands to bind to the target. Crystal structures
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also allow the comparison between the three-dimensional arrangements of the amino acids
determining the active sites of different crystallized members of the family. This information
can be useful for modelling of the three-dimensional structural arrangement of other
noncrystallizable 17β-HSDs. Structural differences between 17β-HSD14 and three related
17β-HSDs (h17β-HSD1, h17β-HSD8, and 17β-HSD10) are discussed, with a focus on each
enzyme’s active site.
As the starting point for the design of the ligands was taken from an already existing library
of 17β-HSD1/2 inhibitors, it was the aim to discover also a new scaffold in order to possibly
overcome the selectivity issue toward other HSDs. Thus, in Chapter 6 (manuscript in
preparation), we initiated a fragment-based lead discovery (FBLD) campaign with the goal to
discover new inhibitor scaffolds. Therefore, a 96-entry fragment library assembled applying
selection criteria following a slightly extended “Rule of 3” was screened. The crystallographic
fragment screening approach comprises the promising perspective that more novel hits are
identified and structurally characterized than by any other biophysical screening technique,
especially for ligands that show a low binding affinity. Nevertheless, such ligands can exhibit
high ligand efficiency and the structural information about their binding modes is of utmost
importance for further optimization.
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New Insights into Human β-Hydroxysteroid Dehydrogenase Type 14:
First Crystal Structures in Complex with a Steroidal Ligand
Introductory remarks
Parts of the following chapter have been published in the Journal of Medicinal Chemistry in
2016. The cloning of the plasmid for the 17β-HSD14 T205 variant was done by Dr. Gabriele
Möller. TLC and fluorescence based assay were designed and performed by Dr. Sandrine
Marchais-Oberwinkler in collaboration with the author of the thesis. The expression and the
purification of the 17β-HSD14, the crystallization study, the elucidation of the crystal
structures and the TSA assay were established and performed by the author of this thesis.
Furthermore, the author significantly contributed to the writing of the manuscript in
collaboration with Dr. Sandrine Marchais-Oberwinkler and Florian Braun.
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2.1 Introduction
17β-Hydroxysteroid dehydrogenase type 14 (17β-HSD14), also called retSDR3, DHRS10 or
SDR47C19, is the latest 17β-HSD which has been identified [11, 32, 34]. It belongs to the
short-chain dehydrogenase-reductase (SDR) family and its physiological role is yet unknown.
Estradiol (E2), 5-androstene-3β,17β-diol (5-diol) and testosterone (T) have been identified as
substrates in vitro [32]. 17β-HSD14 catalyzes the alcohol oxidation, NAD+ dependent, of the
aforementioned estrogens and androgens at their position 17 giving rise to estrone (E1),
dehydroepiandrosterone (DHEA), and 4-androstene-3,17-dione (4-dione), respectively [32].
A library of 50 ligands of SDR enzymes were tested at 17β-HSD14 but only the
aforementioned steroids showed significant enzyme affinity, indicating that this enzyme
might be involved in steroid metabolism [32].
The gene coding for 17β-HSD14 was first isolated from the human retinal epithelium by
Haeseleer et al. [100] and contains a serine at position 205 (S205). An alternate version of the
gene was subsequently isolated from a melanotic melanoma cell during a genome sequencing
campaign [101]. This allelic variant, termed T205, carries a threonine at position 205. The
meaning of the observed polymorphism has not been analyzed until now and the T205
variant has also never been characterized to date. In this study, the structural and the
biochemical characterization of the T205 will be addressed as well as its comparison to the
S205 enzyme.
Concerning its localization, northern blot analyses have shown that the human HSD17B14
gene is dominantly expressed in the brain, liver, placenta [32], and in the kidney [100]. In
another study, using an immunochemical based method Sivik et al.[103] demonstrated that
the protein is also expressed in adrenals and testis as well as in eye, heart, kidney, esophagus,
liver, rectum, salivary glands and skeletal muscle. 17β-HSD14 has also been identified in
breast cancer tissue [35, 103]. 17β-HSD14 is a cytosolic enzyme [32].
The S205 variant of 17β-HSD14 has been previously crystallized and the 3D-structure of the
apoenzyme determined was by Lukacik et al. [32]. Crystal structures of a target protein
provide important structural insights into binding sites. However, from the existing
structure, no information about the protein/ligand interaction, either with the cofactor or
with the substrate, can be extracted.
In this study, the characterization of the new T205 variant and four new crystal structures of
the protein as apoenzyme (S205), holoenzyme (T205 and S205) and as inhibitor-enzyme
complex (T205) are presented. These results provided further insights for the
characterization of this enzyme.
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2.2 Results and discussion
Protein expression and purification
Both recombinant 17β-HSD14 protein variants (S205 and T205) were overexpressed in E.coli
BL21 pLysS via transformation with the corresponding N-6His-tag plasmid, following
Lukacik’s procedure [32], applying minor modifications. Pure enzyme was obtained with a
yield between 8-15 mg of protein per liter of bacterial culture. During the expression and
purification process, protein content was followed either by a TLC plate activity assay or by a
fluorimetric assay, based on the detection of the formed NADH.
During the establishment of the expression protocol several E.coli bacteria lines were tested.
It turned out that only the E.coli BL21 (DE3) pLysS cells were able to overexpress the enzyme
in satisfactory amount. The enzyme showed a particular tendency to aggregate and to
precipitate with the pellet during the first centrifugation step of the purification of the
bacteria homogenate suspension. The problem was resolved by resuspending the pellet
deriving from four liters of culture with more buffer (about 400 mL vs 120 mL used by
Lukacik et al. [32]) and by the addition of 0.5% of Triton X-100, a detergent that helped to
keep the protein in solution. To avoid protein precipitation, it was beneficial to lower
centrifugation (from 30000g to 17700g). Another issue was the constant contamination with
DNA in the fraction containing the recombinant enzyme. DNA contamination could be
avoided by using a DE-52 column. As such column is rather expensive, we directly applied
the supernatant to a 5 mL Ni-NTA column and we removed DNA with a first washing step
using a buffer composed of 50 mM Tris and 1.5 M NaCl. Such high salt concentration
removed any nonspecific bound DNA. Unfortunately, the enzyme was still fairly unstable in
solution. It was necessary to discover additives to add to the different buffers during
purification having the capacity to keep the enzyme in solution. This issue is discussed in the
following paragraph.
Protein stability and Thermal Shift Assay (TSA) experiment
The main challenge encountered during protein purification was the low stability of 17β-
HSD14. In the absence of any buffer additives, no or only minor amounts of protein could be
isolated. Glycerol is known to stabilize proteins by compacting their structures to a globular
shape [128, 129] and its addition substantially increased the efficiency of protein purification.
However, it must be emphasized that glycerol in presence of NAD+ and the enzyme, without
substrate, induces the production of a fluorescent substance which, after investigation, turned
out to have the same fluorescence fingerprint as NADH. We concluded that glycerol is
recognized as a substrate by 17β-HSD14, thereby transforming NAD+ into NADH. Ethylene
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glycol, MPD and PEG400 caused the same effect as observed with glycerol. Glucose, which is
commonly used as a cryo protectant and is also known to stabilize proteins [130, 131], was
identified not to be a substrate and was therefore added during purification. The protein was
further stabilized by adding NAD+ (0.5 mM) during the purification steps and for storage
(0.25 mM).
Glycerol is often used as protein stabilizer during activity assays. To the extent of our
knowledge, it is not systematically investigated whether or not glycerol can be accepted as a
substrate during enzymatic assays, and whether it interferes with substrate binding. The
presence of glycerol might therefore lead to some discrepancies in the interpretation of
biological results.
The search for sufficient stabilization conditions, compatible with our fluorimetric activity
assay, was supported by TSA.  The TSA can be used to quantify the stabilization of a protein
upon addition of different buffer additives (Figure 2.1). The reference curve was obtained in
the absence of any additive and revealed two inflection points (Tm1= 35.5 °C, Tm2= 59 °C,
Table 2.1). Conversely, in the presence of glycerol, a curve with a single melting point can be
observed (Tm= 57.5 °C), indicating that it effectively stabilizes the protein. Similar curves
were obtained with MPD, PEG400 and ethylene glycol, but at lower melting temperatures
than observed with glycerol (Table 2.1). This indicates a weaker stabilizing effect on the
protein [116, 118].
Remarkably, adding glucose or NAD+ resulted in TSA curves with two maxima. Both
molecules independently induced a slight shift in the Tm1 of the protein but did not greatly
affect the Tm2. The combination of glucose and NAD+ has a greater influence on Tm1 (ΔTm1=
+13 °C, compared to the measurement without any additive) while Tm2 remains unchanged.
Figure 2.1: TSA curves of 17β-HSD14 obtained in presence of glycerol (red), NAD+ (cyan), glucose
(blue) or without any additive (magenta).
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This result suggests that the first maximum corresponding to Tm1 might represent a fraction
of the protein in a less-stable conformation or the tetramer/dimer disruption, while the
second maximum Tm2 represents the true melting point of the protein in its most stable
conformation.
Table 2.1: Effect of different buffer additives on the Tm of 17β-HSD14
Tm1 in °C Tm2 in °C
No additive 35.5 59.0
Glycerol 20%  57.5
MPD 10%  47.0
PEG400 10%  53.0
Ethylene glycol 10%  53.0
Glucose 250 mM 37.5 59.5
NAD+ 0.2 mM 41.5 59.0
Glucose 250 mM, NAD+ 0.25 mM 48.5 59.0
The influence of different ligands on 17β-HSD14 stability was also tested. Pure DMSO was
used as control and a Tm of 56 °C was obtained (Table 2.2). No second maximum was
identified. However, in the presence of excess of E1 and E2, only a slight shift could be
observed (ΔTm= 1.5-2 °C).
Table 2.2: Effect of different ligands on the Tm of 17β-HSD14
Tm in °C
DMSO 2.5% 56.0
Estradiol 0.25 mM 58.0
Estrone 0.25 mM 57.5
Activity assay and biochemical characterization of both S205 and T205
The activity of 17β-HSD14 was determined by fluorescence intensity measurement of NADH
formed during the catalytic reaction. The reaction was carried out using the purified enzyme,
E2 as substrate and NAD+ as cofactor. High substrate concentration (32 µM) had to be
applied because of the low sensitivity of the method. All the other 17β-HSDs have the
characteristic ability to perform both oxidative and reductive reactions in vitro depending on
the oxido-reduction state of the cofactor. Therefore, the activity of 17β-HSD14 in the
presence of E1 and NADH (corresponding to the back reaction) was also tested. However, no
conversion to NAD+ could be detected after 15 min. In vivo, the cytoplasmic NAD+
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concentration is about 500 times higher than NADH. This indicates that in vivo this enzyme
should be a pure dehydrogenase.
In order to carry out a biochemical comparison of S205 and T205 variants, kinetic
experiments were performed with the substrates E2, 5-diol and T. With all substrates, the
enzyme follows Michaelis-Menten kinetics. However, with testosterone, no saturation curve
could be observed, and consequently the kinetic parameters could not be determined. For 5-
diol and E2 the Michaelis-Menten constants (Km), the maximum velocities (Vmax) and the
turnover rate values (kcat) were determined (Table 2.3). For the S205 variant, the Km values
obtained are in the same range as those published by Lukacik et al. [32]. The kinetic data of
the T205 variant are very similar to those of the S205 protein, indicating that the T205
mutation does not influence the catalytic efficiency of the enzyme. This result appears
reasonable as the amino acid 205 is not located in the proximity of the catalytic triad. The
rather high Km and low turnover of 17β-HSD14 for both, 5-diol and E2, had already been
pointed out by Lukacik et al.[32] and might indicate that the enzyme could bind other types
of substrates. The specific activity, in presence of E2, is 1.35 and 1.21 nmol.min-1.mg-1 for
S205 and T205, respectively.
Table 2.3: Kinetic analysis of 17β-HSD14
 S205 T205
Substrate Km (µM) Vmax (nM·min-1) kcat (min-1)  Km (µM) Vmax (nM·min-1) kcat (min-1)
5-diol 6.6±1.5 58±0.4 0.017  7.8±1.2 68±0.3 0.019
E2 6.2±1.4 82±0.1 0.024  7.9±1.7 114±0.3 0.033
Mean values and given standard deviations were calculated based on 5 - 7 measurements
Crystallization of 17β-HSD14
One crystal structure for 17β-HSD14 had already been published as apoenzyme before this
study was conducted [32]. As described in Chapter 1, this structure showed various
limitations that made conclusive structure-based drug design hardly possible. Accordingly,
we embarked onto a broad screening for alternative crystallization conditions.
After screening of more than 1200 conditions, our crystallization trials led to four different
crystal structures: 17β-HSD14 as apoenzyme (S205), as binary complexes with NAD+ (with
both variants S205 and T205), as a complex with the product E1 (T205). All crystal structures
of the protein complexes were obtained by co-crystallization. The data processing and the
refinement statistics are summarized in Table 2.4.
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Table 2.4: Data collection and refinement statistic for the crystal structures.
a Values in parenthesis describe the highest resolution shell. b Calculated with Matthews_coef program from CCP4
suite version 6.4.0 [132]. c Calculated with PROCHECK [133]. d Mean B factors were calculated with MOLEMAN [134]
PDB code a
Apo structure
(5ICS)
Holo structure
S205 (5JSF)
Holo structure
T205 (5JS6)
E1 complex
(5HS6)
(A) Data collection and processing
space group P1211 I23 I23 I422
unit cell parameters a, b, c (Å) 77.0, 92.2,
87.3
130.2, 130.2,
130.2
130.2, 130.2,
 130.2
91.0, 91.0, 131.9
Matthews coefficient b (Å3/Da) 2.5 3.2 3.2 2.4
solvent content b (%) 49.9 61.7 61.7 49.0
(B) Diffraction data
resolution range (Å) 50-1.52
 (1.61-1.52)
50-1.84
(1.95-1.84)
50-2.00
 (2.12-2.00)
50-2.02
(2.14-2.02)
unique reflections 169468 (27103) 31827 (5106) 24734 (3933) 18613 (2930)
R(I)sym (%) 5.8 (48.1) 4.7 (49.1) 4.2 (48.3) 9.1 (48.6)
Wilson B factor (Å2) 13.7 35.06 44.6 26.1
completeness (%) 99.5 (98.8) 99.9 (99.6) 99.4 (98.5) 99.7 (98.7)
redundancy 3.8 (3.8) 6.6 (6.8) 6.6 (6.5) 7.5 (7.6)
<I/σ(I)> 15.2 (2.7) 21.3 (4.2) 22.7 (3.9) 15.9 (4.3)
(C) Refinement
resolution range (Å) 43.95-1.52 46.05-1.84 46.03-2.00 46.11-2.02
reflections used in refinement
(work/free)
169468
(160994/8474)
31827
(30235/1592)
24734
(23497/1237)
18793
(17682/931)
final R value for all reflections
(work/free) (%)
0.13/0.16 0.16/0.19 0.17/0.19 0.16/0.19
protein residues 1033 268 268 257
water molecules 735 86 64 136
RMSD from ideality: bond lengths (Å) 0.008 0.007 0.007 0.007
RMSD from ideality: bond angles (°) 0.937 0.817 0.817 0.868
Ramachandran plot:c
residues in most favored regions (%) 92.5 92.2 92.2 93.3
residues in additionally allowed
regions (%)
7.5 7.8 7.8 6.7
residues in generously allowed
regions (%)
0.0 0.0 0.0 0.0
residues in disallowed regions (%) 0.0 0.0 0.0 0.0
Mean B factor protein (Å2) d 18.4 45.8 56.3 29.1
Mean B factor ligand (Å2) d - - - 44.9
Mean B factor water molecules (Å2) d 32.2 49.7 56.0 35.6
26  |  Chapter 2
The apo structure was reproduced using different crystallization conditions than those
described by Lukacik et al. [32], leading to a structure of 1.52 Å resolution. In the apo form a
homotetramer is present in the asymmetric unit of the monoclinic space group P 21 (Figure
2.2 A). It exhibits the A2B2 symmetry as described by Lukacik et al. [32], however, in this
new structure the C-terminalus segment is visible. The tetramer is built-up by the interaction
of two identical dimers (A2 and B2) each composed of two monomers. The two dimers A2
and B2 differ in the conformation of the flexible loop, formed by the α-helices αFG1 and
αFG2 (residues 189–212), which is open in A2 and closed in B2. A maximum shift of about 7
Å is observed between the two conformations of the flexible loop, which adjusts the size of
the active site (Figure 2.2). In the dimer A2, the C-terminus of each monomer is inserted into
the wide-open active site of the opposite monomer.
The structure highlights a major hydrophobic area at the interface between two monomers
(Figure 2.3 A). This information, together with the interacting C-terminal tail, raises the
hypothesis that the tetrameric form of this protein is quite stable and might have some
functional meaning. The binding pocket constitutes a second rather hydrophobic region
(Figure 2.3 B). It is not surprising as this protein catalyzes the oxidation of hydrophobic
molecules like E2 and 5-diol.
Figure 2.2: (A) Surface representation of the apoenzyme homo-tetramer (PDB code: 5ICS). (B)
Ribbon representation of the superimposition of the four chains in the apo structure. The two
chains forming dimer B2 are shown in pink shades and the two chains forming dimer A2 are
shown in blue shades. All structural representations were prepared with PyMOL [33].
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Concerning the structural determination of the two C-terminal tails of the dimer A2 of the
apoenzyme the electron density map revealed a quite complicated scenario: It was not clear
which density belonged to which monomer (Figure 2.4 A). Two possible scenarios were
modeled and refined, but both possibilities presented some issues. The first construct was
modeled in a way that the C-terminus of the first monomer interacts with the binding site of
the second monomer and vice versa (Figure 2.4 B). Thereby, the model fits well to the
electron density map and it was possible to explain most of the density. However, it was not
possible to build the side chains for Cys255 and Lys256 because they would clash with the
backbone of the C-terminus of the other monomer. Furthermore, there is no evidence of a
second conformation of the C-terminal tail. The second construct was modeled in a way that
the C-terminal tail of a monomer reverts back to its own binding pocket. However, after
Figure 2.3: Surface representation of one monomer of the apoenzyme (PDB code: 5ICS).
Hydrophobic amino acids are colored in blue and hydrophilic in white. (A) View on the interface
between two monomers. (B) The binding site area is circled in red.
Figure 2.4: Crystal structures of apo 17β-HSD14 without (A, PDB code: 5ICS) and with two different
models of the C-terminus (B and C, see main text). The two monomers of the protein are shown in
light blue and dark blue, respectively. The amino acids from Gly252 to Ser258 are shown as sticks.
The 2Fo-Fc electron density is shown as blue mesh at a contour level of 1 σ. The Fo-Fc difference
electron density is shown as green and red mesh at contour levels of 3 σ and -3 σ, respectively.
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refinement, the model did not fit well to the electron density, and also showed the clash of the
sidechain of Lys256 with the C-terminus of the other monomer (Figure 2.4 C). In addition, to
achieve the second construct, the geometries of some amino acids were unfavorable.
Therefore, we decided that the first motife, where one C-terminus enters into the binding site
of the other monomer, is the most likely conformation and consequently we decided to
model this construct. However, we could not model Cys255 and Lys256 for one of the
monomers and Gly254 and Cys255 for the other monomer.
In the case of the holo structure, both variants of the protein S205 and T205 were co-
crystallized in complex with NAD+. Both variants contain only one monomer in the
asymmetric unit in the cubic space group I23. Here, the tetramer is formed by four identical
molecules. The PISA calculation [135] with a total buried area of 6610 Å2 for each monomer
and the analysis by native ESI mass spectrometry (result not shown) support that the
tetrameric form is the assembly present in solution. Unfortunately, due to the high solvent
content (61.5%, calculated with the Matthews Probability Calculator[136],[137]), these
crystals are characterized by a lower resolution (1.84 – 2.00 Å). No structural differences
between the S205 and the T205 holoenzymes were evident from their 3D-structures as both
isoforms were identical, with the mutated amino acid being the only exception (Figure 2.5 B).
The flexible loop (αFG1 and αFG2) is fixed in a closed conformation, which reduces the
volume of the binding pocket (Figure 2.5 A). The active site cleft is also downsized by the
presence of Tyr253’ belonging to the C-terminus from the adjacent crystal mate (Figure 2.6
A). The C-terminal part of the monomer is completely defined in the density and reveals a
different conformation compared to the dimer A2 of the apo structure: It is not entering the
binding pocket of the monomer but it is arranged around the surface of the bordering
monomer (Figure 2.6 B). No further major conformational changes are observed.
Figure 2.5: (A) Ribbon representation of the superimposed full length binary complexes of variant
S205 (green) and a chain of the apoenzyme in the open conformation (blue). (B) Ribbon
representation of the superimposed binary complexes of variant S205 (green) and T205 (gray)
together with bound NAD+; the catalytic triad and the residues 205 are shown as stick model. The
C-terminal tail is hidden for an easier comparison (S205 PDB code: 5JSF, T205 PDB code: 5JS6).
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In the structure of the E1-protein-NAD+ ternary complex a single monomer is present in the
asymmetric unit. However, the generation of the symmetry equivalent molecules reveals that,
also for this structure, the protein monomers interact with each other in a similar way as for
the holo form, generating a tetramer via crystal symmetry. The C-terminal tail of the complex
with E1 is very flexible and the amino acids from Ser258 to Ile268 are not defined by the
electron density map. Only Pro269, Ser270 and Gly271, which are stabilized by a contact with
the asymmetrical equivalent molecule, can be seen. A backbone comparison between the holo
form and the ternary complexes does not reveal any differences between the structures. E1 is
located in the steroid binding pocket (Figure 2.7 A) that is still downsized by the presence of
Tyr253’. The substrate binding site has a conical shape, with the catalytic triad being at the
apex of the cone and a wide solvent-exposed opening at the other side.
In all the structures the catalytic triad, composed of Ser141, Tyr154 and Lys158, maintains an
identical geometry. A special attention should be paid to His93, which is stabilized by
Gln148, located in the substrate binding site and close to the catalytic triad because it is not
present in other human SDR 17β-HSDs (Figure 2.7 B). This fact might be exploited to
optimize inhibitor structures in order to achieve specific interactions with 17β-HSD14 and
thereby increasing selectivity toward other human SDR 17β-HSDs.
Figure 2.6: (A) Ribbon representation of the 17β-HSD14 holoenzyme and cofactor NAD+. The
symmetry equivalent molecule containing Tyr253’ is shown in blue on the right hand side. The
cofactor and Tyr253’ are shown as thin lines. (B) Surface representation of the holoenzyme
homotetramer.
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Description of the NAD+, estrone binding modes
Interactions stabilizing the cofactor in 17β-HSD14 are identified for the first time as the
previously described structure did not contain NAD+. The cofactor NAD+ is buried inside the
cofactor binding pocket and is coordinated via H-bond contacts to several amino acids and a
number of crystallographically observed water molecules (Figure 2.8). These interactions are
similar to those previously observed in other 17β-HSDs, for example in 17β-HSD10 [138].
Figure 2.7: (A) Ribbon representation of the 17β-HSD14 (gray) structure as ternary complex. (B)
Close-up view of the substrate binding pocket. The E1 is shown as stick model. The amino acids
and the cofactor are shown as thin lines. The carbon atoms of E1 are colored in light orange. H-
bonds are depicted as black dotted lines.
Figure 2.8: Interaction scheme between NAD+ and 17β-HSD14 (PDB code: 5ICM). Water molecules
are represented in red spheres. H-bond contacts are shown as dotted lines.
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E1, the product of the catalytic reaction, is found to be bound to the active site in an atypical
fashion with its A-ring positioned in van der Waal’s interaction distance to the nicotinamide
portion of the cofactor (Figure 2.9) thus placing the actual 17-reaction center in remote
position relative to the cofactor. No apparent π-stacking interaction of the steroidal A-ring
can be observed with any amino acid. The only H-bond interaction established is between the
A-ring’s hydroxyl group and the hydroxyl of Tyr154 of the catalytic triad (d= 2.5 Å). The
carbonyl group in position 17 does not form any interactions, neither with any amino acid
nor with the solvent. The steroidal C-ring is placed in the hydrophobic cleft formed by
Leu191, Trp192 and Leu195. The methyl group of the E1 is not detectable in the electron
density of the ligand and therefore it was not included in the model. The orientation we do
observe is, however, not unlikely due to the pseudo symmetry of E1 [139], and this also
allows for the possibility that both orientations occur (with the 17 position of E1 binding to
the catalytic triad or pointing away from it). No back reaction of the enzyme was observable
by fluorescence assay. This result could be explained by the slow transformation rate of E1 to
E2 or by the binding of E1 in a non-productive way or by both at the same time. E1 is not
stabilized by many interactions. This is comparable to the binding mode of 3β-hydroxy-5-
androsten-17-dione (PDB code: 1HXH) described by Benach et al. [22] also with the A-ring
close to the catalytic triad. Our structures confirm that the interactions achieved by the
cofactor in 17β-HDS14 are very similar to those established by NAD+ in other SDR enzymes
[22]. Until now it was not possible to obtain a structure in complex with estradiol, however, it
Figure 2.9: Crystal structures of 17β-HSD14 in complex with E1 (PDB code: 5HS6). Estrone is shown
as stick model, the amino acids within a distance of 4.6 Å and cofactor are shown as thin lines. H-
bond distances are depicted as dotted lines. The methyl group of the E1 is not detectable in the
electron density of the ligand and therefore it was not included in the model. Fo-Fc difference
electron density is shown as green mesh at a contour level of 2 σ.
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is predictable that E2, like E1, may not bind so tight in the active site. Together with the weak
binding affinities and low-turnovers measured for E2 and 5-diol, it is questionable if the
preferred substrates of this enzyme are steroids.
2.3 Conclusion
In this work, we have elucidated the first crystal structures of 17β-HSD14 in complex with
ligands. The structure of the binary complex with the cofactor NAD+ differs from the
apoenzyme with respect to the flexible loop (αFG1 and αFG2 segment) which adopts a
unique closed conformation in the presence of NAD+: It is found in either open (A2 dimer)
or closed (B2 dimer) conformation without cofactor. His93 and Gln148, that stabilized each
other in the substrate binding site close to the catalytic triad, are not present in other human
17β-HSDs and might be involved to achieve specific interactions with 17β-HSD14. Binding
of the cofactor appears to induce a shift of the flexible loop, which reduces the size of the
active site and thereby produces the active conformation of the enzyme. The overall structure
and the active site geometry in the ternary complexes with E1 is very similar to those of the
binary complex, with the flexible loop in the same closed state delimiting an elongated and
conical active site. However, further studies are still necessary to investigate the endogenous
substrate and the physiological role of the enzyme in vivo.
2.4 Experimental section
Site directed mutagenesis
The plasmid p11-HSD17B14 coding for the S205 variant of human 17β-HSD14 (sequence
according to NCBI data bank entry Q9BPX1) was obtained from Udo Oppermann,
Structural Genomics Consortium (SGC) Oxford.
The point mutation in order to gain the T205 variant was introduced into the plasmid by
using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) with
the forward primer 5’-CGGACCCGCGTGCGACCATTCGTGAAGGTATGC-3’ and the
reverse primer 5’-GCATACCTTCACGAATGGTCGCACGCGGGTCCG-3’ and following
the manufacturer’s instructions. Sanger sequencing confirmed the correct mutation.
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Expression of the 17β-HSD14 protein (S205 and T205 variants) and
purification
The pET-based vector, p11-Toronto1 (SGC), containing the coding sequences of the human
gene HSD17B14 variants S205 and T205 with a N-terminal 6His-tag and a TEV (tobacco etch
virus) protease cleavage site between the NdeI and BamHI enzyme restriction sites, was used
for the transfection of the competent cells BL21 (DE3) pLysS strain of E. coli. The
transformed cells were grown in 100 mL Terrific Broth medium containing 100 µg/mL of
ampicillin overnight at 37°C. The bacteria were transferred to bigger volume of Terrific Broth
(4 L) and let growing at 37°C until they reached an OD600 of 0.5. Then the temperature was
lowered to 15°C. When the OD600 reached the value of 1.0, the expression was induced with
0.5 mM of IPTG and the cells were incubated for further 20 hours at 15°C. The cells were
harvested by centrifugation and conserved at -80°C one night before proceeding with the
purification. The pellet resulting of 4 L of culture was resuspended in 400 mL of lysing buffer
containing 50 mM Tris, 500 mM NaCl, 0.5 mM TCEP, 5 mM imidazole, 250 mM glucose, 1
mM NAD+, 0.5% (v/v) Triton X-100 and cOmplet Protease Inhibitor Cocktail Tablet ®
(Roche, Germany) with a set pH of 8. The cells were lysed with a high pressure homogenizer
instrument (EmulsiFlex-C5™, AVESTIN, Mannheim, Germany) and then centrifuged at
17700 g for 2h at 4°C.
For the protein purification, the supernatant was applied to a 5 mL Ni-NTA column
(HisTrap FF, GE Healtcare Life Sciences, Freiburg, Germany), which was washed in two
steps. The first washing step was performed with a buffer composed of 50 mM Tris and 1.5 M
NaCl to remove the DNA. The second washing step was performed with a buffer containing
50 mM Tris, 500 mM NaCl, 0.5 mM TCEP, 250 mM glucose, 0.25 mM NAD+ and 21 mM
imidazole to remove the unspecific binding proteins. For the target protein elution, the buffer
of the second washing step was used with an imidazole concentration of 300 mM. The N-
6His-tag was cleaved off by incubation with the TEV protease while the protein mixture was
dialyzed overnight against 4 L of buffer (50 mM Tris, 500 mM NaCl, 0.5 mM TCEP, 250 mM
glucose and 0.25 mM NAD+) at 4°C. For separation of the TEV protease from the 17β-
HSD14, the sample was again run over the 5 mL Ni-NTA column and the flow through
containing the target protein was collected. As additional purification step, a size exclusion
column (Superdex 75 26/60, GE Healtcare Life Sciences, Freiburg, Germany) was used with a
running buffer comprising 50 mM Tris, 500 mM NaCl, 0.5 mM TCEP and 250 mM glucose.
A NAD+ solution 0.25 mM (batch for enzymatic assay) or 0.6 mM (batch for crystallization
studies) was added. The protein solution was flash frozen in liquid nitrogen and stored at -
80°C. The molecular weight of each variant was verified by mass spectrometry in
denaturation condition using a LTQ-FT Ultra mass spectrometer (ThermoFisher, Dreieich,
Germany) equipped with an ESI source (MW S205 = 28641 Da, MW T205= 28655 Da).
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Thermal shift Assay (TSA)
The thermal shift assay was conducted in a 96 well PCR plate (Bio-Rad, Munich, Germany)
using a real-time PCR instrument (iCycler5, Bio-Rad, Munich, Germany). The running
buffer was obtained by the dilution (1:1000) of SYPRO orange dye (Invitrogen, ThemoFisher
Life Technologies, Darmstadt, Germany) in a buffer composed of 50 mM Tris, 0.5 M NaCl
and 0.5 mM TCEP, pH 8.0. For the protein stability study, the running buffer was mixed with
different additives (20% glycerol, 10% MPD, 10% PEG 400, 10% ethylene glycol, 250 mM
glucose or 0.25 mM NAD+). For the protein complexes, a concentration of 2.5% of DMSO
(reference measurement) or a stock solution in pure DMSO of compound 2, estrone, or
estradiol was added to the running buffer containing 250 mM glucose and 0.25 mM NAD+
(final ligand concentration of 0.25 mM and final DMSO concentration of 2.5%). A protein
concentration of 2.6 µM was used (3 µL) and the different solutions were added to a final
volume of 40 µL.
Fluorimetric assay
The activity assay was based on measuring the fluorescence of the NADH formed. The
oxidation of E2 into E1 in presence of NAD+ and purified 17β-HSD14 was followed.
Fluorescence spectra were recorded on a Tecan Saphir 2. NADH fluorescence emission was
measured at 496 nm following excitation at 340 nm. The slit width for excitation was 7 nm
while that for emission was 15 nm. The assay was performed in 100 mM phosphate buffer at
pH 8.0, mixed with estradiol in DMSO (32 µM) and NAD+ (1.5 mM) to reach a final DMSO
concentration of 0.05%. The enzymatic reaction was started by addition of the pure protein
(1 mg/mL, 3.0 µM) and measured continuously for 15 min at 25°C. Reactions were
performed in 200 µL volumes. The assay was run in 96 well-plates in duplicate in three
independent experiments. A linear relationship between product formation and reaction
time was established. The slope of the reaction, representing the velocity of the NADH
formation, was quantified. For each new batch of protein, a control experiment was run
without E2 to assess the absence of activity in absence of substrate.
Determination of kinetic constants
For the determination of the kinetic parameters the substrate concentration was varied at
least between 12% and 250% of the estimated Km value. Kinetic constants were calculated
from the initial velocity data by direct fitting curves as Hanes Woolf plot.
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Protein crystallization
The activity of the protein was proven before use in each crystallization study. The
crystallization of the apo form as well as the cocrystallization of the holoenzyme and of 17-
HSD14 in complex with E1 were performed by sitting drop vapor diffusion technique.
Initially, an automatized crystallization screening of 1248 conditions was performed
(MarXtal, University of Marburg).
For the apo structure (S205), 0.1 µL of protein solution (10 mg/mL) were combined with an
equal volume of mother liquor having the composition: 0.1 M sodium acetate, 30% (w/v)
PEG 4000, 0.2 M ammonium acetate, 20% glycerol, pH 4.60. After growing for 5 weeks at
18°C, crystals were harvested, exposed to the mother liquor solution with the addition of 20%
glycerol for 30 seconds and finally flash frozen with liquid nitrogen.
The two isoforms (S205 and T205) of the holoenzyme were crystallized by combining 2 µL of
a solution containing protein (9.5 mg/mL) and 0.6 mM NAD+ with 2 µL of a buffer
composed of 0.1 M HEPES and 3.3 M sodium formate, pH 7.00. Over a time period of two
weeks at 18°C, the crystals were grown, harvested and flash frozen using a cryo buffer made
of mother liquor with 20% (w/v) PEG400.
A solution containing 0.1 M CHES, 1 M tri-sodium citrate, 0.4 mM E1 and 1% DMSO, pH
9.5, was mixed with the protein solution (9.5 mg/mL, T205), containing 0.6 mM NAD+, in a
ratio 1:1 to obtain the protein-estrone complex. After growing for 4 weeks at 18°C, the
crystals were exposed to a cryo buffer for 3 sec composed of 0.1 M CHES, 1 M tri-sodium
citrate, 1% DMSO, 20% (w/v) glucose, pH 9.5, containing 0.4 mM of estrone, and
subsequently flash frozen in liquid nitrogen.
Data collection and processing
The data collection of protein-estrone (PDB code: 5HS6) was achieved at Elettra beamline
XRD1 in Trieste, Italy at a wavelength of 1Å and a temperature of 100 K on a silicon Pilatus
2M pixel detector. For the holo structure of both variants (S205 PDB code: 5JSF; T205 PDB
code: 5JS6), the data collection was performed at beamline ID23-1 of the European
Synchrotron Radiation Facility (ESRF) [140] in Grenoble, France at a wavelength of 0.97242
Å and a temperature of 100K on a silicon Pilatus 6M pixel detector. The diffraction data of
apo form dataset (PDB code: 5ICS) was collected on BL 14.1 operated by the Helmholtz-
Zentrum Berlin (HZB) at the BESSY II electron storage ring (Berlin-Adlershof, Germany)
[141] at a wavelength of 0.9184 Å and a temperature of 100 K on a silicon Pilatus 6M pixel
detector. All datasets were indexed, processed and scaled with XDS [142].
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Structure determination and refinement
All structures were determined by molecular replacement with the program PHASER MR
[143] from the CCP4 suite [132]. The structure 5EN4 was used as a search model. In the
refinement, a subset corresponding to 5% of all reflections were omitted during refinement
and used for the calculation of Rfree. Model building was achieved in COOT [144] and
refinement using PHENIX.refine version 1.10.1-2155 [145]. Ligands SMILE codes were
created with Molinspiration v2014.11[146] and built with the Grade Web Server [147], which
was also used for energetically minimization and restraint generation. Cartesian simulated
annealing, applying default parameters, was used as a first refinement step. Subsequently,
refinement of XYZ coordinates, occupancies and individual B-factors were alternated with
structural adaption in COOT [144] until the model was readily built and gave the best
possible explanation of the electron density. For the apo structure (PDB code: 5ICS), the
temperature factors of all atoms, except hydrogen atoms, were refined anisotropically with
additional NCS restraints. TLS refinement was performed for the protein-complex structures
(estrone complex PDB code: 5HS6) and the both variants of the holoenzyme (S205 PDB
code: 5JSF, T205 PDB code: 5JS6) with appropriate TLS groups from the TLSMD web
server[148],[149]. The model of the apo- and holo structure a were refined with hydrogens
automatically added by PHENIX.refine.
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First Structure-Activity Relationship of 17β-Hydroxysteroid
Dehydrogenase Type 14: Nonsteroidal Inhibitors and
Crystal Structures in Complex with the Enzyme
Introductory remarks
Parts of the following chapter have been published in the Journal of Medicinal Chemistry in
2016. The preliminary inhibition assay was done by Dr. Gabriele Möller. Fluorescence-based
assays were designed and performed by Dr. Sandrine Marchais-Oberwinkler in collaboration
with Florian Braun. The synthesis of the compounds and their characterization was carried
out by Florian Braun. The expression and the purification of the 17β-HSD14, the
computational modeling studies, the TSA assay and the crystallization studies and the
elucidation of the first crystal structures of the protein-inhibitor complexes were established
and performed by the author of this thesis. Furthermore, the author significantly contributed
to the discussion and to the writing of the manuscript in collaboration with Florian Braun
and Dr. Sandrine Marchais-Oberwinkler.
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3.1 Introduction
Human 17β-hydroxysteroid dehydrogenase type 14 (17β-HSD14), also called DHRS10 and
retSDR3, is an oxido-reductase belonging to the SDR (Short-chain Dehydrogenase-
Reductase) family [11, 32]. In vitro, the enzyme oxidizes the hydroxyl group at position 17 of
estradiol (E2) and 5-androsten-3β,17β-diol (5-diol) in presence of the cofactor NAD+,
however, in vivo, its natural substrate is still unknown.
While Sivik et al. [103] described a broad distribution pattern of 17β-HSD14 across various
tissues based on immunohistochemistry studies, Northern blotting experiments showed that
the enzyme is predominantly expressed in the brain, liver and placenta [32] as well as in the
kidney [100]. Furthermore, immunofluorescence studies revealed a cytosolic localization
[32].
In order to understand the function of 17β-HSD14, the enzyme needs to be further
characterized. Inhibitors are useful chemical tools, which can be used not only to characterize
the binding site of an enzyme but also to get insight into the physiological role of the latter
upon in vivo administration. No inhibitor has been reported for this enzyme.
The crystal structure of the human 17β-HSD14 has been determined recently as holoenzyme
(PDB code: 5JS6 and 5JSF) and as ternary complex with estrone (E1) (PDB code: 5HS6). In
solution, 17β-HSD14 is a tetramer.[126] The binding cavity was shown to be rather lipophilic
with a conical shape. The substrate active site is narrow in the vicinity of the catalytic triad
and is solvent exposed at the other end. Tyr253’ from the C-terminal chain of the adjacent
unit in the tetramer reduces the size of the active site.
Up to now 14 different 17β-HSD subtypes have been reported [34]. 17β-HSD1 and 17β-
HSD2, the two best characterized subtypes, predominantly catalyze the oxidation and
reduction of estrogens and androgens. Inhibitors of these two enzymes have already been
reported [10, 52, 124, 150–160]. While 17β-HSD1 is a cytosolic enzyme and shows a
reductive activity in vivo (activation of estrogens), 17β-HSD2 is membrane-bound and
catalyzes the oxidation of estrogens and androgens to their less potent analogues similarly to
17β-HSD14. However, 17β-HSD2 and 17β-HSD14 differ in their tissue distribution pattern
since in contrary to 17β-HSD14, 17β-HSD2 is not present in the human brain temporal
lobe [161]. The presence of 17β-HSD14 in the brain might indicate that this enzyme is
involved in the regulation of active estrogens and androgens in this organ [32].
The goal of this work was to identify the first 17β-HSD14 nonsteroidal inhibitors and to
optimize their structures, which led to highly active compounds. The inhibitor optimization
was performed following a ligand-based approach. The synthesis and biological evaluation of
highly active compounds with a nonsteroidal scaffold together with five new crystal
structures of the ternary complexes are reported. Analysis of the crystal structures of the
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ternary complexes revealed the location of the inhibitor binding sites as well as the resulting
protein-inhibitor interactions and a complex pattern of hydrogen bonds (H-bonds)
contributing to the strong affinity of these compounds to the enzyme. The physicochemical
properties of the new inhibitors as well as selectivity considerations were also addressed.
3.2 Results
Design of 17β-HSD14 inhibitor candidates
Although 17β-HSDs belong to the same superfamily they share a low overall sequence
identity (between 15 and 30 %). Nonetheless, considering the fact that 17β-HSD1 and 17β-
HSD2 catalyze the same reaction as 17β-HSD14, the substrate binding site of the three
enzymes should exhibit a high structural similarity. Based on this idea, it was assumed that
some inhibitors developed for 17β-HSD1 and 17β-HSD2 should also bind to 17β-HSD14 and
that a common scaffold could be used as starting point, to optimize them for 17β-HSD14
binding. In a first screen, a small library of 34 17β-HSD1 and 17β-HSD2 inhibitors, chosen
on the basis of structural diversity (Figure 3.1), was tested for 17β-HSD14 inhibitory activity
using a radioactive displacement assay. This assay was performed with the recombinantly
Figure 3.1: Scaffold of inhibitors from a 17β-HSD1 and 17β-HSD2 library tested for 17β-HSD14
inhibitory activity.
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expressed enzyme in a bacterial suspension since the pure protein was not available at that
time. Thereby sets of active and inactive compounds were identified.
While the series of tested naphthalenes A and thiophene amides B contained mostly inactive
compounds, the dihydroxyphenylbenzenes C, -thiophenes and -thiazoles D showed examples
of low to moderate inhibitory activity against 17β-HSD14 (between 10% and 45% inhibition
at 1 µM). In addition, some of the latter derivatives were also reported to possess very high
potency for 17β-HSD1 and/or 17β-HSD2 (IC50 in the low nM range), which might lead to
difficulties achieving high selectivity for 17β-HSD14. These parent scaffolds were therefore
not considered for further optimization. Some members of the pyridine ketone class E also
showed remarkable inhibitory activity for 17β-HSD14, paralleled by rather low or moderate
activity against 17β-HSD1 (Table 3.1, compound 3.2), which rendered this class as promising
scaffold for further investigations. They were therefore chosen as a starting point for the
development of new 17β-HSD14 inhibitors.
Table 3.1: Most interesting compounds identified in the first screen.
Cmpd Structure
Inhibition of
17β-HSD14
% Inh. @ 1 mMa
Inhibition of
17β-HSD1
IC50 (µM)b
Inhibition of
17β-HSD2
IC50 (µM)c
3.2 62% 1.27  0.10
3.3 0% 5.48  0.26
3.4 19% 0.29 0.04
3.5 32% 19.65 0.26
a Recombinant 17β-HSD14 enzyme, bacterial suspension, substrate [3H]-E2 [18.3 nM], NAD+ [7.5 mM], mean value of
3 determinations; standard deviation < 10 %.
b Placental 17β-HSD1 enzyme, cytosolic fraction, substrate [3H]-E1 + E1 [500 nM], NADH [0.5 mM], mean value of at
least 3 determinations; standard deviation < 20 %.
c Placental 17β-HSD2 enzyme, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value of
at least 3 determinations; standard deviation < 20 %
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The most interesting hits identified in the preliminary screen are listed in Table 3.1. The
compounds can be categorized into 2,5- (3.2, 3.3) and 2,6-substituted (3.5) pyridine ketones
and the 1,4-substituted phenyl (3.4). In the 2,5-compound class, 3.2 and 3.3 (62% inhibition
at 1 µM vs 0%) differ by the presence/absence of a fluorine atom in ortho position to the OH
group of the C-ring, suggesting the importance of this atom for inhibitory activity.
Furthermore, comparison of 3.2 with 3.4 (62% inhibition at 1 µM vs 19%) shows that the
pyridine core B is more potent than the phenyl analog, pointing toward the importance of the
nitrogen atom in the B-ring for activity. Concerning the 2,6-compound class, comparison of
3.5 with 2,5-substituted 3.3 (32% inhibition at 1 µM vs 0%) shows that moving the A-ring
from 5- to 6-position leads to a gain in activity.
Furthermore, considering the selectivity aspect, the poor inhibitory activity of the 2,6-
substituted 3.5 toward 17β-HSD1 (IC50= 19.65 µM), compared to the 2,5-substituted analog
3.3 (IC50= 5.48 µM) suggests that the 2,6-substitution pattern might improve selectivity for
17β-HSD14 toward 17β-HSD1. Selectivity against 17β-HSD2 does not become obvious with
the set of studied test compounds. Consequently, the 2,6-pyridine ketone class was selected
for optimization and the derivatives, with modification at the A-ring as well as at the C-ring
by substituents with different properties. Overall, 35 compounds were synthesized and their
synthesis pathways are described in the thesis of Florian Braun. The obtained compounds are
listed in Table 3.2. Special attention was paid to the physicochemical properties of the
designed compounds in order to focus on compounds which should have a promising
bioavailability profile according to the Veber rules [162] and the Lipinski rule of 5 [163].
Calculation of physicochemical parameters
For each synthesized compound (Table 3.2), the molecular weight (MW) was calculated to be
in the range of 300 to 400 g/mol, aside from the trisubstituted compounds 3.31-3.33 with a
slightly higher MW. The clogP was calculated in silico (using Molinspiration [146]) and
turned out to be below 5 except for 3.31-3.33. The total polar surface area (tPSA), the
number of rotational bonds as well as the number of H-bond donors and acceptors fulfill the
Veber rules [162] and the Lipinski rule of 5 [163]. In addition, considering the potential role
of the enzyme in the brain, the capability of the inhibitors to cross the blood–brain barrier
(BBB) should also be taken into account. The physicochemical properties to be met by
compounds showing a good BBB penetration are described by Pajouhesh and Lenz [164].
These criteria are matched for most of the synthesized compounds especially for 3.17 and
3.28 as examples. The solubility range of most of the compounds was also determined by
mixing several concentrations of the studied inhibitors in 100 mM phosphate buffer at pH
7.4 and analyzing its precipitation status at different time points (0, 1, 2 and 24 h). The pKa
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values of the OH groups at the A- and at the C-ring were determined in silico for all
compounds (using Marvin Sketch), showing that the introduction of a fluorine group in
ortho position to a OH group decreases the pKa value by about one unit (e.g. pKa OH/C-ring:
8.8 for 3.7 and 7.8 for 3.8). The physicochemical parameters are summarized in Table 3.2.
The chemical formulas of the listed derivatives are given in the following Table 3.3-3.7.
Table 3.2: Physicochemical property of the synthesized inhibitors.
Cmpd MWa clogPa cpKab tPSAa solubility
Rotat.
bondsa HDa HAa
3.1 325 3.02 1.85 (N)
7.71(O/C-ring)
12.19(4-O/A-ring)
8.74(3-O/A-ring)
90.65 ≥ 200 µM 3 3 5
3.6 323 4.35 1.94(N)
7.76 (O/ C-ring)
9.92 (O/A-ring)
70.42 100-200 µM 3 2 4
3.8 327 3.86 1.82(N)
7.58 (O/C-ring)
8.23 (O/A-ring)
70.42 100-200 µM 3 2 4
3.9 327 3.83 0.78(N)
7.46 (O/C-ring)
8.07 (O/A-ring)
70.42 ≥ 200 µM 3 2 4
3.10 343 3.54 0.69 (N)
6.30(2-O/C-ring)
10.83(3-O/C-ring)
7.76(O/A-ring)
90.65 ≥ 200 µM 3 3 5
3.11 345 3.93 0.67 (N)
6.95(O/C-ring)
7.84(O/A-ring)
70.42 - 3 2 4
3.12 325 3.20 0.69 (N)
7.12(2-O/C-ring)
11.84(3-O/C-ring)
7.88(O/A-ring)
90.65 ≥ 200 µM 3 3 5
3.13 309 3.90 0.70 (N)
6.95(O/C-ring)
7.84(O/A-ring)
70.42 25-50 µM 3 2 4
3.14 341 2.93 0.70 (N)
7.09(2-O/C-ring)
12.94(3-O/C-ring)
8.81(4-O/C-ring)
7.83(O/A-ring)
110.88 ≥ 200 µM 3 4 6
3.15 341 3.14 0.60 (N)
7.06(2-O/C-ring)
13.57(3-O/C-ring)
8.52(4-O/C-ring)
7.78(O/A-ring)
110.88 ≥ 200 µM 3 6 4
3.16a 307 4.26 1.82 (N) 39.20 < 3.13 µM 4 0 3
3.16 293 3.99 1.82 (N)
7.76(O/C-ring)
50.19 25-50 µM 3 1 3
3.17 336 4.06 1.41 (N)
7.76(O/C-ring)
4.85(N/A-ring)
53.43 25-50 µM 4 1 4
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Table 3.2 (continued)
3.18 309 3.48 1.73 (N)
7.75(O/C-ring)
9.24(O/A-ring)
70.42 100-200 µM 3 2 4
3.19 307 2.85 1.64 (N)
7.22(2-O/C-ring)
11.84(3-O/C-ring)
9.23(O/A-ring)
90.65 ≥ 200 µM 3 3 5
3.20 323 4.35 1.81 (N)
7.75(O/C-ring)
9.59(O/A-ring)
70.42 50-100 µM 3 2 4
3.21 311 4.15 1.88 (N)
7.76(O/C-ring)
50.19 < 3.13 µM 3 1 3
3.22 346 4.75 1.82 (N)
7.76(O/C-ring)
50.19 < 3.13 µM 3 1 3
3.23a 335 4.48 2.03(N) 48.43 < 3.13 µM 5 0 4
3.23 327 3.93 2.04(N)
7.48 (O/C-ring)
8.08 (O/A-ring)
70.42 100-200 µM 3 2 4
3.24 217 2.10 2.46(N)
7.76 (O/C-ring)
50,19 ≥ 200 µM 2 1 3
3.25 299 3.57 1.54 (N)
7.76(O/C-ring)
50.19 6.25-12.5 µM 3 1 3
3.26 300 3.45 3.82 (N)
7.76(O/C-ring)
53.43 100-200 µM 3 1 4
3.27 315 2.43 2.54 (N)
6.72(O/C-ring)
7.80(O/A-ring)
56.67 25-50 µM 3 1 5
3.28 309 4.19 7.76(O/C-ring) 59.42 100-200 µM 4 1 4
3.29 324 4.25 7.26(2-O/C-ring)
11.88(3-O/C-ring)
8.05(O/A-ring)
77.75 50-100 µM 3 3 4
3.30 341 1.57 6.95(2-O/C-ring)
11.77(3-O/C-ring)
7.71(O/A-ring)
103.2 ≥ 200 µM 3 3 6
3.31 429 6.46 1.68 (N)
7.75(O/C-ring)
10.08(O/A-ring)
9.45(O/D-ring)
90.65 100-200 µM 4 3 5
3.32 433 5.95 1.52 (N)
7.65(O/C-ring)
9.87(O/A-ring)
8.39(O/D-ring)
90.65 ≥ 200 µM 4 3 5
3.33 357 3.51 0.69 (N)
7.46(O/C-ring)
8.06(O/A-ring)
14.60(O-CH2-)
90.65 ≥ 200 µM 4 3 5
acalculated with Molinspiration [146]
bcalculated with Marvin Sketch 15.9.14
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Inhibition of 17β-HSD14 determined with a fluorimetric assay
A fluorimetric assay, quantifying the NADH fluorescence formed during the catalytic
reaction, was used to evaluate the inhibitory activity of the synthesized compounds. In the
assay, the purified recombinant human enzyme, E2 as substrate, NAD+ as cofactor and the
inhibitors were used. Due to the low sensitivity of the assay, a high enzyme concentration
(between 3.0 µM and 3.5 µM) and a high concentration of substrate E2 (32 µM) was
necessary. The results are expressed as percent of inhibition measured at an inhibitor
concentration of 2 µM. The inhibition constant Ki was experimentally determined using an
inhibitor concentration ranging from 2.6 µM to 100 µM or 260 nM to 10 µM, depending on
the inhibitor potency and solubility. As the inhibitor and protein concentrations were in the
same range, no classical kinetic analysis could be applied [165],[166]. The results were
analyzed applying the quadratic Morrison equation for tight binding [167]. When the
inhibitor was not sufficiently soluble at the required concentration, no Ki could be
determined and the results were expressed as percent inhibition at the highest soluble
concentration of the inhibitor. The results are shown in Tables 3.3-3.6. Compounds showing
less than 10% inhibition at a concentration of 100 µM were considered to be inactive.
Aggregation
It was verified that the compounds did not aggregate or induce aggregation of the protein by
testing the compounds with and without detergent (0.5% v/v Tween 20). No significant
changes in the inhibitor activity could be noticed at the different conditions.
17β-HSD14 inhibitory activity
Starting from the hit 2,6-pyridine ketone 3.5, modifications were undertaken at the C-ring
and A-ring by introduction of different substituents (R, R’, Chart 3.1). These substituents
were selected to represent different electronic properties: Electron donating or electron
withdrawing, H-bond donor, H-bond acceptor, lipophilic and hydrophilic. Changes were
Chart 3.1: Modifications undertaken on the hit compound 3.5.
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also performed at the central B-ring by replacement of the nitrogen by a carbon or a N-oxide
moiety. An additional phenyl ring (D) with various substituents (R’’) was introduced in 5-
position or a hydroxymethyl group (R’’’) in 4-position leading to trisubstituted derivatives.
Substituent variations on the C-ring
In the first inhibitor screen it could be shown, that in the 2,5-pyridine class (Table 3.1) the
addition of a fluorine atom in ortho position to the hydroxyl group at the C-ring (3.2
compared to 3.3) resulted in a notable increase in potency of the inhibitor. The analogous
fluorinated compound 3.6 (2,6-substituted pyridine) was therefore synthesized and proved to
bind 10 times stronger compared to the reference compound 3.5 (Ki = 245 nM for 6 vs 26 nM
for 5, Table 3.3). The affinity enhancement caused by the 4-F substituent at the C-ring could
Table 3.3: 17β-HSD14 inhibitory activity and binding constant (Ki) of 2,6-pyridine derivatives with
different substituents at the C-ring.
Compound R1 R2 R3 R4 R5
17β-HSD14
% inhibition
@ 2 µMa Ki (nM)a
3.5 3-Me 4-OH H 3-OH H 34 245±21
3.6 3-Me 4-OH H 3-OH 4-F 60 26±3
3.7 3-F 4-OH H 3-OH H 16 467±91
3.8 3-F 4-OH H 3-OH 4-F 67 36±5
3.9 2-F 3-OH H 3-OH 4-F 72 13±5
3.10 2-F 3-OH 2-OH 3-OH 4-F 76 11±3
3.11 2-F 3-OH 2-F 3-OH 4-F 72 9±3
3.12 2-F 3-OH 2-OH 3-OH H 65 64±4
3.13 2-F 3-OH 2-OH H H 66 135±2
3.14 2-F 3-OH 2-OH 3-OH 4-OH 25 405±177
3.15 2-F 3-OH 2-OH 3-OH 6-OH 11 796±122
3.16a H H H 3-OMe 4-F ni nd
3.16 H H H 3-OH 4-F 57 63±3
a Recombinantly expressed and purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+
[1.2 mM], 25°C, mean value of at least two independent experiments each with three technical repeats; ni: no
inhibition (<10% inhibition at 100 µM), nd: not determined.
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also be observed using another substitution pattern at the A-ring: 3-F/4-OH (Ki = 467 nM for
7 vs 36 nM for 8, Table 3.3).
The influence of the substituent pattern used for the C-ring was subsequently studied in
more detail with compounds containing a 2-F/3-OH phenyl A-ring motif (compounds 3.9-
3.15, Table 3.3). Addition of a 2-OH or a 2-F to the 3-OH/4-F at the C-ring resulted in
equipotent compounds (Ki= 13 nM; 11 nM and 9 nM, respectively for 3.9, 3.10 and 3.11).
Replacing the 3-OH/4-F at the C-ring (3.9) by a 2-OH/3-OH motif (12; Ki= 64 nM) led to a
slight decrease in affinity. Addition of a 4-OH group (3.14, Ki= 405 nM) or of a 6-OH group
at the C-ring (3.15, Ki= 796 nM) resulted in a strong decrease in activity.
The presence of the 3-OMe group at the C-ring (3.16a, inactive at a concentration of 100
µM) was detrimental for the inhibitory activity compared to the 3-OH analogue (3.16, Ki= 63
nM).
Substituent variations on the A-ring
2,6-Pyridine derivatives containing the C-ring motif (3-OH/4-F or 2-OH/3-OH) were
synthesized with different substituents at varying positions of the A-ring (Table 3.4).
Compounds with one substituent in the 3- or 4-position (3.17: 3-NMe2, Ki= 7 nM; 3.18: 3-
OH, Ki= 7 nM; 3.19: 3-OH, Ki= 44 nM and 3.21: 4-F, Ki= 221 nM) showed that their
substitution with a polar moiety at 3-position (3.17, 3.18, 3.19) led to stronger binding
compared to the one with a lipophilic group at 4-position (3.21). This effect is confirmed in
case the A-ring is disubstituted (3.22) with the 3-Cl and 4-F substituents, which led to a
compound with a similar binding constant as the mono 4-F derivative 3.21 (Ki= 190 nM and
221 nM for 3.22 and 3.21, respectively). These lipophilic groups exerted a detrimental effect
on the binding affinity, which was lower compared to the unsubstituted phenyl (3.16, Ki= 63
nM).
The compounds with two substituents in 2/3- or in 3/4-positions of the A-ring (3.1: 3-OH/4-
OH, Ki= 7 nM; 3.6: 3-Me/4-OH, Ki= 26 nM; 3.8: 3-F/4-OH, Ki= 36 nM; 3.9: 2-F/3-OH, Ki=
13 nM) had similar binding constants with the exception of 3.20 (3-OH/4-Me, Ki= 47 nM)
with a slightly decreased affinity. No significant difference in activity could be observed
between mono- and disubstituted compounds at the A-ring as long as a 3-OH or a 4-OH
moiety was present. In summary, the best affinities were achieved in the presence of a 3-OH
or a 3-NMe2 moiety at the A-ring.
In the 2,5-pyridine class, the affinity of 3.23 (Ki= 17 nM) with a 3-F/4-OH substitution
pattern at the A-ring was similar to that of compound 3.2 (Ki= 24 nM) with a 3-Me/4-OH
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substitution pattern at the A-ring and fell into the same range of compounds in the 2,6-class.
Furthermore, the methoxy derivative 3.23a was less active compared to the hydroxylated
analogue 3.23 as similarly observed for compound 16a.
Table 3.4: 17β-HSD14 inhibitory activity and binding constant (Ki) of pyridine derivatives with
different substituents at the A-ring.
Compound
Position
A-ring R1 R2 R3 R4
17β-HSD14
% inhibition
@ 2 µM a Ki (nM)a
3.1 6 3-OH 4-OH 3-OH 4-F 69 7±1
3.2 5 3-Me 4-OH 3-OH 4-F 60 24±9
3.6 6 3-Me 4-OH 3-OH 4-F 60 26±3
3.8 6 3-F 4-OH 3-OH 4-F 67 36±5
3.9 6 2-F 3-OH 3-OH 4-F 72 13±5
3.12 6 2-F 3-OH 2-OH 3-OH 65 64±4
3.16a 6 H H 3-OMe 4-F ni nd
3.16 6 H H 3-OH 4-F 57 63±3
3.17 6 3-NMe2 H 3-OH 4-F 57 7±1
3.18 6 3-OH H 3-OH 4-F 65 7±2
3.19 6 H 3-OH 2-OH 3-OH 51 44±3
3.20 6 3-OH 4-Me 3-OH 4-F 64 47±7
3.21 6 H 4-F 3-OH 4-F 37 221±46
3.22 6 3-Cl 4-F 3-OH 4-F 44 190±45
3.23a 5 3-F 4-OMe 3-OMe 4-F 12 57%±6b
3.23 5 3-F 4-OH 3-OH 4-F 61 17±5
a Recombinantly and expressed purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+
[1.2 mM], 25°C mean value of at least two independent experiments each with three technical repeats; b%
inhibition @ 22,2 µM
Variation of the A-ring
In order to investigate the role of the phenyl A-ring, pyridine derivatives lacking the A-ring
(3.24) or derivatives decorated with different heterocycles in 6-position of the B-ring (3.25-
3.28) were designed (Table 3.5). Comparison of compound 3.24 (Ki= 1541 nM) with 3.16
(Ki= 63 nM) showed a decrease in activity. The nonaromatic piperidine 3.26 (Ki= 407 nM)
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was also a weaker binder, while the 4-methylpiperazine 27 (Ki= 190 nM) showed a similar
inhibitory activity, when compared to 3.16.
Table 3.5: 17β-HSD14 inhibitory activity and binding constant (Ki) of 2,6-pyridine derivatives with
different substituents in 6-position of the pyridine ring (different A-rings).
Compound R
17β-HSD14
% inhibition
@ 2 µMa Ki (nM)a
3.16 phenyl 57 63±3
3.24 H 13 1541±146
3.25 thiophen-3-yl 50 97±28
3.26 piperidin-1-yl 43 407±16
3.27 4-methylpiperazin-1-yl 31 190±21
3.28 -O-phenyl 55 50±0
a Recombinantly expressed purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2 mM],
25°C mean value of at least two independent experiments each with three technical repeats
Variations on the B-ring
In the design section it was reported that in the 2,5-pyridine class the central ring played a
crucial role in affinity. This aspect was also investigated in the 2,6-class by the synthesis of the
phenyl analogue 3.29 and the corresponding N-oxide 3.30 (Table 3.6). Comparison of the
biological data of these compounds with the pyridine analogue 3.12 (Ki= 64 nM) showed that
both, the phenyl derivative 3.29 (Ki= 21 nM) and the N-oxide derivative 3.30 (Ki= 132 nM)
had a similar affinity as the pyridine 3.12.
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Table 3.6: 17β-HSD14 inhibitory activity and binding constant (Ki) for compounds with different B-
rings.
Compound X
17β-HSD14
% inhibition
@ 2 µMa Ki (nM)a
12 N 77 64±4
29 C 60 21±2
30 N+-O- 47 132±13
a Recombinantly expressed and purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2
mM], mean value of at least two independent experiments each with three technical repeats
Trisubstituted pyridines
Based on the hypothesis that the C-ring and the carbonyl group of both the 2,5- and 2,6-
pyridines achieve the same interaction as a consequence of binding in the same area, the
similarity in affinity of the 2,5-derivative 3.23 (Ki= 17 nM) and the 2,6-derivative 3.8 (Ki= 36
nM, Table 3) suggested that the available space for binding the additional ring must be large,
even tolerating an A-ring attached to the 5- or 6-position. Trisubstituted pyridines
combining substitutions at the 5- and 6-positions were therefore synthesized (3.31 and 3.32,
Table 3.7). These trisubstituted compounds turned out to be equipotent (3.31, Ki= 9 nM;
3.32, Ki= 15 nM) with a similar affinity compared to the disubstituted derivatives 3.6 and
3.23.
Introducing a hydroxymethyl group at the 4-position of the B-ring led to a slight decrease in
activity (3.33 Ki= 86 nM compared to 3.9 Ki= 13 nM, Table 3.7).
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Table 3.7: 17β-HSD14 inhibitory activity and binding constant (Ki) of pyridine derivatives with an
additional D-ring or a substituent in 4-position.
Compound R1 R2
17β-HSD14
% inhibition
@ 2 µMa Ki (nM)a
3.6 60 26±3
3.23 61 17±5
3.31 3-Me 4-OH 71 9±4
3.32 2-F 3-OH 63 15±4
3.33 - - 47 86±7
a Recombinantly and expressed purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2
mM], mean value of at least two independent experiments each with three technical repeats
Pan Assay Interference Compounds [168]
All the biologically evaluated compounds were tested in silico for nonspecific binding in
order to identify false positives using the Pains-remover computer tool [169]. From the
compounds analyzed, seven did not pass the filter, including 3.10, 3.12, 3.14, 3.19, 3.20,
3.29, 3.30 suggested as nonspecific binders. They all share as common characteristic a
catechol moiety. It is known that catechols can be toxic [170], however, the inhibitory data of
these compounds are presented as they are useful to establish a better structure-activity
relationship comprehension. In case these compounds turn out to be highly interesting,
further assays should be performed to characterize their toxicity.
Crystal structure determination
The inhibitors with the highest binding affinity were selected for crystal structure
determination in order to get insight into their binding mode. Crystal structures could be
obtained for five different inhibitors by cocrystallization of the protein in complex with
cofactor and ligands (3.1, PDB code: 5ICM; 3.6, PDB code: 5L7T; 3.9, PDB code: 5L7Y; 3.10,
PDB code: 5L7W; 3.12, PDB code: 5EN4). The data collection, processing, and refinement
statistics are reported in Table 3.8. The crystals were obtained by two different conditions,
however, all crystal structures show the same tetragonal space group (I422) with only one
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monomer present in the asymmetric unit. The crystal structures disclosed, that the protein is
a homotetramer, in accordance with a previous study [126]. The structures obtained have a
resolution ranging from 1.52 Å to 2.02 Å. The C-terminal tail of the complexes is very flexible
and the amino acids from Ser258 to Ile268 remain undefined in the electron density map
with the exception of Pro269, Ser270 and Gly271, which are stabilized by contact to a crystal
mate, like already observed for the structure of the E1-protein complex. A backbone
comparison between the structure of the holoenzyme and the ternary complexes does not
reveal any differences between the structures.
Description of the inhibitor binding site
The superimposition of all five ternary complexes reveals that binding of the different ligands
does not induce conformational changes of the overall geometry of the protein (Figure 3.2),
showing a mean RMSD of 0.15 ±0.04 Å between the alignment based on the coordinates of
the Cα atoms of the structures, as calculated with COOT [171]. The cofactor interacts with
the Rossman fold region and experiences similar interactions as already observed for the 17β-
HSD14 holo structure and in complex with E1 [126]. The inhibitor binds into the substrate
binding site (Figure 3.3), which is restricted by two α-helixes from the flexible loop (αFG1
and αFG2, residues 189-212, in orange), a portion of the αF helix (containing the catalytic
Tyr154, Lys158, in yellow), the short αEF helix (residue 142-146, in cyan), the segment that
connects αE with βD (from Asn89 to Arg98, in green), and the C-terminal tail (in red, Figure
3.4). Furthermore, Tyr253’ from the adjacent monomer (in gray on the right hand side,
Figure 3.4) is pointing toward the inhibitor binding site, reducing the volume of the active
site cleft. The annotation of the different helices and β-sheets follows the nomenclature
described by Lukacik et al. [32]. The flexible loop is in a conformation that closes the binding
pocket, reducing the size of the substrate binding site. Furthermore, the inhibitor binding site
is predominantly hydrophobic, with two main hydrophilic regions: The first one corresponds
to the two residues of the catalytic triad Tyr154 and Ser141, and the second one is formed by
His93 and Gln148 (Figure 3.5). This second region shapes the binding site in a peculiar form
and could be relevant for the achievement of selectivity considering that no other human
SDR 17β-HSDs present a histidine at this position.
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Table 3.8: Data collection and refinement statistic for the crystal structures.
PDB code a
Complex with
3.6, 5L7T
Complex with
3.9, 5L7Y
Complex with
3.10, 5L7W
Complex with
3.12, 5EN4
Complex with
3.1, 5ICM
(A) Data collection and processing
space group I422 I422 I422 I422 I422
unit cell parameters a, b, c
(Å)
91.2, 91.2,
131.4
91.6, 91.6,
132.5
91.0, 91.0,
132.2
91.7, 91.7,
135.0
91.7, 91.7,
133.8
Matthews coefficient b
(Å3/Da)
2.4 2.4 2.4 2.5 2.4
solvent content b (%) 48.5 49.3 48.5 50.4 49.9
(B) Diffraction data
resolution range (Å) 50-1.98
(2.10-1.98)
50-1.91
(2.03-1.91)
50-1.76
(1.86-1.76)
50-1.52
 (1.61-1.52)
50-1.68
 (1.78-1.68)
unique reflections 19413 (3002) 21943 (3336) 27439 (4039) 44532 (7097) 32511 (5122)
R(I)sym (%) 8.2 (48.4) 8.8 (49.7) 8.4 (49.8) 5.3 (47.3) 8.1 (49.3)
Wilson B factor (Å2) 26.0 21.7 20.6 19.5 19.96
completeness (%) 98.9 (97.1) 98.9 (94.8) 97.6 (90.3) 99.9 (99.6) 99.1 (98.3)
redundancy 7.2 (6.7) 7.2 (6.6) 9.3 (8.5) 14.6 (14.6) 6.9 (6.7)
<I/σ(I)> 17.8 (3.5) 16.8 (3.7) 17.1 (3.7) 28.4 (6.6) 14.1 (2.9)
(C) Refinement
resolution range (Å) 46.05-1.98 46.31-1.91 39.7-1.76 46.8-1.52 37.82-1.68
reflections used in
refinement (work/free)
19413
(18442/971)
21943
(20845/1098)
27439
(26067/1372)
44532
(42305/2227)
32511
(30885/1626)
final R value for all
reflections (work/free) (%)
0.15/0.19 0.14/0.16 0.15/0.19 0.11/0.13 0.16/0.19
protein residues 256 256 254 251 255
water molecules 172 188 204 99 189
RMSD from ideality: bond
lengths (Å)
0.007 0.009 0.009 0.008 0.009
RMSD from ideality: bond
angles (°)
0.850 0.993 1.066 1.062 1.004
Ramachandran plot:c
residues in most favored
regions (%)
92.3 93.3 91.8 93.2 92.8
residues in additionally
allowed regions (%)
7.7 6.7 8.2 6.8 7.2
residues in generously
allowed regions (%)
0 0 0 0 0.0
residues in disallowed
regions (%)
0 0 0 0 0.0
Mean B factor protein (Å2)
d
22.2 20.3 24.6 22.9 23.0
Mean B factor ligand (Å2) d 31.3 27.3 (interface)
35.1 (binding
pocket)
26.9 31.6 26.1
Mean B factor water
molecules (Å2) d
29.9 27.9 34.8 33.7 32.9
a Values in parenthesis describe the highest resolution shell. b Calculated with Matthews_coef program from CCP4 suite
version 6.4.0.[132] c Calculated with PROCHECK.[133] d Mean B factors were calculated with MOLEMAN.[134]
Ligand-Based Design of 17ß-HSD14 Inhibitors  |  53
Ch
ap
te
r 3
Figure 3.2: Superimposition of the crystal structures of 17β-HSD14 obtained in ternary complexes
with five inhibitors: 3.1, 3.6, 3.9, 3.10, 3.12. (A) The enzyme 17β-HSD14 is shown as ribbon model
(5ICM in orange, 5L7T in pink, 5L7Y in purple-blue, 5L7W in ocher and 5EN4 in green); inhibitors
are shown as stick models. The cofactor NAD+ is shown as thin line. (B) Close-up view on the
binding pocket. The protein 17β-HSD14 is displayed by use of the solvent accessible surface. The
carbon atoms of the inhibitors are shown for 3.1 in orange, 3.6 in pink, 3.9 in purple blue, 3.10 in
ocher and 3.12 in green. Inhibitors are shown as stick models and cofactor as thin line. The water
molecules W1 and W2 are represented in the same color as the corresponding inhibitor of the
individual structures. W1 corresponds to water molecule 472 in 5ICM, 518 in 5L7T, 508 in 5L7Y, 496
in 5L7W, 450 in 5EN4; W2 corresponds to water molecule 530 in 5ICM and 502 in 5L7T, in the
respective crystal structure. All structural representations were prepared with PyMOL [33].
Figure 3.3: Superimposition of the crystal structures of 17β-HSD14 obtained in ternary complexes
with E1 and an inhibitor. The enzyme 17β-HSD14 is shown in gray as ribbon model; E1, cofactor
NAD+ and inhibitor are shown as stick models. The carbon atoms of E1 are shown in light green, in
beige for the inhibitor and in gray for NAD+.
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Figure 3.5: Surface representation of 17β-HSD14; color coded according to the Eisenberg
hydrophobicity scale (from dark red for highly hydrophobic amino acids to white for highly
hydrophilic amino acids) [172]. The cofactor NAD+ and amino acids are shown as stick models. The
amino acid of the symmetry equivalent molecule is referred as prime (’).
Figure 3.4: Ribbon representation of inhibitor 6 in complex with the protein 17β-HSD14 and
cofactor NAD+. The inhibitor binding site is delimited by αFG1 and αFG2 (orange), αF (the helix
containing the catalytic Tyr154 and Lys158, yellow), αEF (cyan), αE and βD (green) and C-terminal
tail (red). Inhibitor 3.6 is shown as stick model and its carbon atoms are colored in pink. The
symmetry equivalent molecule containing Tyr253’ is shown in gray on the right hand side. The
cofactor and Tyr253’ are shown as thin lines.
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Description of the binding mode of inhibitors in complex with 17β-HSD14
In the surface representation, it is obvious that the V-shape of the inhibitor scaffold matches
well with the geometry of the active site (Figure 3.2 B). For all five crystallized inhibitors,
additional water molecules are observed in the binding pockets: Water W1 is found for all
inhibitors in the same position. W1 is localized between the B- and C-ring, at an approximate
4 Å distance from the B-ring. W1 establishes an H-bond interaction with the side-chain of
Asn186 (d» 2.7 Å). Water W2 is only observed for 3.1 and 3.6 (Figure 3.2 B) and is located
above the plane of the A-ring. W2 interacts with W1 (H-bond contact d» 2.6 Å). In case of
the other three inhibitors, the orientation of the A-ring plane is shifted, inducing the
displacement of W2.
The structures and details of the interactions of all inhibitors are shown in Figure 3.6 (A: 3.1,
B: 3.6; C: 3.12; D: 3.9; E: 3.10). All the inhibitors have the same B-ring scaffold (2,6-pyridine)
differing in the nature of their A- and C-ring substituents. The C-ring is located in vdW
distance to the nicotinamide moiety of NAD+. The 3-OH group at the C-ring interacts via
remarkably short H-bond interactions with the side chain of Tyr154 (d= 2.3-2.5 Å) and the
side chain of Ser141 (d= 2.5-2.6 Å), the latter two amino acids belonging to the catalytic triad.
The 4-F group at the C-ring of 3.6 is not involved in any specific interaction. The angle
between the keto group and the phenyl C-ring is identical in all the inhibitors independent of
the presence or absence of the 2-OH group at the C-ring. The keto group and the pyridine
ring bind exactly at the same position for all of them. Interestingly, the keto group between
the pyridine and the C-ring does not form any interactions but seems to be important for the
inhibitor to adopt the correct geometry.
The central pyridine B-ring is anchored by van der Waals contacts with Trp192 and Leu195,
which wrap around the top part of the pyridine ring. No close contacts are observed with
His93. For 6, the 3-Me group at the A-ring is not involved in any interaction. An H-bond
interaction is formed between the 4-OH at the A-ring of 3.1 and 3.6 with the carbonyl
backbone of Ala149 (d= 2.7-3.1 Å). The two 3-OH groups of the catechol ring of 3.1 form a
polar interaction with the carbonyl backbone oxygen of Ala149 (d= 2.8Å).
The aromatic A-ring is not stabilized by any π-stacking interactions, however, it is in van der
Waals distance with Pro96. No water mediated H-bond interactions are observed;
nonetheless, it is remarkable that W1 remains present in this lipophilic environment. In total
for 3.1 and 3.6, circa 90 van der Waals contacts are achieved by the ligand and its surface is
buried to about 94.0 % (considering only one monomer of the protein, the number of van der
Waals contacts achieved are summed up to 86 and the buried surface is 87.4 %). In 3.9, 3.10
and 3.12, a rotation of the A-ring plane is observed. Nevertheless, the altered orientation still
allows the 3-OH group at the A-ring to be at H-bond distance to Ala149-CO (d= 2.8-3.0 Å, as
observed with 3.6). The aromatic A-ring can also establish a van der Waals interaction with
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Figure 3.6: Crystal structures of 17β-HSD14 in complex with cofactor NAD+, and inhibitors 3.1 (in
orange, A), 3.6 (in pink, B), 3.12 (in green, C), 3.9 (in purple blue, D) and 3.10 (in ocher, E). The
inhibitors are shown as stick models. The amino acids, within a distance of 5 Å, and the cofactor are
shown as thin lines. H-bonds are depicted as dotted lines. Distances are given in Å.
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the amino acid Pro96. In summary for the inhibitor with this A-ring orientation, circa 80 van
der Waals contacts are observed with about 93.0 % of its surface buried in the protein
binding pocket (considering only one protein monomer, the ligand achieves 80 van der
Waals contacts and its surface is buried to 88.2 %).
Interestingly, the crystal structure of 3.9 in ternary complex with 17β-HSD14 shows the
presence of a second inhibitor molecule at the interface between two tetramers (Figure 3.7
A). Close inspection of this interface binding site (Figure 3.7 B) highlights that the inhibitor
is stabilized through an H-bond interaction between the 3-OH group at the A-ring to the
hydroxyl group of the Ser44 side chain (d= 3.2 Å) and with a water molecule W405 (d= 2.6
Å), which is stabilized by Arg19 (d= 3.0 Å). The keto group interacts with the other tetramer
through a water molecule W434 (d= 2.7 Å), which is also bound to the NH from the
backbone of Leu83´ (d= 3.0 Å) and the carbonyl group of the backbone of Tyr128´ (d= 2.9
Å). The copy of 3.9 binding to the interface is placed in a rather hydrophilic environment.
The overall geometry of the interface ligand differs from that of the active site ligand: The
dihedral angles, for the ligand in the active site and for the ligand binding at the interface,
between the keto group and C-ring are -29° and 4° respectively, and between the keto group
and the B-ring are 129° and -133° respectively (considering the plane through the keto group
as 0°). The dihedral angle between C2 at the A-ring and the nitrogen at the B-ring is 131° for
the ligand in the binding pocket and -60° for the ligand present at the interface. A
superimposition of the interface and active site compounds can be seen on Figure 3.8.
Figure 3.7: (A) Overall view of the crystal structure of two 17β-HSD14 tetramers in complex with
3.9. The protein monomers are shown as ribbon models and colored in gray. The inhibitors are
shown as sphere models. The inhibitors located in the substrate binding site are colored in purple
blue while the inhibitors located between the interfaces of the tetramers are shown in yellow. (B)
Close-up view of the second ligand binding site of 3.9 located at the interface between two
tetramers. The enzyme is displayed by use of the solvent accessible surface. Inhibitor 3.9 is shown
as stick model. The amino acids are shown as thin lines. The amino acids of the symmetry
equivalent molecule are referred to prime (’). H-bonds are depicted as black dotted lines. Distances
are given in Å.
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MOE models
The inhibitors 3.16a, 3.17, 3.23, 3.30 and 3.31 were modeled inside the crystal structure of
3.12 and minimized with MOE [173]. During the minimization, the protein and the C-ring
of the ligands were fixed with the exception of 3.16a where the full ligand was set free to
move. The resulting modeled compounds are shown in Figure 3.9.
Figure 3.8: Superimposition of compound 3.9 based on the pyridine B-rings of the ligand at the
interface (in yellow) and active site (in purple blue).
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Figure 3.9: Modeled structures of 17β-HSD14 in complex with inhibitor 3.16a (A), 3.17 (B), 3.23
(C), 3.31 (D) and 3.30 (E). The protein is displayed by use of the solvent accessible surface. The
inhibitors are shown as stick models and their C atoms are colored in light blue. The amino acids,
within a distance of 3.5 Å, and cofactor are shown as thin lines. H-bonds are depicted as black
dotted lines. Distances are given in Å.
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Thermal shift assay
The influence of different ligands on 17β-HSD14 stability was also tested. 2.5% DMSO
solution in the buffer was used as control and a Tm of 56˚C was obtained (Table 3.9). A strong
positive shift was recorded upon addition of our inhibitors (ΔTm=11.5-15.0°C), indicating
that the inhibitors have a strong affinity for the protein resulting in a strong stabilizing effect
[116, 118].
Table 3.9: Effect of different ligands on the Tm of 17β-HSD14 (2.6 µM).
Tm in °C
DMSO 2.5% 56.0
Compound 3.1 0.25 mM 70.5
Compound 3.6 0.25 mM 67.5
Compound 3.9 0.25 mM 71.0
Compound 3.12 0.25 mM 70.5
Comparison of the 17β-HSD1, 17β-HSD2 and 17β-HSD14 structures
The existing crystal structure of 17β-HSD1 in ternary complex with the cofactor NADP+ and
E2 (PDB code: 1FDT) allows the direct comparison with the 17β-HSD14 structure in
complex with the cofactor NAD+ and estrone (E1, PDB code: 5HS6). The superimposition
reveals a structural conservation of the enzymes only in some regions (22% of sequence
identity calculated with COOT [171], Figure 3.10). Small differences in the NAD+/NADP+
binding site can be observed between type 14 and type 1 (RMSD of 1.6 Å calculated with
COOT [171] based on Cα alignment). This result was expected since both enzymes bind a
different cofactor (NAD+ for 17β-HSD14 vs NADP+ for 17β-HSD1). The flexible loop in 17β-
HSD1 restricts the end of the binding cavity, while the corresponding loop in 17β-HSD14 is
shifted upwards leaving the binding site widely open. This results in a smaller binding pocket
for the type 1 enzyme. Furthermore, while the catalytic triad is conserved in both enzymes,
the steroids accommodate in the binding sites with different orientations and achieve distinct
interactions.
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Figure 3.10: (A) Superimposition of 17β-HSD1 (yellow, PDB code: 1FDT) and 17β-HSD14 (light
blue, PDB code: 5HS6) structures as ternary complexes. (B) Close-up view of the superimposed
substrate binding pocket. The proteins are shown as ribbon model. The steroids are shown as stick
models. The amino acids, involved in binding of the steroids (Tyr154 for 17β-HSD14; Tyr155,
Ser142 and His 221 for 17β-HSD1), and the cofactors are shown as thin lines. The carbon atoms of
E1 in complex with 17β-HSD14 are colored in light blue and the carbon atoms of (E2) in complex
with 17β-HSD1 are colored in yellow. H-bonds are depicted as black dotted lines. Distances are
given in Å.
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Selectivity
Taking into account that the parent scaffold of the new 17β-HSD14 inhibitors was derived
from 17β-HSD1 and 17β-HSD2 inhibitors, it was of utmost importance to study their
selectivity profile with respect to 17β-HSD1 and 17β-HSD2 binding.
The 17β-HSD1 and 17β-HSD2 inhibition assay was performed using a radioactive assay,
quantifying the amount of [3H]-labeled E2 (for type 1) and [3H]-labeled E1 (for type 2)
formed after incubation with protein, cofactor and the inhibitor as previously described
[174]. The results are shown in Table 3.10, expressed as percent inhibition when tested at an
inhibitor concentration of 1 µM.
As expected the 2,5-pyridine 3.23 showed the highest affinity for 17β-HSD1 (47% inhibition)
compared to the 2,6-pyridines (3.6-3.20, 9-23% inhibition), which were all nearly inactive in
17β-HSD1.
Inhibition of 17β-HSD2 was slightly higher than that of 17β-HSD1 for the compounds with a
2,6-substitution pattern (between 30% and 62% inhibition at 1µM concentration for 3.6-
3.20) and much higher for the 2,5-pyridine ketones (64% and 85% when tested at 1 µM
concentration for 3.23 and 3.2, respectively).
A direct comparison of the 17β-HSD1 and 17β-HSD2 inhibitory activities with those of 17β-
HSD14 is however problematic as different conditions were used in the assays.
However, under the applied condition in the 17β-HSD2 inhibition assay, using the Cheng-
Prusoff equation for competitive inhibition, a calculated Ki (cKi) could be estimated: For a
compound with an IC50 of around 1 µM (50% inhibition at 1 µM) a cKi of about 450 nM was
expected (with Km 17β-HSD2 = 400 nM in this assay [175] and [S]= 500 nM).
With 48% and 43% inhibition of 17β-HSD2, compounds 3.9 and 3.10 showed a cKi ≥450 nM.
Comparison of their Ki values for 17β-HSD2 and 17β-HSD14 binding allowed to calculate a
selectivity factor (ratio of Ki(HSD2)/Ki(HSD14)), which could be estimated to be around 35 for 9
and ≥41 for 3.10.Compounds 3.9 and 3.10 are relatively selective 17β-HSD14 inhibitors. The
selectivity profile of 3.12 toward 17β-HSD2 (with only 30% inhibition at 1 µM) should be
even better.
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Table 3.10: 17β-HSD14 binding constant (Ki) and 17β-HSD1/ 17β-HSD2 inhibitory activities
(% inhibition) of the most interesting compounds.
Compound
17β-HSD14
Ki (nM)a
17β-HSD1
% inhibition
@ 1 μMb
17β-HSD2
% inhibition
@ 1 μMc
3.2 24±9 47% 85%
3.5 245±21 6% 85%
3.6 26±3 9% 62%
3.9 13±5 23% 43%
3.10 11±3 12% 48%
3.12 64±4 13% 30%
3.18 7±2 13% 34%
3.20 47±7 14% 37%
3.23 17±5 47% 64%
a Recombinant purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2 mM], 25°C, mean
value of at least two independent experiments each with three technical repeats.
b Placental 17β-HSD1 enzyme, cytosolic fraction, substrate [3H]-E1 + E1 [500 nM], NADH [ 0.5 mM], mean value of
2 determinations; standard deviation < 20 %.
c Placental 17β-HSD2 enzyme, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value
of 2 determinations; standard deviation < 20 %
As steroidomimetics, the synthesized compounds might show undesired binding affinity to
the estrogen receptors (ERs) α and β.  Wetzel et al. reported that the most interesting
compounds 3.2-3.5, identified in the first screen, showed very low affinities to both ER
subtypes (< 0.1 %, taking E2 as 100% reference) [176]. It is therefore to expect, that the
synthesized compounds, which bear the same scaffold, do not bind tightly to the ERs.
3.3 Discussion
The combination of the biological results, the crystal structures of the five ligands in ternary
complex with the protein and the physicochemical properties provide the basis for the
understanding of the structure-activity relationship of the 2,5- and 2,6-substituted pyridine
derivatives.
Focus on the C-ring part
The 3-OH group at the C-ring achieves important H-bond interactions with Tyr154 and
Ser141, which stabilizes the inhibitor in the enzyme binding site. The increase in acidity of
this OH moiety, enhanced by the addition of a fluorine atom in ortho position to the OH
group, correlates with a gain in binding affinity. The crystal structures indicate that the H-
bond length between the 3-OH group at the C-ring and Tyr154 is rather short (d= 2.3 - 2.5
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Å). This result supports the hypothesis of Hwang et al. [177] which describes that in SDR
enzymes, the pKa of the OH group from the catalytic tyrosine is decreased (through
electrostatic interaction with the protonated catalytic Lys-NH3+ and NAD+) and that this Tyr-
OH is present as deprotonated species in the active site. In our structures, the negatively
charged (or at least highly polarized) Tyr154-O- can interact via H-bond interactions with 3-
OH groups at the C-ring of the inhibitors, leading to a strong contact between the inhibitor
and the protein. This interaction becomes even more stable in presence of an increasingly
acidic OH group at 3-position, once it is more strongly polarized O(δ-)-H(δ+).
In addition, it can be seen in the crystal structures that the inhibitors are involved in a more
complex H-bonding network via the interaction with Tyr154, also including the ribose-OH
groups of the cofactor, Lys158, Asn88, Asn89 and two to three water molecules (Figure 3.11).
The highlighted H-bonding network reinforces the strength of the interaction between
Tyr154 and the OH group at the C-ring of the inhibitor,[178] thereby strongly stabilizing the
ligand in the binding pocket.
The H-bond donor/acceptor profile involved in the interaction between the 3-OH group at
the C-ring and Tyr154/Ser141 can be interpreted in more details: A deprotonated Tyr154
implies that the 3-OH group at the C-ring of the inhibitor interacts with Tyr154-O- as H-
bond donor and with the hydroxyl group of Ser141 as H-bond acceptor. For the inhibitors
Figure 3.11: H-bonding network stabilizing the inhibitor 3.12 in the 17β-HSD14 binding site. The
carbon atoms of 3.12 are colored in green and shown as stick model. The amino acids, involved in
the H-bonding network, and the cofactor NAD+ (beige) are shown as thin lines. H-bond
interactions are depicted as dotted lines. Distances are given in Å. Water molecules are shown as
spheres. The water molecules present in all protein-inhibitor complex structures are colored in red,
an additional water molecule is visible in the case of the complexes with 3.1 and 3.12 (higher
resolution crystal structures) and is colored in green.
Ligand-Based Design of 17ß-HSD14 Inhibitors  |  65
Ch
ap
te
r 3
also bearing a 2-OH group at the C-ring moiety, an intramolecular H-bond with their keto
groups can be formed and no interaction with Tyr154 is expected (the OH group of Tyr 154
is already involved in a contact with the ribose-OH and the 3-OH group at the C-ring
inhibitor, and is not available for an additional interaction). In addition, it can be remarked
that the rigidification induced by the intramolecular H-bond does not correlate with an
increase in binding affinity (comparison of compounds 3.9 and 3.10).
Replacing the 3-OH group at the C-ring by a 3-OMe moiety was shown to be detrimental for
inhibitory activity (3.16a: no inhibition @100 µM compared to 3.16: Ki= 63 nM). When
compound 16a was modeled into the crystal structure of 17β-HSD14 (Figure 3.9 A), it
resulted in a shift of the binding pose (compared to the compounds observed in the crystal
structures, see Figure 3.6), which could allow an H-bond interaction between the oxygen of
the 3-OMe group and the OH group of Tyr154 of the catalytic triad, however, the H-bond
contact is only possible when the 3-OMe group acts as an acceptor (Figure 3.9 A). The
inactivity of this compound confirms the hypothesis that an H-bond donor in 3-position of
the C-ring is necessary for the inhibitory activity of the compound. In addition, no
interaction with Ser141 could be observed in the presence of the 3-OMe group in the model
structure.
Focus on the A-ring part
Based on the biological results, it is evident that the removal of the A-ring leads to a strong
decrease in activity (3.16, Ki= 63 nM compared to 3.24 Ki= 1541 nM), indicating an
important interaction of the A-ring with the protein. The crystal structures show that no
amino acid is able to achieve a π-stacking interaction in the vicinity of the aromatic A-ring.
This result suggests that the aromatic A-ring must be stabilized by hydrophobic interactions
with Pro96.
Furthermore, it can be observed that the introduction of a 3-OH or 4-OH group on the A-
ring induces a slight increase in affinity compared to the unsubstituted A-ring. Either these
hydroxyl moieties interact with the carbonyl backbone of Ala149 via a weak H-bond
interaction or the benefit of a strong interaction with Ala149 is decreased by the desolvation
cost. It is also striking that neither an electron donating nor an electron withdrawing group
has an influence on the potency.
The significant affinity enhancement of the dimethylamino derivative 3.17 was investigated
using the modeled structure (Figure 3.9 B). Here, the NMe2 moiety comes into close contact
with the carbonyl group of Ala149. A strong interaction would only be possible between the
NMe2 group and the carbonyl oxygen when the tertiary amine is protonated. However,
taking into account the pKa value of the NMe2 group it is unlikely that this group is charged.
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The gain in affinity might come from additional hydrophobic interactions between the latter
group and Pro96.
In the complex structure with 3.6 the 3-Me group at the A-ring interacts neither with the
protein nor with the solvent. Instead, it is pointing toward an empty cavity, while the 3-OH
group of 3.12 is oriented in the opposite direction interacting with Ala149. The swapped
orientation of the 3-Me group at the A-ring of 3.6 might result from electrostatic repulsions
between the methyl group and the carbonyl moiety of Ala149.
Regarding the almost equipotent 2,5-substituted (3.23, Ki= 17 nM) and the 2,6-substituted
derivative (3.8, Ki= 36 nM), it was previously suggested, that the C-rings of both compounds
achieve the same interaction and that the space available for accommodating the A-ring at
either 5- or 6-position must be large to host a ring at both positions. From the modeled
structure of 3.23 (Figure 3.9 C), it can be assumed that the A-ring in 5-position fits well into
the binding pocket, interacting through hydrophobic contacts with Met199. Furthermore, the
modeled 2,5,6-trisubstituted derivative 3.31 (Ki= 9 nM) also suggests that compounds
bearing rings at 5- and 6-position can fit in the cavity and may achieve an intramolecular π-
stacking interaction (d= 4 Å, Figure 3.9 D).
Focus on the B-ring part
Investigating the importance of the nitrogen at the B-ring indicates that inhibitor 3.12 (Ki=
64 nM) and its phenyl analogue 3.29 (Ki= 21 nM) show similar affinities. Obviously, the
nitrogen does not achieve any specific interaction with the protein, as confirmed by the
crystal structure. However, the pyridine moiety enhances the solubility for the compounds of
this inhibitor class. Concerning the N-oxide derivative 3.30 (Ki= 132 nM), the previously
observed interaction between the 3-OH group at the A-ring of compound 3.12 with Ala149
can no longer be accomplished, however, this OH-group can now address the backbone
carbonyl group of Gln150, as suggested by the modeled structure (Figure 3.9 E). An
additional H-bond interaction of N+-O- with Gln148 could be gained, but the high
desolvation penalty induced by the introduction of the charges might not be compensated,
overall resulting in no increase in affinity.
Second binding site for compound 3.9
For compound 3.9, a second binding pose at the tetramer interface was observed. The
inhibitor was refined to occupancy of 80% at this additional binding site, suggesting that this
ligand exhibits a lower affinity for this region compared to the active site. The binding of the
inhibitor in this position might be irrelevant for the inhibitory process, while it might be an
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artefact resulting from crystal packing as the binding at the interface does not induce any
conformational changes of the ternary structure and of the ligand binding site. However, it is
striking that Michiels et al. [179] reported in their NMR studies that phytoestrogens might
also bind at the dimer interface of 17β-HSD1.
Comparison of the 17β-HSD1, 17β-HSD2 and 17β-HSD14 structures
A positive influence of a fluorine atom in ortho position to a phenolic hydroxyl group was
already reported during the development of 17β-HSD1 dihydroxyphenylthiophenes
inhibitors [150] and 17β-HSD2 hydroxyphenyl-N-methylsulfonamide thiophenes inhibitors
[89]. As no crystal structures of 17β-HSD1 and 17β-HSD2 in complex with these
nonsteroidal compounds are available, their binding modes remain unclear. As 17β-HSD
type 1, type 2 and type 14 belong to the SDR superfamily, they share similarities in the region
in the vicinity of the catalytic triad. The presence of the complex H-bonding network was
also identified in the type 1 enzyme after analysis of its crystal structure (PDB code: 1FDT). It
could be expected that the 17β-HSD1 and 17β-HSD2 inhibitors with an acidic OH-phenyl
group have a similar binding mode, interacting with the catalytic triad as observed in the
crystal structure of type 14. Therefore, these new 17β-HSD14 structures in complex with
nonsteroidal inhibitors can represent a useful comparative data for 17β-HSD1 docking
studies and 17β-HSD2 homology modelling.
Basis for structure-based drug design
Based on these results, it should be possible to optimize the current ligands using structure-
based drug design. In this compound class the interactions with the catalytic Tyr154 and
Ser141, as well as with Ala149 are very important to anchor the ligand scaffold in the correct
position. Specific interactions involving His93 and Gln148 in inhibitor binding should result
in an improved activity and selectivity, particularly as His93 is not present in other human
SDR 17β-HSDs. Addressing the water molecule W1 should also lead to an additional
interaction with the protein. As the active site is open and solvent exposed, the polar amino
acids which are in close neighborhood to the active site next to the surface could also be
targeted by specific interactions.
3.4 Conclusion
Nonsteroidal 17β-HSD14 inhibitors have been identified. The initial hits identified in a
preliminary screen in the 2,6-susbtituted pyridine class showed a Ki around 250 nM/300 nM
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which was optimized to result in six highly active compounds with Ki< 15 nM and two with a
Ki of 7 nM. The considerations of substituent effects applied during optimization were
successful. It appears that at the C-ring, an acidic 3-OH group is essential to achieve high
potency, interacting via strong H-bond contacts to Tyr154 and Ser141 thereby stabilizing the
interaction through an extensive H-bonding network. The structure-activity relationship
found for the A-ring shows, that a 3-OH or a 4-OH group increases the potency of the
inhibition by interacting with Ala149. The crystal structures in complex with the inhibitors
confirm the rather large active site, reduced by the C-terminal chain from an adjacent
monomer. The new 17β-HSD14 inhibitors show good physicochemical properties, which
should be associated with a good bioavailability profile. They also present a good selectivity
profile toward both closely related subtypes 17β-HSD1 and 17β-HSD2. The determined
crystal structures give important insights not only to characterize the novel protein target but
also to understand the binding poses of these nonsteroidal inhibitors and provide the basis
for their further structure-based optimization.
3.5 Experimental section
17β-HSD14 inhibition assay
In a preliminary study compounds 3.1-3.5 were tested using a radioactive displacement assay
(Procedure A, % of inhibition at a concentration of 1 µM). The newly synthesized
compounds were tested using a fluorimetric assay (Procedure B, as percent inhibition at 2
µM, percent inhibition at the concentration of highest solubility of the compound and Ki).
Procedure A and B use the same enzyme source, obtained from a bacterial culture. In
procedure A, the assay is performed with a bacterial suspension, and in procedure B with the
purified form of the enzyme. Due to differences in assay conditions only results within the
same assay can be compared.
Enzyme expression
The pET based plasmid containing the coding sequences of the human gene HSD17B14
(using the T205 variant), with a N-terminal 6His-tag and a TEV (Tobacco Etch Virus)
protease cleavage site was used for the transfection of E. coli BL21 (DE3) pLysS competent
cells. The transformed bacteria cells were grown overnight in 100 mL of Terrific Broth
medium containing 100 µg/mL of ampicillin at 37°C. Subsequently, 25 mL of the overnight
culture were transferred in 1 L of the aforementioned medium and allowed to grow at 37 °C
until an OD600 of 0.4 was reached. Then the temperature was lowered to 15° C. When the
culture reached the OD600 of 1.0 the cells were induced with 0.5 mM of IPTG. The bacteria
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cells were harvested by centrifugation and conserved at -80° C overnight before proceeding
with the purification.
Radioactive assay using Procedure A
The bacterial pellet obtained was resuspended in 100 mM phosphate buffer pH 7.7. The
bacterial suspension was incubated with [3H]-E2 (final concentration: 18.3 nM) in the
presence of the potential inhibitor in DMSO (final concentration in assay: 1µM,  final DMSO
concentration: 1%) at 37°C. The enzymatic reaction was started by addition of NAD+ (7.5
mM) and incubated for 2 h. The reaction was stopped by addition of 0.21 M ascorbic acid in
a methanol/acetic acid mixture (99:1, v/v). Substrate and product were extracted from the
reaction mixture by SPE (Strata C18-E columns from Phenomenex on a vacuum device).
Separation and quantification of the radioactive steroids was performed with HPLC (Luna
5µm C18(2), 125 x 4.00 mm from Phenomenex, with an acetonitrile/water mixture (43:57,
v.v), flow rate 1mL/min). Substrate conversion in % was calculated after integration of the
product and substrate peaks. Inhibition was calculated based on conversion without potential
inhibitor (DMSO only) which was set to 0% inhibition.
Enzyme Purification
The cell pellet, previously obtained after IPTG induction, was resuspended in a buffer
containing 50 mM Tris, 500 mM NaCl, 0.5 mM TCEP, 250 mM glucose, 1 mM NAD+, 0.5%
(v/v) Triton X-100 and cOmplet Protease Inhibitor Cocktail Tablet (Roche, Germany)
adjusted at a pH of 8. The cells were disrupted with a high pressure homogenizer
(EmulsiFlex-C5™, AVESTIN, Mannheim, Germany) and the obtained homogenate was
centrifuged at 17700 g for 2h at 4°C. The supernatant was applied to a Ni-NTA column (5 mL
HisTrap FF, GE Healtcare Life Sciences, Freiburg, Germany). Two washing steps were
applied: in the first, to remove the DNA, a buffer composed of 50 mM Tris and 1.5 M NaCl
was run against the Ni-column. The second washing step was then performed with a buffer
containing 50 mM Tris, 500 mM NaCl, 0.5 mM TCEP, 250 mM glucose, 0.25 mM NAD+ and
21 mM imidazole to remove the unspecific binding proteins. The target protein was eluted by
increasing the imidazole concentration in the buffer to 300 mM. TEV protease was added to
the protein mixture to cleave the N-6His-tag and the product solution was dialyzed overnight
at 4°C to reduce the imidazole concentration in the sample (50 mM Tris, 500 mM NaCl, 0.5
mM TCEP, 250 mM glucose and 0.25 mM NAD+). A second Ni-NTA column was used for
separation of the TEV protease from the 17β-HSD14. In this step the protein was collected
from the flow through of the column, while the TEV protease remained on the column. With
the goal to increase the purity of the protein, an additional purification step, using a size
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exclusion chromatography (Superdex 75 26/60, GE Healtcare Life Sciences, Freiburg,
Germany) was performed with a running buffer comprising 50 mM Tris, 500 mM NaCl, 0.5
mM TCEP and 250 mM glucose. To the isolated target protein, an NAD+ solution 0.25 mM
(batch for enzymatic assay) or 0.6 mM (batch for crystallization studies) was added. The
protein solution was flash-frozen in liquid nitrogen and stored at -80°C.
Fluorimetric assay using Procedure B
The potential inhibitor (in DMSO, final DMSO concentration in assay: 1%) was added to a
mixture of NAD+ (1.2 mM) and E2 (32 µM) in 100 mM phosphate buffer pH 8. The
enzymatic reaction was started by addition of the purified enzyme (1 mg/ml) and the
production of the fluorescent NADH formed was measured continuously for 15 min at 25°C.
The fluorimetric assays were recorded on a Tecan Saphire 2 (λex at 340 nm and λem at 496
nm). The slit width for excitation was 7 nm and for emission 15 nm. Reactions were
performed in 200 µL volumes. The assay was run in 96 well-plates in duplicate, each
experiment resulting from three technical repeats. A linear relationship between product
formation and reaction time was obtained. The slope of the progress curves was calculated by
linear regression. The inhibitors do not show fluorescence at the concentrations used in the
assay.
The Ki values were calculated using the Morrison equation [167]. For calculation, three
constants were necessary: the substrate concentration (32 µM), the Km for 17β-HSD14 with
this substrate E2 (6.18 µM [126]) and the concentration in active protein, which was
determined experimentally for each experiment (3.2 or 3.3 µM), using the procedure detailed
by Copeland [167]. The fitting and data analysis was performed using GraphPad Prism 7.
Protein co-crystallization with inhibitors 3.1, 3.6, 3.9, 3.10, 3.12
Protein activity was verified before performing the crystallization studies for each inhibitor.
The co-crystallization of 17β-HSD14 in complex with the four inhibitors 3.1, 3.6, 3.9, 3.10
and 3.12 was performed by sitting drop vapor diffusion technique.
For the crystallization of inhibitors 3.6 and 3.9 in complex with the protein an inhibitor stock
solution in pure DMSO was added to the protein solution (9.5 mg/mL) containing 0.6 mM
NAD+ with a final inhibitor concentration of 0.8 mM and a DMSO concentration of 1%. 2 µL
of the mother liquor containing 0.1 M CHES, 1 M tri-sodium citrate, pH 9.5, was mixed with
2 µL of the protein solution. After growing for 4 weeks at 18°C, the crystals were exposed to a
cryo buffer composed of the mother liquor with the addition of 20% (w/v) glucose and 0.4
mM of either 3.6 or 3.9, and subsequently flash-frozen in liquid nitrogen.
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The inhibitors 3.1, 3.10 and 3.12 were crystallized under different conditions. The same
concentration of the protein containing 0.6 mM of NAD+, was mixed with inhibitor and
DMSO, to the final concentration of 4 mM of inhibitor and 5% DMSO. Afterwards, 2 µL of
this protein-inhibitor solution were mixed with 2 µL of mother liquor composed of 0.1 M
HEPES, 20% (w/v) PEG6000 and 5% (v/v) DMSO, adjusted to pH 7.0. Crystals were grown at
a temperature of 18°C for four weeks. The crystals obtained with 3.10 were exposed to a cryo
buffer obtained by the combination of mother liquor with the addition of 20% glucose and
successively flash-frozen with liquid nitrogen. The crystals resulting from the complex with
3.12 were kept at room temperature.
Data collection and processing
The data for the protein-inhibitor complex structure containing 3.1 (PDB code: 5ICM) and
3.10 (PDB code: 5L7W) were collected at Elettra Sincrotrone at beamline XRD1 in Trieste,
Italy. The data collection was achieved at a wavelength of 1Å and a temperature of 100 K on a
DECTRIS Pilatus 2M pixel detector. The diffraction data of 3.6 and 3.9, were obtained at
beamline P13 at a wavelength of 0.8 Å and a temperature of 100 K (PDB code: 5L7T and PDB
code: 5L7Y, respectively) and 3.12 at beamline P14 at a wavelength of 0.9763 Å and a
temperature of 291 K (PDB code: 5EN4) at PETRA III (EMBL/DESY) in Hamburg,
Germany, on a silicon Pilatus 6M pixel detector. All datasets were indexed, processed and
scaled with XDS [142].
Structure determination and refinement
The structures were determined by molecular replacement with the program PHASER MR
[143] from the CCP4 suite [132]. The structure 5EN4 was determined using 1YDE [32] as
starting point for the molecular replacement search. For the remaining structures, 5EN4 was
used as a search model. A subset that corresponds to 5% of the reflections was used for the
calculation of Rfree and consequently was omitted from the refinement. The model was built
in Coot [171] and refined using PHENIX.refine version 1.10.1-2155 [145]. The ligands were
energetically minimized and their restraints were generated using Grade Web Server [147]
and eLBOW [145] based on the SMILEs codes obtained with Molinspiration v2014.11 [146].
As first refinement step, for all the structures, a Cartesian simulated annealing was performed
using default parameters. The final models were built in Coot with alternating structural
modification and refinement of XYZ coordinates, occupancies and individual B-factors in
Phenix. With exception of 5L7T, hydrogens were included in the models of the structures.
For 5EN4, the temperature factors of all atoms, except hydrogen atoms and solvent
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molecules, were refined anisotropically. For 5L7W and 5ICM, TLS refinement was
performed with TLS groups selected from the TLSMD web server [148, 149]. For 5L7T and
5L7Y, the temperature factors were refined isotropically.
Hydrogen bonds and van der Waals contacts between the protein 17β-HSD14 and the
inhibitors were assigned with the aid of the program CONTACTSYM [180, 181]. The buried
surfaces of the inhibitors in the binding pocket were calculated using the program MS [182,
183].
Thermal shift Assay (TSA)
The thermal shift assay was conducted in a 96 wells PCR plate (Bio-Rad, Munich, Germany)
using a real-time PCR instrument (iCycler5, Bio-Rad, Munich, Germany). The running
buffer was obtained by the dilution (1:1000) of SYPRO orange dye (Invitrogen,
ThermoFisher Life Technologies, Darmstadt, Germany) in a buffer composed of 50 mM Tris,
0.5 M NaCl and 0.5 mM TCEP, pH 8.0. For the protein complexes, a concentration of 2.5%
of DMSO (reference measurement) or a stock solution in pure DMSO of compound 3.2,
estrone, or estradiol was added to the running buffer containing 250 mM glucose and 0.25
mM NAD+ (final ligand concentration of 0.25 mM and final DMSO concentration of 2.5%).
A protein concentration of 2.6 µM was used (3 µL) and the different solutions were added to
a final volume of 40 µL.
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Introductory remarks
The following chapter is part of a manuscript in preparation. Fluorescence-based assays were
designed and performed by Dr. Sandrine Marchais-Oberwinkler in collaboration with
Florian Braun. The synthesis of the compounds, their characterization and the Pgp efflux
pumps assay were carried out by Florian Braun. The expression and the purification of the
17β-HSD14, the crystallization studies and the elucidation of the crystal structures of the
protein-inhibitor complexes were established and performed by the author of this thesis. The
selectivity assay was done by Dr. Gabriele Möller (Helmholtz Zentrum Munich) and Dr.
Martin Frotscher (Saarland University). The cytotoxicity study was performed by Nathalie
Guragossian and Prof. Dr. Marc Le Borgne (University of Lyon, France). Furthermore, the
author significantly contributed to the discussion and to the writing of the manuscript in
collaboration with Florian Braun and Dr. Sandrine Marchais-Oberwinkler.
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4.1 Introduction
17β-hydroxysteroid dehydrogenase type 14 (17β-HSD14), also known as DHRS10 and
retSDR3, is the latest 17β-HSD enzyme identified and belongs to the Short-chain
Dehydrogenase-Reductase (SDR) superfamily [11, 32]. In vitro, the enzyme catalyzes the
oxidation at the 17 position of two prominent steroid hormones, estradiol (E2) and 5-
androsten-3β,17β-diol (5-diol), in presence of the cofactor NAD+ thus converting them into
their less active analogs, estrone (E1) and dehydroepiandrosterone (DHEA) [32]. However,
considering the low turnover of the enzyme for E2 and 5-diol (0.02 and 0.033 min-1,
respectively [126]) and their low binding affinity as substrates (about 6 µM [126]), it is not
really clear whether the enzyme is also involved in the steroid regulation in vivo.
The enzyme was described by Sivik et al. [103] to show a broad distribution across various
tissues as evaluated by immunohistochemistry studies, while northern blot analyses
demonstrated that the enzyme is predominantly expressed in brain, liver, placenta [32] and
kidney [100]. 17β-HSD14 is a cytosolic enzyme, as highlighted by immunofluorescence
studies, and its quaternary structure consists of a homotetramer [32, 126].
The crystal structures of 17β-HSD14 in complex with NAD+ were determined (PDB codes:
5JS6 and 5JSF) and they revealed that the enzyme has a rather lipophilic conical active site,
narrow in the proximity of the catalytic triad and is solvent exposed at the other end [126]. In
addition, the binding pocket is reduced in size by Tyr253´ from an adjacent enzyme
monomer in the tetrameric assembly.
The first class of nonsteroidal inhibitors for this enzyme were recently described by us [127].
One of the most promising inhibitor is the compound 3.9 (Figure 4.1) [127]. It is a member
of the (6-phenyl)pyridin-2-yl methanone class and it exhibits a high binding affinity to the
enzyme (Ki = 13 nM). The crystal structure of this inhibitor with the enzyme was elucidated
and showed that the inhibitor adopts a conformation with a complementary shape to the
substrate binding pocket [127]. It is bound to in the active site via different interactions: The
most relevant interactions that the inhibitor achieves are strong H-bond contacts between
3-OH group on the C-ring and the catalytic residues Tyr154 and Ser141. An additional H-
bond interaction between the 3-OH group on the A-ring and the Ala149 is also observed.
The carbonyl group and the pyridine ring of the inhibitor addresses the hydrophobic pocket
formed by Leu191, Trp192 and Leu195 (Figure 4.1).
Goal of this study was the optimization the structure of 3.9 in order to develop an optimal
tool compound that could be used to investigate the physiological role of the enzyme in vivo.
To reach this goal, a structure-based optimization of 3.9 was undertaken to extensively
exploit potentially new interactions provided by the enzyme and to therefore improve the
binding affinity of the compounds. The newly designed compounds were synthesized, tested
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for 17β-HSD14 inhibition and for seven of them the crystal structures of the corresponding
inhibitor-enzyme complex were determined. The crystal structures were crucial for the better
understanding of the structure-activity relationship (SAR) additionally disclosing a shifted
binding mode in case of one inhibitor. The profiling of the most potent inhibitors of the
series was subsequently initiated. The selectivity towards different 17β-HSD enzymes along
with cytotoxicity and ligand solubility were tested and their in silico physiochemical
properties were calculated. As 17β-HSD14 is also present in the brain, it is important that the
tool compound is also capable of crossing the blood brain barrier (BBB). The most
interesting 17β-HSD14 inhibitors of our series (selective, no cytotoxic and with promising
physicochemical properties) were tested for their ability to pass the BBB. As, Pgp efflux
pumps are the most important transporters involved in multiple drug resistance and present
in the BBB and liver [184], the behavior of the tool compounds toward these efflux pumps
was also investigated and taken into account in order to choose the best tool compounds for
follow-up in vivo studies.
4.2 Results
Structure design of the new inhibitors
The scaffold of 3.9 was used as a starting point for structure-based modification in order to
optimize the geometry of the inhibitor toward higher affinity for 17β-HSD14 with the
intention to identify the key interactions between the individual inhibitors and the protein.
Figure 4.1: Schematic representation of the binding mode of 3.9 in the binding pocket of
17β-HSD14. Amino acids with polar functional groups are colored in red. Prevalent hydrophobic
amino acids are colored in blue. The different pockets formed by the amino acids are highlighted
with gray lines. H-bonds are depicted as orange dotted lines.
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In the (6-phenyl)pyridin-2-yl methanone class, the interaction of the 3-OH group of the C-
ring with Tyr154 from the catalytic triad is essential to achieve high inhibitory activity. The
increased acidity of the 3-OH function is boosted by the substitution with an adjacent
fluorine atom (in ortho position to the OH group). This correlates with a significant gain in
binding affinity [127], thus, the 3-OH/4-F pattern at the C-ring was maintained during the
development process.
In the first optimization strategy (A) we focused on the replacement of the linking carbonyl
group of 3.9 (Chart 4.1), acting as a bridge between the B- and C-ring. The crystal structure
disclosed that the carbonyl group is important to induce the overall V-shape of the inhibitor
scaffold to perfectly match the architecture of the protein’s active site (Figure 4.2).
Nevertheless, the carbonyl group does not form any direct interaction with any neighboring
amino acid of the protein. Therefore, our idea was to investigate the role of this linker by
replacing the carbonyl group with polar linker groups such as an ether oxygen, a secondary
amine or apolar groups such as a tertiary amine and an ethenyl group. The geometry of the
modified scaffold (angle between the B- and C-rings) had to be kept similar to that of 3.9 also
leaving the positions of the B- and C-rings virtually unchanged. Furthermore, amide groups
were introduced to grow the distance between B- and C-ring and to evaluate the
consequences of pushing the pyridine B-ring deeper into the substrate binding site.
Additionally, a relatively large hydrophobic pocket next to the B-ring in the direction of the
exit vectors at the 5 and 6 position of the pyridine core is observed in the crystal structure of
3.9 (Figure 4.2). Therefore, another optimization strategy (B) was selected to address this
hydrophobic pocket by extending the pyridine core and fusing the A- with the B-rings, which
will result in a quinoline-based scaffold. In addition, the rigidity of the quinoline scaffold
compared to that of the pyridine-based inhibitors [127] may also be beneficial for inhibitory
activity [185]. Furthermore, the possible establishment of another scaffold may give access to
compounds with modified pharmacokinetic properties. Hydrophilic and hydrophobic
substituents can be introduced in 6- and 7-position of the quinoline moiety to explore
chemical space in this region of the binding pocket (Chart 4.1).
Chart 4.1: Synthetic modifications starting from the 2,6-pyridine ketone 3.9.
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Figure 4.2: Close-up view of the binding pocket as formed in the crystal structure of 17β-HSD14
obtained as ternary complexe with 3.9 (PDB code: 5L7Y). The protein is represented in gray by the
solvent accessible surface. The inhibitor is shown as stick model. Carbon atoms of the ligand 3.9
are shown in yellow. The relatively large hydrophobic pocket adjacent to the B-ring is highlighted
in green. All structural representations were prepared with PyMOL [33].
Pan Assay Interference Compounds [168]
In order to identify undesired compounds, which might bind unspecifically to numerous
biological targets, all designed compounds were validated in silico using the PAINS-remover
computer tool [169]. As none of them was signed as unspecific binder, all were synthesized.
Physicochemical Parameters
Prior to synthesis, the physicochemical properties of all designed compounds were computed
to only consider compounds which match with a good predicted bioavailability profile. The
molecular weight was selected to fall into a range of 250-400 g/mol. The clogP, the total polar
surface area (tPSA), the number of rotational bonds and H-bond donors and acceptors were
calculated in silico using ACD/Percepta (14.0.0) and adhere to the Veber Rule [162] and the
Lipinski Rule of five [163].
The potential of the designed compounds to cross the BBB was also taken into account, as
17β-HSD14 has been reported to be also present in the brain [32]. Therefore, the tool
compounds to be studied in vivo should be able to permeate the BBB. Especially for the
pyridine compounds 3.9, 4.1, 4.2, 4.3 and 4.4 as well as for the quinolines 4.8, 4.10, 4.12  and
4.16 the physicochemical properties fit well with the profile defined by Pajouhesh and Lenz
[164] for compounds showing a good BBB penetration. The solubility range of most of the
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compounds was also determined by mixing the studied inhibitors at several concentrations in
100 mM phosphate buffer at pH 7.4 and analyzing the precipitation status at different time
points (0, 1, 2 and 24 h). The calculated physicochemical parameters and experimental
determined solubilities are summarized in Table 4.1.
Table 4.1: Physicochemical property table of the designed inhibitors.
compd MWa clogPa
rotatable
bondsa
H-bond
donora
H-bond
acceptora tPSAa Solubilityb
3.9 327.28 2.98 3 2 4 70.42 > 200 µM
4.1 315.27 3.32 3 2 4 62.58 > 200 µM
4.2 314.19 3.49 3 3 4 65.38 > 200 µM
4.3 328.31 3.73 3 2 4 56.59 > 200 µM
4.4 325.31 4.06 3 2 3 53.35 > 200 µM
4.8 267.25 3.08 2 1 3 50.19 100-200 µM
4.9 266.27 4.45 2 1 2 37.30 25-50 µM
4.10 281.28 3.43 2 1 3 50.19 25-50 µM
4.11 284.15 2.59 2 2 4 70.42 > 200 µM
4.12 292.26 2.86 3 1 4 73.98 25-50 µM
4.14 282.27 2.24 2 3 4 76.21 50-100 µM
4.15 339.32 1.03 4 4 6 105.31 > 200 µM
4.13 335.29 2.22 3 2 7 104.65 > 200 µM
4.16 373.38 4.19 3 2 4 70.42 12.5-25 µM
aCalculated with ACD/Percepta 14.0.0
bSolubilty tested in Phosphate-Buffered Saline (PBS, pH 7.4) at various inhibitor concentrations (3.13-200 µM,
final DMSO concentration 2%). Clarity of the solutions was evaluated optically.
Biological Evaluation
The inhibitory activity of the synthesized compounds was evaluated by means of a
fluorescence-based assay, quantifying the fluorescence of NADH produced during the
catalytic reaction. The assay was carried out using the purified, recombinantly expressed
enzyme, E2 as substrate, NAD+ as cofactor, and the inhibitors, as already reported [126]. A
high enzyme concentration (between 2.2 µM and 3.4 µM) and substrate concentration of E2
(32 µM) had to be used because the sensitivity of the assay was low. As no classical kinetic
analysis could be applied for the determination of Ki [165, 166] (as the inhibitor
concentration studied was in the same range as the enzyme concentration used) the results
were analyzed using the quadratic Morrison equation for tight binding inhibitors [167]. This
procedure was recently described by us for the inhibitors in the (6-phenyl)pyridin-2-yl
methanone class [127]. For 4.8a, no Ki could be determined due to its limited solubility and
its inhibitory activity was expressed as percentage at the highest soluble concentration of the
inhibitor (100 µM).
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17β-HSD14 Inhibitory Activity
Starting from the (6-phenyl)pyridin-2-yl methanone 3.9, the linker between the B- and the
C-ring was investigated following our first optimization strategy concept by replacing the
carbonyl group with different functional groups. Ether 4.1 (Ki = 58 nM), amine 4.2
(Ki = 47 nM), and methylamine 4.3 (Ki = 42 nM) were shown to be equipotent ligands with
slightly decreased affinity compared to 3.9 (Ki = 13  nM). The introduction of an ethenyl
group resulted is a ten times more potent inhibitor 4.4 (Ki = 1.5 nM), whereas the presence of
an amide linker led to a decrease in inhibitory activity (4.5, 686 nM, 4.7, 336 nM) and a
methylated amide (4.6, 2030 nM) was even detrimental for 17β-HSD14 inhibition compared
to 3.9 (Table 4.2).
Table 4.2: 17β-HSD14 binding constant (Ki) of 2,6-pyridine derivatives with different linkers
between the B- and C-ring.
compd X
17β-HSD14
Ki (nM)a
3.9 C=O 13 ± 5
4.1 O 58 ± 12
4.2 NH 47 ± 7
4.3 NMe 42 ± 8
4.4 C=CH2 1.5 ± 0.4
4.5 -NHCO- 686 ± 54
4.6 -NMeCO- 2030 ± 180
4.7 -CONH- 336 ± 54
a Recombinantly expressed, purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2
mM], 25°C, mean value of at least three independent experiments each with three technical repeats.
In a second approach to modify the basic scaffold, the pyridine B-ring of compound 3.9 (Ki =
13 nM) was expanded and led to the equipotent quinoline-based inhibitor 4.8 (Ki = 12 nM).
The presence of the 3-OMe group at the C-ring (4.8a, no inhibition @ 2 µM; 21% inhibition
@ 100 µM) was detrimental for the inhibitory activity compared to the 3-OH analogue 4.8
(69% inhibition @ 2 µM). The role of the nitrogen atom of the quinoline moiety with respect
to the inhibitory activity was further investigated by the synthesis of naphthalene 4.9
(Ki = 6 nM), which was shown to have a similar binding affinity as the quinoline derivative
4.8 (Table 4.3).
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Table 4.3: 17β-HSD14 binding constant (Ki) of quinoline and naphthalene derivatives.
Compd X R
17β-HSD14
Ki (nM)a
3.9   13 ± 5
4.8a N OMe 21% @ 100 µM
4.8 N OH 12 ± 3
4.9 CH OH 6 ± 2
a Recombinantly expressed, purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2
mM], 25°C, mean value of at least three independent experiments each with three technical repeats.
Furthermore, compound 4.8 (Ki = 12  nM) was decorated with different substituents in 6-
and 7-position to investigate their role regarding inhibitory activity. A methyl group in 6-
position (4.10, Ki = 6 nM) did not influence notably the binding affinity, whereas a
hydrophilic OH-group reduced potency ten times as indicated by inhibitor 4.11 (Ki = 119 -
 nM) compared to 4.8. In 7-position, the introduction of non-hydrophilic substituents (4.12,
Ki = 9  nM; 4.16, Ki = 6  nM) as well as of polar substituents (4.13, Ki = 10  nM; 4.14,
Ki = 34  nM; 4.15, Ki = 23  nM) resulted in inhibitors with virtually unchanged affinities
compared to 4.8 (Table 4.4).
Table 4.4: 17β-HSD14 binding constant (Ki) of 6- and 7-substituted quinoline derivatives.
compd R
17β-HSD14
Ki (nM)a
4.8 H 12 ± 3
4.10 6-Me 6 ± 2
4.11 6-OH 119 ± 7
4.12 7-CN 9 ± 1
4.13 7-(tetrazole-5-yl)  10 ± 2
4.14 7-NH2 34 ± 7
4.15 7-NHGly 23 ± 2
4.16 3-Me,4-OH-C6H3 6 ± 2
a Recombinantly expressed, purified 17β-HSD14 enzyme, fluorimetric assay, substrate E2 [32 µM], NAD+ [1.2 mM],
25°C, mean value of at least three independent experiments each with three technical repeats.
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Crystal structure determination
Inhibitors of both, the pyridine and the quinoline series, showing the best binding affinity for
17β-HSD14 were selected for crystallization study. Seven inhibitors could be co-crystallized
in complex with the protein resulting in crystals of sufficient quality for structure
determination (4.1, PDB code: 5O6O; 4.3, PDB code: 5O43; 4.4, PDB code: 5O42; 4.8, PDB
code: 5O6Z; 4.10, PDB coed: 5O6X; 4.12, PDB code: 5O7C and 4.15, PDB code: 5O72). All
the crystals exhibited tetragonal symmetry in space group (I422) with only one monomer
forming the asymmetric unit of the homotetramer formed with other symmetry equivalent
molecules in accordance with the previous study [126]. The structures obtained have a
resolution ranging between 1.35 Å to 1.91 Å. The crystal structures disclosed that only small
changes of the inhibitor’s substituent pattern can induce important variations of their
binding modes. Data collection, processing and refinement statistics can be found in the
Table 4.5 A and B.
Description of the binding mode of the pyridine-based inhibitors in complex
with 17β-HSD14
The superimposition of the crystal structures of the enzyme in ternary complexes with 4.1,
4.3 and 4.4 revealed that these three inhibitors, despite a chemically varied linker between the
C- and the B-ring, adopted a similar binding mode compared to 3.9 (Figure 4.3 A). For all
three crystallized inhibitors, the same conserved water molecule (W1) is founded at
unchanged position as described for the others known pyridine-based inhibitors [127]. All
inhibitors with the different linkers adopted the same V-shaped conformation as observed
for 3.9. As expected, the ether oxygen (4.1, Figure 4.3 B) is not involved in any direct
interaction with the protein, whereas the methyl amine (4.3, Figure 4.3 C) and ethylene
moiety (4.4, Figure 4.3 D) accommodate well in the hydrophobic pocket formed by Leu191,
Trp192 and Leu195. The enhanced flexibility of the ligand with the ether linker is reflected in
the split conformation of the A- and B-ring of 4.1. Compared to 3.9, remarkably the slightly
different valence angle between the B- and C-ring (~ 1°) of the ethylene linker pushes the B-
ring of 4.4 into the direction of Leu195 leading to about 180°-flip of the A-ring plane and
resulting in an orientation of the OH- and F- substituents in opposing direction. The 4-OH
group at the A-ring of all the inhibitors is within H-bond distance with the carbonyl
backbone of Ala149 (d = 2.7-2.9 Å).
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Table 4.5 A. Data collection and refinement statistic for the crystal structures.
PDB ID code a
Complex with 4.1,
5O6O
Complex with  4.3,
5O43
Complex with 4.4,
5O42
(A) Data collection and processing
space group I422 I422 I422
unit cell parameters a, b, c (Å) 91.4, 91.4, 133.3 91.6, 91.6, 133.1 91.5, 91.5, 133.1
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4
solvent content b (%) 49.4 49.5 49.4
(B) Diffraction data
resolution range (Å) 50-1.45 (1.54–1.45) 50-1.50 (1.59-1.50) 50-1.76 (1.86-1.76)
unique reflections 50086 (7930) 45487 (7233) 28404(4435)
R(I)sym (%) 7.3 (49.2) 9.0 (50.4) 9.8 (52.0)
Wilson B factor (Å2) 12.6 13.9 18.1
completeness (%) 99.8 (99.3) 99.9 (100.0) 99.6 (98.1)
redundancy 8.6 (8.2) 8.6 (8.8) 7.9 (8.1)
<I/σ(I)> 18.1 (3.9) 13.7 (3.3) 15.3 (3.4)
(C) Refinement
resolution range (Å) 45.69-1.45 46.41-1.50 46.38-1.76
reflections used in refinement (work/free) 50086(47581/2505) 45487 (43212/2275) 28404 (26983/1421)
final R value for all reflections (work/free)
(%)
0.15/0.17 0.15/0.17 0.15/0.19
protein residues 256 253 256
water molecules 206 220 208
RMSD from ideality: bond lengths (Å) 0.008 0.007 0.008
RMSD from ideality: bond angles (°) 1.039 0.981 0.986
Ramachandran plot:c
residues in most favored regions (%) 91.8 91.3 91.3
residues in additionally allowed regions (%) 8.2 8.7 8.2
residues in generously allowed regions (%) 0 0 0.5
residues in disallowed regions (%) 0 0 0
Mean B factor protein (Å2) d 17.7 18.2 21.6
Mean B factor ligand (Å2) d 25.0 23.1 20.5
Mean B factor water molecules (Å2) d 28.2 30.7 32.0
a Values in parenthesis describe the highest resolution shell. b Calculated with Matthews_coef program from CCP4 suite
version 6.4.0.[132] c Calculated with PROCHECK.[133] d Mean B factors were calculated with MOLEMAN.[134]
Structure-Based Design of 17ß-HSD14 Inhibitors  |  83
Ch
ap
te
r 4
Table 4.5 B. Data collection and refinement statistic for the crystal structures.
PDB code a
Complex with
4.8, 5O6Z
Complex with
4.12, 5O7C
Complex with
4.15, 5O72
Complex with
4.10, 5O6X
(A) Data collection and processing
space group I422 I422 I422 I422
unit cell parameters a, b, c (Å) 91.3, 91.3, 132.6 91.2, 91.2, 131.8 92.2, 92.2, 134.1 91.1, 91.1, 133.4
Matthews coefficient b (Å3/Da) 2.4 2.4 2.5 2.4
solvent content b (%) 49.0 48.7 50.2 49.1
(B) Diffraction data
resolution range (Å) 50-1.57
(1.67-1.57)
50-1.60
(1.70-1.60)
50-1.91
(2.03-1.91)
50-1.35
(1.43-1.35)
unique reflections 39289 (6231) 36906 (5872) 22541 (3581) 117838 (19085)
R(I)sym (%) 5.1 (50.6) 7.5 (47.5) 8.3 (4.3) 5.9 (51.9)
Wilson B factor (Å2) 16.4 15.3 22.3 11.8
completeness (%) 99.8 (99.9) 99.5 (99.8) 99.7 (99.7) 99.9 (99 9)
redundancy 8.6 (8.6) 8.5 (8.2) 8.3 (8.6) 6.8 (6.6)
<I/σ(I)> 26.5 (3.9) 17.4 (3.5) 18.1 (4.0) 19.1 (3.7)
(C) Refinement
resolution range (Å) 45.7-1.57 46.1-1.60 46.6-1.91 46.4-1.35
reflections used in refinement (work/free) 39289
(37324/1965)
36906
(35060/1846)
22541
(21414/1127)
117838
(111952/5886)
final R value for all reflections (work/free)
(%)
0.14/0.16 0.16/0.19 0.17/0.21 0.12/0.14
protein residues 257 257 255 253
water molecules 222 218 203 246
RMSD from ideality: bond lengths (Å) 0.008 0.008 0.010 0.006
RMSD from ideality: bond angles (°) 0.996 0.993 1.045 0.947
Ramachandran plot:c
residues in most favored regions (%) 91.4 91.4 91.3 91.7
residues in additionally allowed regions (%) 8.1 8.1 8.2 7.8
residues in generously allowed regions (%) 0.5 0.5 0.5 0.5
residues in disallowed regions (%) 0 0 0 0
Mean B factor protein (Å2) d 19.0 19.7 23.8 13.9
Mean B factor ligand (Å2) d 27.6 31.7 35.7 18.5
Mean B factor water molecules (Å2) d 30.7 30.7 31.7 27.8
a Values in parenthesis describe the highest resolution shell. b Calculated with Matthews_coef program from CCP4 suite
version 6.4.0.[132] c Calculated with PROCHECK.[133] d Mean B factors were calculated with MOLEMAN.[134]
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Figure 4.3: Close-up view on the binding pocket after superimposition of the four crystal
structures of 17β-HSD14 obtained as ternary complexes with the pyridine-based inhibitors: 3.9
(PDB code: 5L7Y, A) [127], 4.1 (PDB code: 5O6O, A and B), 4.3 (PDB code: 5O43, A and C), and 4.4
(PDB code: 5O42, A and D). The carbon atoms of the ligands are shown for 3.9 in yellow, 4.1 in
orange (two conformers), 4.3 in blue, 4.4 in purple and NAD+ in light beige. (A) The protein is
displayed in gray as solvent accessible surface. Inhibitors and cofactor are shown as stick models.
The individual sites of the water molecule W1 are represented in the same color as the
corresponding inhibitor in the various structures. W1 corresponds to water molecule 472 in 5ICM,
501 in 5O6O, 472 in 5O43 and 488 in 5O42 in the respective crystal structures. The amino acids
within a distance of 4.6 Å are shown as thin lines. In panel B, C and D, the carbon atoms of the
amino acids are shown in white, H-bond distances are depicted as dotted lines. Distances are given
in Å.
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Description of the binding mode of three quinoline-based inhibitors in
complex with 17β-HSD14
The C-ring of the three quinoline-based inhibitors 4.8, 4.12 and 4.15 is located in the same
region as in the 2,6-pyridine inhibitor class. The 3-OH group of the C-ring experiences the
same H-bond interactions with Tyr154 (d = 2.4-2.5 Å) and Ser141 (d = 2.4-2.5 Å) as
described for the previous inhibitor class (Figure 4.4 A and B and Figure 4.5). The quinoline
core addresses the hydrophobic region formed by Pro95, Pro96, Leu191, Trp192 and Leu195
(amino acids shown in Figure 4.1). The amine substituent of 4.15 is in H-bond distance with
the carbonyl group of the side chain of Gln150 (d = 2.9 Å), while no additional interaction
can be observed for the nitrile substituent of 4.12 (Figure 4.5).
Figure 4.4: Close-up view of the binding pocket of the superimposed crystal structures of 17β-
HSD14 obtained in ternary complexes with different inhibitors. The protein is displayed in gray as
solvent accessible surface. Inhibitors and cofactor are shown as stick models. The carbon atoms of
the NAD+ are shown in light beige. The water molecules W1, W2, W3, W4 and W5 are represented
in the same color as the corresponding inhibitor of the individual structures. (A) The carbon atoms
of the ligands are shown for 3.9 (PDB code: 5L7Y) [127] in yellow and 4.8 (PDB code: 5O6Z) in blue.
(B) The carbon atoms of the ligands are shown for 4.8 in blue, 4.12 (PDB code: 5O7C) in green and
4.15 (PDB code: 5O72) in light orange. (C) The carbon atoms of the ligands are shown for 4.8 in
blue and 4.10 (PDB code: 5O6X) in red.
Compound 4.10 displays a slightly deviating binding mode when compared to the other
inhibitors described so far. The entire compound is pushed deeper into the active site and it
is the only inhibitor that induces an altered conformation of the sidechain of Tyr253’ of the
neighboring monomer in the functional tetramer (Figure 4.4 C). The C-ring of 4.10 is now
stacked behind Tyr253’. The 3-OH group of this phenyl ring succeed to remain within
H-bond distance of the side chain hydroxy group of Ser141 (d = 2.4 Å) which is part of the
catalytic triad. Furthermore, it involves the carbonyl group of the backbone of Pro184 in an
H-bond contact (d = 3.4 Å). However, the direct H-bond interaction between the 3-OH
group and the side chain of Tyr154, found in all other structures with 17β-HSD14 inhibitors,
is no longer present. Instead, the carbonyl group of the ligand interacts with Tyr154 mediated
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via a water molecule W6 (d = 2.7 and 2.8 Å). The methylquinoline moiety is completely
buried in the hydrophobic pocket composed by Pro95, Pro96, Leu191, Trp192 and Leu195
and, in addition, the quinoline nitrogen is within H-bond distance to the sidechain of Gln148
(d = 3.1 Å, Figure 4.5 D). The conserved water molecule W1 is also present as described for
the pyridine-based inhibitor (Figure 4.4). It is found in conserved position as for all the
quinoline-based inhibitors. However, in the case of the protein complex with 4.10, the water
Figure 4.5: Crystal structures of 17β-HSD14 in complex with cofactor NAD+ and inhibitors. The
carbon atoms of 4.8 are shown in blue (A), 4.12 in green (B), 4.15 in light orange (C) and 4.10 in
red (D). The inhibitors and cofactor NAD+ are shown as stick models. The amino acids are shown as
thin lines with carbon atom in white. The water molecule W6 is represented as red sphere. H-
bonds are depicted as dotted lines. Distances are given in Å.
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molecule is shifted upward due to the different conformation of this inhibitor. Overall three
additional conserved water molecules can be observed in the four structures, located in the
pocket usually occupied by the A-ring of the pyridine-based inhibitors (Figure 4.4). In case of
the complex with 4.15, one water molecule (W3) is displaced by the amino group of the
glycine moiety of the inhibitor.
Comparison of the structures of 17β-HSD14, and 17β-HSD10.
Structural comparison between the cofactor binding site of human 17β-HSD14 (PDB code:
5L7Y [127]) and 17β-HSD10 (PDB code: 1U7T [94]) reveals how the overall geometry of the
enzymes is conserved. The structure of 17β-HSD14 can be divided into two distinct regions.
The first region contains the Rossmann-fold scaffold where the cofactor binds, while the
second region is responsible for substrate recognition [32, 126, 127]. Structural comparison
between the two enzymes revealed that the cofactor is found with nearly identical geometry
in the pocket, with an RMSD value of 0.6 Å (calculated with fconv [186]). The second region
deviates among the protein residues in both cases, although the position of the catalytic triad
and Asp114 (number referred to 17β-HSD14) is preserved. The flexible loop of 17β-HSD10 is
slightly shorter compare to the one of 17β-HSD14. Nevertheless, the resulting binding
pockets are of similar volume and shape. However, 17β-HSD10 has an additional
solvent-exposed loop (residues 141–146, Figure 4.6). For both example of 17β-HSD10 and
17β-HSD14, the C-terminal tail is completely unstructured. In case of 17β-HSD14, it is
involved in the interactions between both monomers. The position of Gln165 in 17β-HSD10
enzyme is occupied by His93 and Gln148 in the case of 17β-HSD14. The different
arrangement of the amino acids results in a shallower binding pocket for 17β-HSD10
compare the one of 17β-HSD14. The inhibitors occupy a similar region in types 14 and 10,
However, the inhibitor for 17β-HSD10 adopts a rather planar geometry, reinforced by
Leu206 that orients toward the center of the pocket, suggesting that a more kink-shaped
inhibitor such as 3.9 would not fit in to the binding pocket (Figure 4.6). As there is no other
structures of the human 17β-HSD10 enzyme, it is hard to tell if the conformation of the
flexible loop is ligand induce.
Selectivity
We initially derived the class of 2,6-pyridine ketone inhibitors taking 3.9 as reference
compound retrieved from a library of known 17β-HSD1 and 17β-HSD2 inhibitors [127]. It
was therefore important to validate whether a preference of binding toward 17β-HSD1 and
17β-HSD2 was maintained or whether the optimized compounds showed already a good
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selectivity profile toward 17β-HSD14. In addition, as mentioned previously, the investigation
of the selectivity profile with respect to binding toward 17β-HSD10 is of high concern
considering the given high similarity of 17β-HSD14 with the latter enzyme.
We selected inhibitors that showed good inhibition of 17β-HSD14 (Ki < 100 nM) to validate
the selectivity profile towards 17β-HSD1, 17β-HSD2 and 17β-HSD10. The potential of the
selected 14 inhibitors to inhibit 17β-HSD1, 17β-HSD2 and 17β-HSD10 was studied using a
competitive radioactive assay, by quantifying the formation of of [3H]-labeled E2 (for 17β-
HSD type 1) and [3H]-labeled estrone (E1, for 17β-HSD type 2 and 10) after incubation of the
protein with the cofactor and the inhibitor [174]. The results of the assay are shown in Table
4.6 and expressed as percentage of inhibition.
The first approach to modify the scaffold of the pyridine derivatives resulted in the
production of less selective compounds (4.1, 4.2, 4.3 and 4.4), which showed even higher
affinity for 17β-HSD1 and 17β-HSD2, (57-99% 17β-HSD1 inhibition @ 1 µM and 82-100%
Figure 4.6: Superimposition of 17β-HSD14 (yellow, PDB code: 5L7Y) and 17β-HSD10 (orange, PDB
code: 1U7T) structures. The proteins are shown as ribbon model. The ligands and cofactors are
shown as stick models and their carbon atoms are colored as the corresponding protein structure.
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17β-HSD2 inhibition @ 1 µM) compared to the initial compound 3.9 (8% 17β-HSD1
inhibition and 56% 17β-HSD2 inhibition @ 1 µM).
The second strategy to optimize the scaffold, which led to the quinoline-based compounds
4.8-4.16, resulted in inhibitors which showed no significant inhibitory activity toward
17β-HSD1, only the naphthalene derivative 4.9 falls out of this profile and exhibits high 17β-
HSD1 inhibitory activity (64% inhibition @ 1 µM).
In our previous study [127], we could show that 3.9 shows a 17β-HSD2 inhibition of 50% at
1µM, corresponding to an IC50 of 1 µM. Taking into account the kinetic constant of the assay
(Km= 400 nM, substrate concentration = 500 nM), a Ki for 3.9 can be estimated to be about
450 nM. The determined Ki for 3.9 in the 17β-HSD14 assay was 13 nM. 3.9 is therefore about
35 fold more selective on 17β-HSD14 compared to 17β-HSD2. As compounds 4.12, 4.13 and
4.15 exhibit a 17β-HSD2 inhibition in the same range as 3.9 (52-63% inhibition @ 1 µM), it
can be expected that they will be as selective as 3.9 toward 17β-HSD2, thus underlining the
satisfactory selectivity discrimination of the quinoline-based inhibitors against 17β-HSD1
and 17β-HSD2.
With respect to 17β-HSD10, only compounds 4.1 and 4.3 showed a weak inhibitory activity
(17% and 19% inhibition @ 1 µM, respectively) while all the other synthesized derivatives are
inactive suggesting an overall very convincing selectivity profile toward 17β-HSD10 (Table
4.6).
Cytotoxicity evaluation
Seven compounds, selected on the basis of their 17β-HSD14 inhibition profile and selectivity
were evaluated for their cytotoxicity using an MTT assay based on the HEK293 cell line. All
tested compounds, 3.9, 4.4, 4.11, 4.13 and 4.15 displayed a very low cytotoxicity (IG50 >
100 µM). Due to insufficient solubility, 4.11 and 4.12 could not be tested at 100 µM, however,
the cells showed 80% survival at a concentration of 20 µM, the maximally possible
concentration tested.
Pgp ATPase Activity Assays
Pgp, also termed MDR1 and ABCB1, is an integral plasma membrane protein expressed at
the luminal surface of the BBB [187]. The enzyme is an ATP-dependent drug efflux pump,
which plays an important role in multi-drug resistance [184]. As mentioned, 17β-HSD14 was
described to be also expressed in the brain and liver [100]. Goal of the project is the
development of tool compounds to study the physiological role of 17β-HSD14 in vivo, it was
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Table 4.6: 17β-HSD type 1, 2 and 10 inhibitory activities (% inhibition) of the most interesting
compounds.
compd
17β-HSD1
% Inh. @ 1 µM a
17β-HSD2
% Inh. @ 1 µM b
17β-HSD10
% Inh. @ 1 µM c
3.9 8 56 n.i.
4.1 69 100 17
4.2 57 82 n.i.
4.3 99 100 19
4.4 88 100 n.i.
4.8 6 76 n.i.
4.9 64 96 n.i.
4.10 12 78 n.i.
4.11 20 71 n.i.
4.12 n.i. 56 n.i.
4.13 n.i. 52 n.i.
4.14 21 83 n.i.
4.15 3 63 n.i.
4.16 11 80 n.i.
a Placental 17β-HSD1 enzyme, cytosolic fraction, substrate [3H]-E1 + E1 [500 nM], NADH [ 0.5 mM], mean value of
2 determinations; standard deviation < 10 %.
b Placental 17β-HSD2 enzyme, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value
of 2 determinations; standard deviation < 10 %.
sc Recombinantly expressed 17β-HSD10 enzyme, bacterial suspension, substrate [3H]-E2 [25 nM], NAD+
[0.75 mM], mean value of 3 determinations; standard deviation < 10 %.
important to validate whether the most promising compounds in both the pyridine and the
quinoline class, affect Pgp either as substrate or as inhibitor or leave this transporter
unaffected [164]. The following four compounds from the two classes were selected to test for
Pgp interaction: 3.9, 4.12, 4.13 and 4.15. They combine good 17β-HSD14 inhibitory potency
with convincing selectivity profile.
The assay was performed in successive manner. At first the tested inhibitor and ATP were
incubated simultaneausly with the Pgp protein present in a cell membrane fraction. After
quenching of the reaction, unmetabolized ATP was detected by means of an ATP-dependent
luminescence signal which was generated after addition of firefly luciferase. The impact of the
tested compounds 3.9, 4.12, 4.13 and 4.15 on the efflux pump was examined in comparison
to untreated samples (control) and samples treated with the selective Pgp inhibitor sodium
orthovanadate (Na3VO4) and verapamil, a known substrate of the Pgp. The results can be
seen on Figure 4.7.
The untreated sample (a) showed some luminescence indicating the production of some ATP
originating from other sources than Pgp as cell fraction membranes were used and no
purified Pgp. The ATP consumption for samples exposed to the Pgp inhibitor (Na3VO4, b)
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was blocked resulting in luminescence increase compared to the untreated samples. The
difference in the luminescence signal of these samples represented the basal activity of the
tested protein Pgp. Verapamil (c) stimulated the Pgp ATPase activity as it is a substrate of the
protein. A decrease in ATP was observed correlating with a significant drop in luminescence
compared to untreated samples. For samples containing 3.9, 4.12, 4.13 and 4.15 no
significant change in luminescence compared to untreated samples could be observed. In
consequence our compounds can be classified as neither substrates nor inhibitors of the
efflux pump Pgp (Figure 4.7).
4.3 Discussion and conclusion
SAR of pyridine derivatives
Our first structure-based modifications of the initial pyridine-based scaffold led to the
ten-fold more potent compound 4.4 (Ki = 1.5  nM) compared to 3.9 (Ki = 13 nM). The crystal
structure with this ligand revealed that its ethylene linker is more deeply buried in the
hydrophobic pocket defined by Leu191, Leu195 and Trp192. Obviously this hydrophobic
linker maintains the conformational properties but is beneficial for binding due to its lower
desolvation penalty compared to the carbonyl analog (3.9) which does not use its polar
oxygen for any interaction. The flipped A-ring (compared to 3.9) led to an improved
Figure 4.7: Effect of the four 17β-HSD14 inhibitors 3.9, 4.12, 4.13 and 4.15 on Pgp ATPase activity.
(a), untreated sample, (b) Pgp inhibitor Na3VO4 and (c) Pgp substrate verapamil. Data were
analyzed in term of relative light units (RLU) from two independent experiments with three
technical repeats.
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geometry where this ring comes in proximity of the hydrophobic region build up by Pro95,
Pro96 and Leu195. In addition, the 3-OH group attached to the A-ring is moved to a more
favorable H-bond distance (d = 2.7 Å) toward the carbonyl group of the Ala149 backbone.
Taken together these aspects might be responsible for the gain in affinity. Using an ether-
(4.1), amine- (4.2) or methylamine linker (4.3) does not enhance activity over 3.9.
Compounds 4.5, 4.6 and 4.7 lose in affinity possibly owing to the introduced polar amide
linkers which are exposed to a predominantly hydrophobic environment. In addition, the A-
rings of these inhibitors remain partly solvent exposed, likely as the compounds appear
rather long for the binding site.
Selectivity of pyridine derivatives
All the newly synthetized pyridine-based inhibitors showed a high selectivity toward 17β-
HSD10. However, a less satisfactory selectivity profile toward 17β-HSD1 and 17β-HSD2 was
caused by all the pyridine which do not bear a carbonyl linker including 4.1, 4.2, 4.3and 4.4.
A rational explanation of the observed selectivity profile of the inhibitors toward 17β-HSD1,
17β-HSD2 and 17β-HSD10 in structural terms appears rather difficult elucidate. Due to the
conformational properties of the 17β-HSD1 binding pocket — with the flexible loop
restricting the remote part, opposite to the catalytic triad, and its several adapted
conformations — it is extremely challenging to perform reliable docking studies. The lack of
a crystal structure of 17β-HSD2, the rather flat binding site and the completely different
mechanism of action of the 17β-HSD10 inhibitor AG18051 [94] (covalently attached to the
cofactor, PDB code: 1U7T) do not allow a detailed conclusive comparison. Taken together
the activity profile and the selectivity profile of the pyridines, it appeared reasonable to
maintain the carbonyl linker for further investigation in the quinoline class.
SAR and selectivity of the quinoline/naphthalene derivatives
According to the second optimization step, the goal was to extend the central pyridine core to
address the empty lipophilic pocket adjacent to the A- and B-ring (Figure 4.2). The designed
quinoline-based inhibitor 4.8 was modelled into the crystal structure and the simulation
suggested a good fit into the active site of the protein (Figure 4.8). The binding mode of 4.8
was verified by the co-crystal structure and allowed the understanding of its very high
potency (Ki = 12 nM) as anticipated (Figure 4.8). As already remarked by Braun et al. [127],
replacing the 3-OH group at the C-ring by a 3-OMe moiety resulted in a strong drop of
binding affinity (4.8a, 21% inhibition @ 100 µM). The naphthalene compound 4.9 was
synthetized to investigate the importance of the pyridine nitrogen in the core ring system of
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4.8. The derivative 4.9 (Ki = 6  nM) showed a similar binding affinity compared to the
quinoline analogue 4.8. However, the nitrogen of the quinoline core enhances the solubility
over its naphthalene analogue. In addition, it was shown that the selectivity profile toward
17β-HSD types 1 and 2 was less favorable for naphthyl analog 4.9 and therefore not further
developed.
The decoration of the quinoline core with substituents showing different hydrophobicity
profiles resulted in highly active inhibitors (4.10-4.16). From the crystal structures of 4.12
and 4.15 (Figure 4.5), it became apparent that all ligands adopted the same binding mode as
4.8, interacting with Tyr154 and Ser141 from the catalytic triad. The additional hydrophobic
interactions of the extended core motif with the pocket built-up by Leu191, Trp192, Leu195
and Met199 may have compensated the loss of the A-ring and of the H-bond interaction with
Ala149 which were observed for compound 3.9 [127] (e.g. 4.8, Ki = 12  nM vs. 3.9
Ki = 13  nM). The nitrile group of 4.12, pointing off from the active site without performing
any additional interactions with the protein, resulted in no significant change in the binding
affinity (Ki = 9  nM). For 4.15, an additional H-bond interaction of the exocyclic amino
group was experienced. However, no increase in affinity compared to compound 4.8 was
observed (Ki = 23  nM). A similar experience with respect to the inhibitory potency was made
for 4.13 bearing a rather hydrophilic tetrazole moiety (Ki = 10  nM). As no crystal structure
could be obtained for 4.13, the ligand was modeled as a complex with 17β-HSD14 and an
Figure 4.8: Superimposition of the modeled structure of 17β-HSD14 in complex with inhibitor 4.8
and its crystal structure (PDB code: 5O6Z). The protein is displayed in gray by use of the solvent
accessible surface. The ligands are shown as stick models. The C atoms of the modeled ligand are
colored in pink and in blue for the crystalized compound. Amino acids and cofactor are shown as
thin lines. H-bonds are depicted as black dotted lines.
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H-bond interaction of the quinoline core with the side chain of Gln148 could be identified
(Figure 4.9 C).
The analog modeling of the binding mode of the 7-aminoquinoline derivative 4.14
(Ki = 34  nM) also did not revealed any additional interactions of the amino group (Figure 4.9
B). The introduction of a 6-OH group at the quinoline core led to a loss in affinity by a factor
of ten as observed for 4.11 (Ki = 119 nM). The modeled complex structure of 4.11 predicted a
similar binding mode as the one adopted by the other quinoline-based inhibitors (Figure 4.9
A). However, the polar 6-OH group is pointing into the rather hydrophobic region formed
Figure 4.9: Modeled structures of 17β-HSD14 in complex with inhibitors 4.11 (A), 4.13 (C), 4.14
(B) and 4.16 (D). The protein is displayed in gray by use of the solvent accessible surface. The
inhibitors are shown as stick models. The C atoms of the modeled ligand are colored in pink.
Amino acids and cofactor are shown as thin lines. H-bonds are depicted as black dotted lines.
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by Met199 and Thr205 which might explain the observed loss in activity. The structurally
increased ligand 4.16 showed a high affinity to the protein (Ki = 6  nM). The modelled
complex suggests an enhanced contact surface between ligand and protein resulting in
improved potency (Figure 4.9 D).
The deviating binding mode of the 6-methylquinoline derivative 4.10 did not parallel a
significant change in binding affinity compared to 4.8 (Ki = 6  nM vs Ki = 13  nM,
respectively). Surprisingly, the 3-OH group of the C-ring did not form an H-bond interaction
with Tyr154 of the catalytic triad, which was reported to be essential to achieve high potency
[127], but it is in H-bond distance with Ser141. Instead, Tyr154 forms an H-bond network
via a water molecule (W6) with the ligand’s carbonyl linker. In addition, an H-bond
interaction between Gln148 and the central quinoline nitrogen was formed. The quinoline
core along with the 6-methyl group are deeply buried in the hydrophobic pocket flanked by
Leu191, Tpr192, Leu195, Met199 and Thr205 (Figure 4.5). Taken together, these effects seem
to compensate the loss in the direct interaction to Tyr154.
Interestingly, a water molecule (W6) is entrapped to mediate a contact between ligand and
protein. This water is also found at the same position in the complex structures with 4.10,
4.12 and for the holoenzyme (PDB code: 5JSF and 5JS6). The fact that this water molecule is
in close proximity to the catalytic triad and overall present in four structures, raises the
question about its possible involvement in the catalytic mechanism (Figure 4.10).
Regarding the selectivity of the synthesized quinoline-based inhibitors, the affinity toward
17β-HSD1 and 17β-HSD10 was minor rendering these compounds prominent as quite
selective binders. Adding the selectivity profile toward 17β-HSD2 to this comparison, 4.12,
4.13 and 4.15 can be highlighted to exhibit signatures comparable to that of 3.9. Considering
the potency and selectivity profiles, the initial compound 3.9 and the newly synthesized
quinoline-based inhibitors 4.12, 4.13 and 4.15 exhibit the best profiles. Furthermore, these
four compounds displayed very low cytotoxicity (IG50 > 100 µM) and disqualify them as
neither substrates nor inhibitors of the multi-drug resistance protein Pgp ATPase, suggesting
them as potent tool compounds for the further investigations regarding putative in vivo
administration to reveal insights into the physiological role of 17β-HSD14.
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4.4 Experimental section
Enzyme expression and purification
The pure recombinant 17β-HSD14 enzyme was obtained via heterologous expression using
p11-Toronto1 vector and the competent cells BL21 pLysS strain of E.coli as previously
described [126, 127]. The protein purification was performed applying two steps of affinity
chromatography (Ni-NTA column) followed by size-exclusion chromatography. The stability
of the protein was increased by the addition of the cofactor (NAD+) and of 250 mM of
glucose to the buffer during the purification and storage. Purity was confirmed by SDS page
and mass spectrometry (result not shown).
Figure 4.10: Superimposition of the crystal structures of 17β-HSD14 holoenzyme (PDB code: 5JSF
and 5JS6) and in complex with cofactor NAD+ and inhibitors. The carbon atoms of 4.12 are colored
in green (PDB code: 5O7C) and 4.10 in red (PDB code: 5O72). The inhibitors and cofactor NAD+ are
shown as stick models. The amino acids are shown as thin lines with carbon atom in white. H-
bonds are depicted as dotted lines. The water molecules W6 are represented in the same color as
the corresponding inhibitor of the individual structures and are colored in blue for 5JSF and in pink
5JS6.
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Inhibition of 17β-HSD14
Inhibitory activities were evaluated with a fluorimetric assay as previously described.[127]
Briefly, to a mixture of NAD+ (1.2 mM) and E2 (32 µM) in 100 mM phosphate buffer pH 8,
the potential inhibitor was added in DMSO (final DMSO concentration in assay: 1%) and the
enzymatic reaction was started by addition of the purified enzyme (1 mg/ml). The
production of the fluorescent NADH formed was measured continuously for 15 min on a
Saphir Tecan2. A linear relationship between product formation and reaction time was
obtained and the slope of the progress curves was calculated by linear regression. The Ki
values were calculated by means of the Morrison equation using the procedure detailed by
Copeland [167] as previously described.[127] The fitting and data analysis were performed
using GraphPad Prism 7.
Inhibition of 17β-HSD1 and 17β-HSD2
17β-HSD1 and 17β-HSD2 were partially purified from human placenta according to
previously described procedures [174, 188]. For the 17β-HSD1 inhibition assay the cytosolic
fraction was incubated with NADH [500 µM], and the potential inhibitor was added in
DMSO (final concentration in assay: 1 µM, final DMSO concentration: 1%) at 37°C in a
phosphate buffer (50 mM). The enzymatic reaction was started by addition of radioactive
[2,4,6,7-3H]-E1 in a mixture with the unlabeled substrate E1 (final concentration: 500 nM)
and stopped with HgCl2 after 10 min. Separation and quantification of the extracted
radioactive steroids were performed by HPLC coupled to a radioflow detector. The 17β-
HSD2 inhibition assay was performed similarly incubating the microsomal fraction in the
presence of NAD+ [1500 µM] and [2,4,6,7-3H]-E2  in a mixture with the unlabeled substrate
E2(final concentration: 500 nM).
Inhibition of 17β-HSD10
A suspension of the bacterial pellet in 100 mM phosphate buffer pH 7.7 was incubated with
[6,7-3H]-E2 (final concentration: 25 nM) in presence of the potential inhibitor in DMSO
(final concentration in assay: 1µM, final DMSO concentration: 1%) at 37°C. The enzymatic
reaction was started by addition of NAD+ (0.75 mM) and stopped by means of 0.21 M
ascorbic acid in a methanol/acetic acid mixture (99:1, v/v) after an incubation time of 30 min.
Substrate and product were extracted from the reaction mixture by SPE (Strata C18-E
columns from Phenomenex on a vacuum device). Separation and quantification of the
radioactive labeled steroids was performed with HPLC (Luna 5µm C18(2), 125 x 4.00 mm
from Phenomenex, with an acetonitrile/water mixture (43:57, v.v), flow rate 1mL/min).
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Substrate conversion is given in % as calculated after integration of the product and substrate
peaks. Inhibition was calculated based on conversion without potential inhibitor (DMSO
only) which was set to 0% inhibition.
Co-crystallization of the protein with inhibitors
The co-crystallization of 17β-HSD14 in complex with the different classes of inhibitors was
performed following the already described slightly optimized protocols [126, 127].
The final inhibitor concentration of 4 mM was incubated with the protein solution (9.5
mg/mL) containing 0.6 mM NAD+ and 5% DMSO for 30 minutes. The mixture was then
centrifuged at 10000 g for 20 minutes in order to separate the precipitated. Afterwards, 2 µL
of the supernatant was mixed with 2 µL of mother liquor composed of 0.1 M HEPES, 20%
(w/v) PEG6000 and 5% (v/v) DMSO, adjusted to pH 7.0. Crystals of sufficient quality for data
collection were grown at a temperature of 18°C for 10 days and then exposed for a few
seconds to a cryo buffer obtained by the combination of mother liquor with the addition of
20% glucose. Finally the specimen were successively flash-frozen in liquid nitrogen.
Crystallography
Data collection and processing
All the datasets of the structures of the protein-inhibitor complexes were collected at
beamline 14.1 at BESSY II in Berlin, Germany. The data collection was achieved with a
wavelength of 0.9184 Å and a temperature of 100 K on a DECTRIS Pilatus 6M pixel detector.
All datasets were indexed, processed and scaled with XDS [142].
Structure determination and refinement
The structures were determined by molecular replacement with the program PHASER
MR[143] from the CCP4 suit.[132] In all cases, coordinates of the PDB entry 5EN4 were used
as a search model. A subset, corresponding to 5% of the reflections, was used for the
calculation of Rfree and consequently was omitted from the refinement. The model was built
in COOT [171] and refined using PHENIX.refine version 1.10.1-2155 [145]. The ligands were
energetically minimized and their restraints were generated using  Grade Web Server [147]
and eLBOW [145] based on the SMILEs codes obtained with Molinspiration v2013.91 [146].
As first refinement step for all structures, a Cartesian simulated annealing was performed
using default parameters. The final models were built in COOT with alternating structural
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modification and refinement of XYZ coordinates, occupancies and individual B-factors in
PHENIX. Hydrogens were included in the models of the structures. For 5O6X, the
temperature factors of all atoms, except hydrogen atoms and solvent molecules, were refined
anisotropically. For 5O72, the temperature factors were refined isotropically. For the other
five structures, TLS refinement was performed with nine TLS groups selected from the
TLSMD web server [148, 149].
MOE models
The inhibitor 4.8, 4.11, 4.13, 4.14 and 4.16 were model inside the crystal structure PDB code:
5L7Y [126] and minimized with MOE [173]. During minimization, the AMBER12 force field
was applied. The heavy atoms of the protein and the 3-OH group at the C-ring of the
inhibitors were fixed. In order to give to the ligand sufficient freedom to move also the
residues His93, Gln148 and Met199 where allowed unrestricted to move during
minimization.
Cytotoxicity Assay
Potential cytotoxicity of inhibitors 3.9, 5.12, 5.13 and 5.15 toward HEK293 cells was
determined by an MTT assay [189] as previously described [190]. The cells were seeded into
96-well plates overnight at a 1 x 104 cells/well density. Series of inhibitor concentrations
(from 0 to 100 μM) were added to the well and incubated for 72 h, at 37 °C under 5% CO2.
The cell viability was subsequent evaluated by the MTT colorimetric assay.
Pgp ATPase Activity Assays
The effect of inhibitors 3.9, 5.12, 5.13 and 5.15 on Pgp ATPase activity was evaluated by
means of the Pgp-GloTM assay system (Promega, Madison, WI, USA).In a white 96-well plate,
the inhibitors 3.9, 5.12, 5.13 and 5.15 were incubated in DMSO (final concentration in assay:
10 µM) with 25 μg of recombinant human Pgp membrane. The Pgp-glo assay buffer was used
as the untreated sample control. The positive control of drug induced Pgp ATPase activity
was obtained by addition of 200 μM verapamil to the assay buffer. As selective inhibitor of
Pgp ATPase activity, 100 μM sodium orthovanadate in the assay buffer was used. All the
samples contained a final DMSO concentration of 1%. The Pgp ATPase activity was initiated
by the addition of 5 mM MgATP and incubated at 37 °C for 60 min. Luminescence was
recorded after adding 50 μL of ATP detection reagent. After 25 min of incubation at room
temperature, the total luminescence signal was detected on a Tecan Saphire 2.

Structural Comparison between 17β-HSD Enzymes
and Virtual Screening of Inhibitors
Introductory remarks
This chapter is based on the results preliminary addressed in Chapters 2 and 3. In the
following a detailed discussion of the structural differences between 17β-HSD14 and the
other 17β-HSD proteins will be provided. Furthermore, docking studies performed during
the early stage of this project will be discussed.
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5.1 Introduction
Crystal structures of proteins provide valuable structural information on how a ligand binds
to a target protein. Additionally, mechanistic insights can be obtained by comparing the
three-dimensional arrangement of amino acids that determine the active site of different
enzymes of the 17β-HSD family.
In the following, a structural comparison is performed between 17β-HSD14 and other
17β-HSDs that have been deposited as crystal structures in the publicly available Protein
Databank (PDB). The structures of 17β-HSDs used for comparison were selected based on
the catalyzed reaction, the formed complex and the quality of the respective crystal
structures. The information obtained from this comparison will assist in the modelling of the
three-dimensional structures of other not yet crystallized 17β-HSDs. In the following,
structural differences between 17β-HSD14 and three related 17β-HSDs (h17β-HSD1, h17β-
HSD8, and 17β-HSD10) are discussed. A focus is put on the enzymes’ active sites. 17β-HSD5
is the only 17β-HSD protein that belongs to the AKR superfamily. However, a direct
comparison to 17β-HSD14 is difficult due to its low structural similarity (Figure 5.1), and
thus will not be considered in the following. 17β-HSD2 catalyzes the same reaction as 17β-
HSD14. Unfortunately, no crystal structure of 17β-HSD2 is available to date and thus a
structural comparison between type 2 and type 14 is not possible.
Figure 5.1: Superimposition based on the coordinates of the cofactor of the crystal structures of
the 17β-HSD14 variant T205 (orange) and 17β-HSD5 (green) displayed as ribbon models; the
bound cofactor is shown as stick model. (A) Overview of the superimposed tertiary structures. (B)
Close up view of the cofactor binding pockets. His93 of 17β-HSD14 and His117 of 17β-HSD5 are
shown as stick models (PDB code for 17β-HSD14: 5JS6; 17β-HSD5: 1S1P). Structural
representations were prepared with PyMOL [33].
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5.2 Comparison of the crystal structures of 17β-HSD1 and 17β-
HSD14
Until now, 22 crystal structures of 17β-HSD1 as apoenzyme or in complex with a
substrate/product or inhibitor have been deposited in the PDB. Five of these structures with a
resolution between 1.60 to 2.24 Å have been selected for the structural comparison with
17β-HSD14. Ten of the aforementioned 22 17β-HSD1 crystal structures had to be excluded
from the comparison since they showed differences between Rfree and Rwork larger or equal to
10%. The large difference in the R values possibly indicates inaccuracies in the crystal
structure models (severe overfitting) that would consequently lead to an erroneous
discussion. Additional seven structures had to be excluded since the flexible loop of
17β-HSD1 (residues 190-201), that contributes structurally to the binding pocket, was not
resolved in their electron density maps. The superimposition based on the Cα coordinates of
the five selected crystal structures of 17β-HSD1 reveals how the adopted conformation of the
flexible loop drastically deviates depending on the bound state of the enzyme (apoenzyme,
PDB code:1BHS; complex with steroid, PDB code: 1DHT; ternary complex with cofactor and
estradiol, PDB code: 1FDT; inhibitor complexes, PDB code: 1I5R and 3HB5), whereas the
remaining part of the enzyme stays conformationally virtually unchanged (Figure 5.2).
Figure 5.2: Superimposition of the five 17β-HSD1 crystal structures selected for geometrical
comparison. The residues 190-201 that comprise the flexible loop are displayed in gray for 1BHS,
magenta for 1DHT, dark green for 1FDT, pink for 1I5R and in light green for 3HB5. The structurally
conserved parts of the protein are colored in white. Ligands are displayed as stick models.
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An analysis of the superimposition of the 17β-HSD1 apoenzyme (PDB code 1BHS [21]) with
the DHT-enzyme complex in absence of the cofactor (PDB code 1DHT [50]) highlights that
the hormone alone does not induce a large structural rearrangement of the flexible loop
(Figure 5.3 A). However, it cannot be excluded that this conformational transition does not
occur because DHT is not the preferred substrate of the enzyme. In fact, 17β-HSD1 prefers
the oxidized form of estrogen as substrate. The comparison between the apoenzyme and the
ternary E2-NADP+-enzyme complex (PDB code 1FDT [20]) reveals that, in the case of the
latter complex, the flexible loop restricts the available space of the binding pocket due to a
shift of maximally about 10 Å in distance (Figure 5.3 B). An analysis of the steroid binding
pose reveals that the DHT molecule is slightly displaced and thus — in contrast to E2 — it
does not establish interactions with Tyr155, a residue being part of the catalytic triad (Figure
5.3 A and C).
The finding that the loop undergoes a larger conformational rearrangement upon cofactor
binding to the enzyme 17β-HSD1 is in accordance with our observations of similar
properties of 17β-HSD14 (as discussed in Chapter 2). It seems unlikely that the deviating
conformations of the flexible loop are caused by differences in crystal packing, since all three
crystal structures occur in identical space group with very similar unit cell parameters.
As already mention earlier, no crystal structures of 17β-HSD1 in complex with a nonsteroidal
inhibitor have been reported yet. In contrast, crystal structures of the enzyme in complex
with steroidal inhibitors do exit. It is remarkable how chemically different inhibitors can
Figure 5.3: Superimposition of the 17β-HSD1 crystal structures. Cofactor, steroidal ligands and
amino acids that are part of the catalytic tetrad (Asn114, Ser142, Tyr155 and Lys159) and that bind
the steroids are shown as stick models. Portions of the enzymes that do not undergo significant
conformational changes are colored in white. Distances are given in Å. (A) The flexible loop in the
crystal structures of the apoenzyme (1BHS) is colored in gray and for 1DHT in magenta. The carbon
atoms of DHT and of relevant amino acids of 1DHT are colored in dark pink. (B) The flexible loop in
the crystal structures of the apoenzyme (1BHS) is colored in gray and for the complex with NADP+
and E2 (1FDT) in dark green. Carbon atoms of E2, NADP+ and of relevant amino acids in the
structure of 1FDT are colored in dark green. (C) Close up view of the binding pocket of 17β-HSD1.
The carbon atoms for 1DHT are colored in magenta and for 1FDT in dark green.
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induce deviating conformational changes of the flexible loop. The enzyme-NADP+-steroidal
inhibitor (E2B) complex (PDB code 3HB5 [191], Figure 5.4) does not show significant
differences compared to the enzyme-NADP+-E2 complex structure (PDB code 1FDT). Only
a slight inhibitor-induced adaptation of the flexible loop is observed for the latter structure
(Figure 5.5 A). In fact, the main steroidal part of the inhibitor is placed in an area where
usually the steroids are bound (interacting with Ser142 and Tyr155 on the one side and with
His 221 on the other side). However, the benzamide moiety induces a slight structural
adjustment of the binding mode of the inhibitor; as a consequence, the interactions with
His221 and Tyr155 are no longer established (Figure 5.5 C). In the crystal structure of the
enzyme in complex with a chemically merged estradiol-adenosine hybrid inhibitor (EM1745)
(PDB code 1I5R [192], Figure 5.4), the flexible loop is displaced by the aliphatic chain of the
hybrid inhibitor and thus adopts a different geometry compared to the crystal structure of the
enzyme-NADP+-E2 complex, 1FDT (Figure 5.5 B). However, the binding mode of the steroid
core of the inhibitor is closely matching the one of E2 (Figure 5.5 D). This induced-fit
behavior triggered by the inhibitor, at least with the presently studied ligands, is not observed
for the 17β-HSD14 enzyme, where a significant transition of the conformation of the flexible
loop was only observed between the apo- and holoenzyme. The flexibility of the binding
pocket observed for these enzymes is a clear obstacle for in silico studies, for instance ligand
docking or selectivity studies following a correlation of the three-dimensional shape of the
binding pocket and the bound potential ligand. It seems impossible to predict which ligand
does and which one does not induce a structural rearrangement of the loop.
The determined crystal structure of 17β-HSD1 in complex with the cofactor NADP+ and E2
(PDB code 1FDT) allows a direct comparison with the crystal structure of 17β-HSD14 in
complex with the cofactor NAD+ and estrone (E1, PDB code 5HS6). The superimposition
reveals a spatial conservation between the structures only in some regions (Figure 5.6 A). The
calculated overall sequence identity is about 20% as determined by the program Clustal
Omega [193–195].
Figure 5.4: Structure of the ligands in complex of the 17β-HSD1 enzyme.
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The structure of 17β-HSD14 can be divided into two distinct regions. The first region
consists of a Rossmann-fold motif that contains the cofactor binding site, whereas the second
region is responsible for substrate recognition [32, 126, 127]. Small differences in the
NAD+/NADP+ binding site can be experienced between type 14 and type 1 (RMSD of 1.6 Å
based on an alignment of all Cα atoms as calculated with COOT [171] and fconv [186]). This
result comes not unexpected since both enzymes recognize different cofactors (NAD+ for
17β-HSD14 versus NADP+ for 17β-HSD1). The flexible loop of 17β-HSD1 restricts the outer
Figure 5.5: Superimposition of the 17β-HSD1 crystal structures. The macromolecules are shown as
ribbon models. Cofactor, inhibitors and amino acids, that are part of the catalytic tetrad (Asn114,
Ser142, Tyr155 and Lys159) and that bind the steroids, are shown as stick models. The portions of
the enzymes that do not undergo conformational changes are colored in white. Distances are
given in Å. (A-B) The flexible loop found in the crystal structure of 1FDT is colored in dark green,
for that of 1I5R in light green and for 3HB5 in pink. (C-D) Close up view of the binding pocket of
17β-HSD1. The carbon atoms for E2 (PDB code 1FDT) are colored in dark green, for the steroid
inhibitor (PDB code 3HB5) in light green and for the hybrid inhibitor (PDB code 1I5R) in pink.
Structural Comparison between 17ß-HSD Enzymes and Virtual Screening of Inhibitors  |  107
Ch
ap
te
r 5
Figure 5.6: Superimposition of the crystal structures of 17β-HSD14 and 17β-HSD1. The protein
structures are shown as ribbon models. The steroids, cofactors, inhibitors and key amino acids
(His93, Asn114, Ser141, Gln148, Ala149, Tyr154 and Lys158 for 17β-HSD14; Gly94, Asn114, Ser142,
Leu149, Tyr155, Lys159 and His 221 for 17β-HSD1), are shown as stick models. H-bonds are
depicted as black dotted lines. Distances are given in Å. (A) Superimposition of 17β-HSD1 (dark
green, PDB code 1FDT) and 17β-HSD14 (yellow, PDB code 5HS6) as ternary complexes and close-
up view of the superimposed substrate in the binding pocket. The carbon atoms of E1 in complex
with 17β-HSD14 are colored in yellow and the carbon atoms of E2 in complex with 17β-HSD1 are
colored in dark green. (B) Superimposition of 17β-HSD1 (light green, PDB code 3HB5) and 17β-
HSD14 (purple, PDB code 5L7Y) as ternary complexes with compound 3.9 and close-up view of the
superimposed inhibitors in the binding pocket. The carbon atoms of 3.9 in complex with 17β-
HSD14 are colored in purple and the carbon atoms of the steroidal inhibitor in complex with 17β-
HSD1 are colored in light green. (C) Superimposition of 17β-HSD1 (pink, PDB code: 1I5R) and 17β-
HSD14 (purple, PDB code 5L7Y) as ternary complexes with compound 3.9 and close-up view of the
superimposed inhibitors in the binding pocket. The carbon atoms of the hybrid steroidal inhibitor
in complex with 17β-HSD1 are colored in pink.
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part of the binding pocket resulting in a smaller volume of the latter one, whereas the
corresponding loop in 17β-HSD14 leaves one side of the binding pocket widely open.
Furthermore, while the catalytic triad is conserved in both enzymes, the steroids adopt
different orientations in the binding sites and thus establish deviating interactions. Another
difference is that in E2 is stabilized by the Ser142 and Tyr155 on one side and by His221 on
the other side in 17β-HSD1. This double stabilization could not be seen in the structure of
17β-HSD14 as the histidine residue is not present in this region of the binding pocket and E1
is interacting only with Tyr154 (Figure 5.6 A). The superimposition of the ternary complex
structures of 17β-HSD14 (PDB code 5L7Y [127]) and 17β-HSD1 (PDB codes 3HB5 and
1I5R) highlights further differences between the protein structures. For example, the C-
terminal portion of 17β-HSD1 is folded in term of two α-helices that enclose the active cleft.
This stands in contrast to the other three enzyme structures (17β-HSD8, 17β-HSD10 and
17β-HSD14), where the C-terminal tail does not adopt any ordered secondary structural
element, and in case of 17β-HSD14 it is involved in interactions between two monomers.
While the inhibitors in 17β-HSD14 adopt a V-like shape in order to properly fit into the
binding pocket, inhibitors of 17β-HSD1 adopt a rather planar binding pose (Figure 5.6 B-C).
The V-like shape of the 17β-HSD14 binding pocket is determined by the two amino acids
His93 and Gln148, which are not present in 17β-HSD1. Instead, in the latter enzyme their
positions are occupied by Gly94 and Leu149, respectively. In addition, His93 and Gln148 are
also decreasing the hydrophobicity of the binding pocket. It can be expected that designing
inhibitors that match with the given three-dimensional requirement of 17β-HSD14 and that
optionally address His93 and/or Gln148 should result in a larger selectivity discriminating
with respect to 17β-HSD1. The superimposition of the enzyme in complex with E1 and with
inhibitor 3.9 (Chapter 3) reveals how His93 and Gln148 need to rotate slightly in order to
accommodate the different ligands (Figure 5.7). This fact supports the hypothesis that the
latter residues are potentially responsible for the substrate selectivity of this enzyme.
5.3 Comparison of the structures of 17β-HSD8, 17β-HSD10 and 17β-
HSD14
In contrast to the plethora of structures determined for 17β-HSD14 and 17β-HSD1, only few
are published for 17β-HSD8 and 17β-HSD10. Thus, it is difficult to perform the same
analysis of the flexible loop for the latter two enzymes as performed for 17β-HSD14 and
17β-HSD1 (vide supra). Only one structure where the loop is fully determined is available for
either 17β-HSD8 or 17β-HSD10.
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A structural comparison between the cofactor binding site of human 17β-HSD14 (PDB code
5L7Y [127]), 17β-HSD8 (PDB code 2PD6, unpublished results) and 17β-HSD10 (PDB code
1U7T [94]) reveals how the overall geometry of the cofactor binding pocket is maintained in
the three proteins. In the crystal structures of 17β-HSD14, 17β-HSD8 and 17β-HSD10 the
geometry of the bound cofactor within the pocket is almost identical, with RMSD values of
0.5 Å and 0.6 Å, respectively (relative to 17β-HSD14, calculated with fconv [186]). The
substrate binding site is deviating very much in amino acid composition for each protein, in
contrast to the cofactor binding site, even though the position of the catalytic triad and
Asp114 (number refers to 17β-HSD14) is preserved in all three enzymes. The flexible loops of
17β-HSD8 and 17β-HSD10 have approximately similar size, but are shorter than in
17β-HSD14 (Figure 5.8). Nevertheless, the resulting substrate binding pockets are of similar
volume and shape, narrow in the proximity of the catalytic triad and open and solvent
exposed on the other side. Consequently, the inhibitors occupy almost the same area in types
14 and 10. However, 17β-HSD10 has an additional solvent exposed loop between βD and αE
(Figure 5.8 B). A close comparison of the binding pockets reveal that the catalytic tetrad,
consisting of Asn-Ser-Tyr-Lys, is perfectly conserved in all three enzymes. However,
17β-HSD8 and 17β-HSD10 share a common Gln (166 and 165, respectively), whereas the
position of this Gln is occupied by His93 and Gln148 in the case of 17β-HSD14. The different
arrangement of the amino acids results in an overall flatter binding pocket for 17β-HSD8 and
17β-HSD10 compared to the one of 17β-HSD14 (Figure 5.9). In conclusion, in order to
achieve a sufficient selectivity toward 17β-HSD14, spatially demanding inhibitors, potentially
Figure 5.7: Close-up view of the binding mode of the ligands of the superimposed 17β-HSD14
complexes. The cofactors, inhibitor 3.9 and amino acids are shown as stick models. Carbon atoms
of the inhibitor-complex structure (PDB code 5L7Y) are colored in purple and for 5HS6 in yellow. H-
bonds are depicted as black dotted lines and labeled with their distances in Å.
110  |  Chapter 5
interacting with His93 and Gln148, are probably preferred by the latter enzyme compared to
17β-HSD8 and 17β-HSD10.
5.4 Docking studies with 17β-HSD14
At the early stage of this study, a docking study with the program GOLD (Genetic
Optimization for Ligand Docking) [196] was performed with the aim to rationally select
ligands from a library of about 400 17β-HSD1 and 17β-HSD2 compounds for an intial in
vitro screening. As the docking studies were performed before the crystals structures of 17β-
Figure 5.8: Superimposition of 17β-HSD14 (purple, PDB code 5L7Y), 17β-HSD8 (cyan, PDB code
2PD6) and 17β-HSD10 (orange, PDB code 1U7T). The proteins are shown as ribbon models.
Ligands and cofactors are shown as stick models, their carbon atoms are colored in the color of the
corresponding protein.
Figure 5.9: Close up view of the binding pocket in the superimposition of 17β-HSD14 (purple, PDB
code 5L7Y), 17β-HSD8 (cyan, PDB code 2PD6) and 17β-HSD10 (orange, PDB code 1U7T). The
inhibitors, amino acids and cofactors are shown as stick models and their carbon atoms are shown
with the same color as the corresponding protein structures (His93, Asn114, Ser141, Gln148,
Tyr154 and Lys158 for 17β-HSD14; Thr107, Asn127, Ser156, Asn163, Gln166, Tyr169 and Lys173 for
17β-HSD8;Ala95, Asn121, Ser155, Asn163, Gln165, Tyr162 and Lys172 for 17β-HSD10).
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HSD14 in complex with ligands had been determined the only reference that could be taken
was the already published apo-structure (PDB code 1YDE [32]). Several issues had to be
overcome to perform the docking study. For instance, identifying the best performing
scoring function for this class of enzyme was not trivial as there were not published
structures of 17β-HSDs in complex with an inhibitor available to validate the docking
attempts. Therefore, the docking performance was evaluated using 24 structures of the
ternary complex of 11β-HSD1. This enzyme had been selected due to the availability of the
many crystal structures of the protein in complex with nonsteroidal inhibitors and due to its
rough similarity with 17β-HSD14. In fact, these two enzymes share the same tertiary
structure (Rossmann-fold motif) and 22% of sequence identity (calculated with COOT [144,
171], based on the alignment of the Cα atoms of PDB code 1YDE for 17β-HSD14 and PDB
code 1XU9 for 11β-HSD1 [197]). Furthermore, their catalytic residues are conserved and the
flexible loop shaping the binding pocket is approximately similar in size (Figure 5.10).
To evaluate the four scoring functions of GOLD (GoldScore, ChemScore, ASP and
CHEMPLP) and to elucidate which of them performs best with 17β-HSD14, the inhibitors
bound in the crystal structures of 11β-HSD1 were first removed from the complex and then
redocked into the respective binding pocket from where they had been removed.
Figure 5.10: Superimposition of 17β-HSD14 (open loop in blue and closed loop in salmon, PDB
code 1YDE) and 11β-HSD1 (light blue, PDB code 1XU7). The proteins are shown as ribbon model
and the catalytic tetrad as stick model (Asn114, Ser141, Tyr154 and Lys158 for 17β-HSD14; Asn143,
Ser170, Tyr183 and Lys187 for 11β-HSD1). (A) Overview of the tertiary structures. (B) Close-up view
of the catalytic residues.
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Subsequently, every inhibitor was docked into the binding pockets of each of the individual
24 crystal structures of 11β-HSD1 (cross-docking attempt). The docking was set in a way to
generate only three poses for each ligand. A visual inspection of the docking results revealed
that ChemScore and CHEMPLP produced the best fit of the ligands into the binding pocket
and generated the closest binding pose with respect to the one observed in the crystal
structures. Before the validated settings could be applied to 17β-HSD14, a model of the
enzyme in complex with its cofactor had to be generated with MOE [173]. The cofactor
model was derived from the crystal structure of 17β-HSD8 (PDB code 2PD6), the most
similar enzyme to 17β-HSD14 of this protein family. The NAD+ was manually inserted into
the cofactor binding pocket followed by a minimization with MOE using the MMFF94X
force-field. During minimization, protein atoms except for H atoms were kept rigid. The
enzyme-cofactor model was generated using the monomer of the protein with the flexible
loop in the open as well as in the closed conformation leading to two final models.
A preliminary study to dock E2 (the substrate of 17β-HSD14) into the binding pocket was
performed using both generated models. However, only the model with the open
conformation resulted in a satisfying result. Therefore, the model with the loop in the open
conformation was selected to proceed further with the simulation. To additionally refine the
docking settings, a set of 15 molecules consisting of 5 active compounds and 10 decoys found
by an initial enzymatic testing was docked into the model (Chapter 3). ChemScore ranked the
5 active compounds within the top 8 scored molecules and thereby confirmed that this
scoring function performs best for this enzyme. Consequently, the model with the open loop
conformation and ChemScore, as scoring function, were selected to perform the docking of
the 400 entries from the 17β-HSD1 and 17β-HSD2 nonsteroidal inhibitor library. According
to the visual inspection of the top 100 generated poses, 15 molecules where selected to be
tested experimentally for their inhibitory activity against the enzyme 17β-HSD14.
Unfortunately, a reliable hit rate for this study could not be determined for two reasons:
Firstly, only about half of the selected molecules were available for testing. Secondly, with
successfully determination of the crystal structure of 17β-HSD14 it became obvious that only
the closed conformation of the flexible loop is adopted upon ligand binding and not, as
anticipated in this initial docking runs, the open conformation of the loop. Thus, all binding
poses predicted by docking are significantly shifted relative to their binding poses in the
crystal structure. This study shows the limitation of a virtual screening attempt for a rather
flexible protein in the absence of crystal structures. Even if some of the ligands would be
correctly selected, the results would be based, to some extent, on incorrect assumptions.
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X-ray Crystallographic Fragment Screening
and Hit Optimization
Introductory remarks
A library of 96 fragments was assembled in the framework of the BMBF project Frag2Xtal.
Protein expression and purification, crystallization experiments, soaking experiment and
structure determination were designed and carry out by the author of this thesis. Part of the
soaking experiments was performed by Lorena Zara under the supervision of the author of
this thesis. The optimized ligands were designed by the author of this thesis in collaboration
with Florian Braun. The synthesis of the optimized ligands and the determination of their
binding affinity were performed by Florian Braun.
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6.1 Introduction
Within the last decade, fragment-based lead discovery (FBLD) has become a promising
approach for the discovery of new lead structures. Since fragments are significantly smaller
(<300 Da) than typical ligands discovered in high-throughput screening (HTS) campaign —
which focus on screening candidates usually comprising already drug-like properties
particularly in term of size and molecular weight — fragments are smaller and weaker
binding with respect to the interaction features provided by a binding pocket. Consequently,
fragment screening usually results in a significantly higher hit rate than a HTS screening, and
therefore a fragment library usually contain much less entries than HTS libraries to cover a
large variety of chemical functional groups to map the properties of a protein binding site
(~1000 entries of a fragment library compared to 100,000 up to millions entries for a HTS
library) [198]. Hence, the design of a fragment library and its screening on a given target is
also feasible in an academic setting which usually cannot afford the resources necessary for
an HTS campaign. Fragments usually contain multiple heteroatoms and even though the
affinity of fragments is low, the established interactions are usually of high quality and
indicate the hot spots of binding. Therefore, fragment hits are good starting points for the
further lead optimization [199]. Furthermore, since starting fragments are designed for low
lipophilicity, also the resulting drug-like molecule will usually show lower lipophilic than an
HTS hit giving rise to superior pharmacokinetic properties of the evolved lead candidates
[200]. However, since the fragment can, due to its limited size, establish only a few
interactions with the residues of the binding pocket of the target protein, fragments usually
have a very low affinity. Thus, their successful identification is very challenging. The
detection of fragment binders commonly follows a screening cascade, starting with a
biophysical screening assay (e.g. SPR, NMR, thermal shift assay), and subsequently
confirmed hits are characterized by X-ray crystallography. However, in a recent
comprehensive case study [201, 202], it could be shown that the preselection of a on first
sight promising subset of fragments by the biophysical assays followed by a subsequent
crystallographic characterization misses a fairly large amount of putative crystallographic hits
(nearly 50%), and does not even achieve the expected enrichment rate making the subsequent
crystallographic analysis more efficient [198, 203, 204]. We therefore decide to perform the
screening of the entire 96-entry in-house fragment library directly on protein crystals without
application of any pre-filter on the target protein 17β-HSD14. So far, the reported
nonsteroidal 17β-HSD14 inhibitors all comprise a very similar and highly lipophilic scaffold.
Consequently, the discovery of a novel scaffold using a fragment-based lead discovery
approach could result in the development of new lead candidates with improved
physicochemical properties.
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6.2 Results and Discussion
Crystallization and Soaking experiments
Crystals of 17β-HSD14 as holoenzyme were used to perform the soaking experiments with
the 96 fragment library. As described by Bertoletti et al. [126], in crystal of the apoenzyme
two of the binding pockets of the assembled homotetramer are not available for binding,
since they are occupied by the C-terminal tail of an adjacent monomer. Furthermore, due to
the high concentration of the cofactor NAD+ present under physiological conditions, it is
unlikely that the apo form of the enzyme is available in a significant concentration in vivo.
Consequently, crystals of the enzyme-NAD+ complex display the more relevant system for
the soaking experiments. In addition, the cubic symmetry space group (I23) of these crystals
only requires data collection of 45° to achieve completeness, substantially speeding up data
collection time and/or closing for collection of highly redundant dataset which will improve
the electron density maps and thus facilitating the identification of which are often only
bound fragments partially occupied. Since fragment cocktails have been reported to decrease
hit rates [199], we decided to soak of the 96 fragments individually. The concentration of the
fragment in the soaking solution and the soaking time were adjusted depending on how the
exposed crystals tolerated the applied conditions.
High quality datasets of individual crystals exposed to the 96 fragments could be obtained.
All datasets exhibit a resolution of at least 2.7 Å and are 99.9-100% complete. All solved
crystal structures were initially refined with an automatic refinement pipeline [198] in order
to reduce the phase error and thus improve the quality of the Fo-Fc difference electron
density to facilitate fragment hit identification. After thorough visual inspection, two hits (J6
and J15) were unequivocally identified in the electron density. Data processing and
preliminary refinement statistics are found in Table 6.1.
Binding mode of the fragment hits
The superimposition of the crystal structures of the enzyme in complex with fragments J6
and J15 (chemical structures in Charts 6.1 and 6.2) reveals that these two ligands occupy
different regions of the binding pocket (Figure 6.1). Fragment J15 is found in close proximity
to the catalytic triad with its carboxyl group in H-bonding distance to the sidechains of
Tyr154 and Ser141, as well as to the sidechain of Tyr253’ contributed by a symmetry related
monomer of the functional tetramer (Figure 6.2). The hydroxyl group of J15 is pointing
toward Asn186, however, it is out of interaction distance. Surprisingly, fragment J6 occupies
a position remotely from the catalytic amino acids. The oxygen atamos of the 1,3-
benzodioxole moiety of the latter fragment are within H-bonding distance to the sidechain of
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Table 6.1. Data collection and refinement statistics.
Complex with J6 Complex with  J15
(A) Data collection and processing a
space group I32 I32
unit cell parameters a, b, c (Å) 129.5, 129.5, 129.5 129.8, 129.8, 129.8
Matthews coefficient b (Å3/Da) 3.2 3.2
solvent content b (%) 61.1 61.3
(B) Diffraction data
resolution range (Å) 50-2.25 (2.39–2.25) 50-2.47 (2.62–2.47)
unique reflections 17085 (2783) 13260 (2123)
R(I)sym (%) 7.3 (50.1) 7.1 (50.5)
Wilson B factor (Å2) 38.8 46.5
completeness (%) 98.5 (99.5) 100.0 (99.9)
redundancy 11.3 (11.2) 6.6 (6.6)
<I/σ(I)> 24.4 (4.7) 19.2(3.5)
(C) Refinement*
resolution range (Å) 45.79-2.25 45.89-2.47
reflections used in refinement (work/free) 17085 (16230/855) 13260 (12597/663)
final R value for all reflections (work/free) (%) 0.16/0.19 0.16/0.21
protein residues 268 268
water molecules 85 13
RMSD from ideality: bond lengths (Å) 0.007 0.007
RMSD from ideality: bond angles (°) 0.840 0.868
a Values in parenthesis describe the highest resolution shell. b Calculated with Matthews_coef program from CCP4
suite version 6.4.0.[132] *Preliminary data.
Figure 6.1: Close-up view of the binding pocket of 17β-HSD14. In both panels, the crystal
structures of J6 and J15 are superimposed for comparison. Carbon atoms of J6 are displayed in
light blue, of J15 in light green, and of NAD+ in dark blue. H-bond contacts are depicted as dashed
lines. Fo-Fc difference electron density is shown as green mesh at a contour level of 3 σ. (A) The
solvent-excluded surface of the protein is displayed in light gray. Inhibitors and cofactor are shown
as stick models. (B) The amino acids involved in the binding of the fragments are shown as thin
lines with C atoms in gray (hetero-atoms color coded).
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Gln148 and Asn186. Furthermore, the secondary amino group establishes a hydrogen-bond
interaction with the backbone carbonyl group of Tyr253’ from the symmetry equivalent
crystal mate being part of the functional tetramer (Figure 6.2 B).
Fragment optimization applying fragment growing
After analysis of the crystal structures, we initiated a structure-based optimization of the
discovered fragment hits with the goal to design a new lead inhibitor scaffold. The discovered
fragments were decorated with different substituents in order to achieve additional
interactions with the binding site and thereby increase binding affinity.
As a first step to optimize J15 (Chart 6.1), we eliminated the hydroxyl group since the crystal
structure revealed that this moiety does not establish any interaction to the protein.
Furthermore, the hydroxyl group can potentially present a steric impediment for further
synthetically optimization of the fragment hit. As a next step, moieties were attached to 6.1
with the aim to address the hydrophobic binding pocket of 17β-HSD14 that is composed by
Leu191, Trp192 and Leu195 (Figure 6.2). Two of the designed inhibitors (the pyridine 6.4
and the quinoline 6.6) were modeled with MOE [173] into the crystal structure of
17β-HSD14 applying the crystallographically determined binding mode of the scaffold of J15
as a starting point. According to the derived models these compounds should theoretically fit
nicely into the binding pocket (Figure 6.3). Therefore, 6.4, 6.6 and the other four compounds
(Chart 6.1) were synthesized.
Figure 6.2: Crystal structures of 17β-HSD14 in complex with cofactor NAD+ and (A) fragment J6
and (B) fragment J15. Close-up view of the binding pocket. Carbon atoms of J6 are shown in light
blue, of J15 in light green and of the cofactor NAD+ in blue. The inhibitors and cofactor NAD+ are
shown as stick models. The amino acids within a distance of 4.6 Å are shown as thin stick models
with carbon atom in white. H-bonds are depicted as dashed lines.
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The strategy for fragment growing of J6 is displayed in Chart 6.2. The N-methyl-
cyclopentanamine tail was removed from the compound since, according to the crystal
structure, this moiety should not contribute significantly to the affinity as no pronounced
interaction could be identified. Furthermore, removal of the moiety facilitated the synthesis
of follow-up derivatives. Similar as in the case of J15, the designed inhibitors were first
modeled into the crystal structure obtained with J6 (Figure 6.4), and, since the modeled
binding mode looked promising, compound 6.9 was subsequently synthesized.
Chart 6.1: Fragment growing strategy for fragment J15.
Figure 6.3: Modeled structures of 17β-HSD14 in complex with compounds 6.4 (A) and 6.6 (B). The
surface of the protein is displayed in gray. The inhibitors are shown as magenta stick models
(hetero-atoms color-coded). Amino acids (white) and cofactor NAD+ (beige) are shown as thin stick
models. H-bonds are depicted as black dotted lines.
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Fragment optimization applying fragment linking
Since fragments J6 and J15 occupy positions in the binding cleft of 17β-HSD14 directly
adjacent to each other, covalent linking of both fragments appeared as a feasible strategy to
generate a new ligand with improved potency. However, covalent linking to two fragments is
known to be a non-trivial and risky endeavor, since already small reinforced special changes
either of the valence and torsion angles or even distances of the two fragments with respect to
each other can partly or entirely diminish affinity of the generated compound. The trimmed
fragments J15 and J6, also used in our fragment growing strategy (6.1 and 6.8, respectively)
were covalently connected via an ethyl linker to give compound 6.10 (Chart 6.3). Prior to
synthesis, 6.10 was validated by modelling. Since the original fragment portions of the
Chart 6.2: Fragment growing strategy for fragment J6.
Figure 6.4: Modeled structure of 17β-HSD14 in complex with compound 6.9. The surface of the
protein is displayed in gray. The inhibitor is shown in magenta as stick model with color-coded
heteroatoms. Protein residues (white) and the cofactor NAD+ (beige) are shown as thin sticks. H-
bonds are depicted as black dotted lines.
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generated supermolecule maintained binding modes (Figure 6.5), the ligand was
subsequently synthesized.
Inhibitory Activity validation
The original fragment hits J6 and J15 and the building blocks 6.1 and 6.8 were tested for
their inhibitory activity against 17β-HSD14. Even at high concentration of 250 μM, all four
molecules did not show any significant affinity to block the protein (Table 6.2). Most likely it
would have been difficult to identify them in a biophysical screening cascade.
Chart 6.3: Fragment linking strategy for fragment J6 and J15.
Figure 6.5: Modeled structure of 17β-HSD14 in complex with compound 6.10. The surface of the
protein is displayed in gray. The inhibitor is shown in magenta as stick model with color-coded
heteroatoms. Protein residues (white) and the cofactor NAD+ (beige) are shown as thin sticks. H-
bonds are depicted as black dotted lines.
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Table 6.2: 17β-HSD14 binding constant (Ki) of the starting fragments.
cmpd.
17β-HSD14
(% Inh. @ 250 mM)a
J15 16
J6 n.i.
6.1 n.i.
6.8 n.i.
Subsequently, also the newly synthesized, size-increased compounds were tested for their
inhibitory activity against 17β-HSD14. All compounds that resulted from fragment growing
showed an improved affinity relative to the starting fragments. From the optimized
fragments, compound 6.4 (derived from fragment J15) showed the highest affinity with a Ki
of 1.9 µM. The optimized compound starting from fragment J6, ligand 6.9, also showed an
improved in affinity toward the enzyme with 63% @ 100 µM (Table 6.3). However, due to its
poor solubility, it was impossible to determine its Ki value.
Table 6.3: 17β-HSD14 binding constants (Ki) of the design compounds.
cmpd. R
Pos.
CO2H
17β-HSD14
(% Inh. @ 250 mM)a Ki (µM)a
6.2 H 3 76 8.7 ± 0.8
6.4 OH 3 93 1.9 ± 0.1
6.3 H 4 80 6.8 ± 1.2
6.5 OH 4 83 4.8 ± 1.0
6.6 - 3 86 8.1 ± 0.8
6.7 - 4 92 7.0 ± 0.5
6.9 - - 63 @ 100 mM -
The generated compound 6.10 from the fragment linking strategy was identified to have an
increased affinity compared to the individual starting fragments (Table 6.4). This is a very
encouraging result since there are only a few examples of successful fragment linking in
literature.
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Table 6.4: 17β-HSD14 binding constant (Ki) of the ligand designed by employing the fragment
linking strategy.
cmpd.
17β-HSD14
(% Inh. @ 250 mM)a Ki (µM)a
6.10 67% 17.6 ± 0.5
Binding mode confirmation of the optimized compounds
To further validate the best compounds from each fragment optimization strategies, we co-
crystalized them in complex with 17β-HSD14 in order to confirm the predicted binding
mode. Two crystal structures were determined and the data collection and refinment statistic
are reported in Table 6.5.
Table 6.5. Data collection and refinement statistics.
a Complex with 6.4, Complex with  6.10,
(A) Data collection and processing
space group I422 I422
unit cell parameters a, b, c (Å) 91.4, 91.4, 133.1 91.0, 91.0, 133.0
Matthews coefficient b (Å3/Da) 2.4 2.4
solvent content b (%) 49.2 49.4
(B) Diffraction data
resolution range (Å) 50-1.62 (1.72–1.62) 50-2.08 (2.21–2.08)
unique reflections 36077 (5762) 17131 (2714)
R(I)sym (%) 7.1 (49.8) 10.2 (50.9)
completeness (%) 99.9 (99.7) 99.9 (99.9)
redundancy 8.5 (8.5) 8.8 (9.2)
<I/σ(I)> 18.9 (3.5) 17.0(4.2)
(C) Refinement*
resolution range (Å) 39.90-1.62 46.22-2.08
reflections used in refinement (work/free) 36077 (34273/1804) 17131 (16274/857)
final R value for all reflections (work/free) (%) 0.13/0.16 0.19/0.21
protein residues 254 251
water molecules 126 48
RMSD from ideality: bond lengths (Å) 0.008 0.007
RMSD from ideality: bond angles (°) 0.994 0.818
a Values in parenthesis describe the highest resolution shell. b Calculated with Matthews_coef program from CCP4
suite version 6.4.0.[132] *Preliminary data.
The superimposition of the crystal structures of the enzyme in complex with fragment J15
and ligand 6.4 reveals that the benzoic acid moiety of the optimized ligand establishes the
same interaction as fragment J15 (Figure 6.6 A). In addition, the central pyridine moiety
addresses the hydrophobic pocket composed by Leu191, Trp192 and Leu195 and its 3-OH
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group is in H-bonding contact to the backbone carbonyl oxygens of Ala149 and Gln150.
These additionally interactions lead to a strong improvement in affinity of 6.4 compared to
the starting fragment J15. Also the benzoic acid moiety of compound 6.10 (designed by
fragment linking) adopts the same binding mode as in the crystal structure of J15. However,
compared to fragment J6, the benzodioxole portion of 6.10 is shifted in space and
accomodates the hydrophobic pocket composed of Leu191, Trp192, Leu195, Met199 and
Thr205 (Figure 6.6 B).
6.3 Conclusion and Outlook
From the sample of 96 candidate fragments screened against 17β-HSD14, two fragments
could be identified as hits in the electron density maps. Two different optimization strategy
strategies (fragment growing and fragment linking) where employed for the development of
new size-increased ligands with affinity against the enzyme. After computer-aided design of
putative synthesis improved candidates, the most promising ones were synthesized and
subsequently tested for their inhibitory activity against the target protein. All compounds
that resulted from this fragment optimization proved to have enhanced affinities toward the
enzyme compared to the original fragments that have been used as starting material.
Figure 6.6: Superimposition of the crystal structures of 17β-HSD14 in complex with cofactor NAD+
and fragment J15 and 6.4 (A) and fragment J15, J6 and 6.10 (B). A close-up view of the binding
pocket is depicted. Carbon atoms of J6 are shown in turquis, of J15 in light green, 6.4 in light blue,
6.10 in purple-blue, and of the cofactor NAD+ in dark blue. The inhibitors and cofactor NAD+ are
shown as stick models. The amino acids within a distance of 4.6 Å are shown as thin stick models
with carbon atom in white. H-bonds are depicted as dashed lines. Fo-Fc difference electron density
is shown as green mesh at a contour level of 3 σ.
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Compounds 6.4 and 6.10 could be successfully crystallized in complex with 17β-HSD14.
Whereas the part from the starting fragment of compound 6.4 showed a conserved binding
mode, the observed pose of 6.10 was only partially conserved as the benzodioxole moiety
occupied a shifted position relative to its position found for the starting fragment J6. The
shifted position of the benzodioxole moiety is possibly caused by the introduction of the ethyl
linker and thus it is worthwhile to test linkers of deviating length and different chemical
composition to find one that allows the benzodioxole moiety to adapt an orientation better
matching that observed for fragment J6. In order to exclude that, besides the two fragments
that have been clearly identified, any additional fragments are still bound to 17β-HSD14 and
have been overlooked due to insufficiently defined electron density, the Fo-Fc difference
electron density maps should be reinspected applying the PanDDA program. The latter
program enables a sharpening of the electron density features of a bound fragment and
thereby facilitates its identification.
6.4 Experimental session
Enzyme expression and purification
The pure recombinant 17β-HSD14 enzyme was obtained via heterologous expression as
previously described [126, 127]. The protein purification was accomplished by two steps of
affinity chromatography (Ni-NTA column) followed by size-exclusion chromatography. The
stability of the protein was maintained by the addition of 0.6 mM cofactor NAD+ prior to our
crystallization trials with the soaking technique. The purity was confirmed by SDS page.
Protein crystallization and soaking
The crystallization of 17β-HSD14 in complex with cofactor NAD+ was carry out as already
described [126]. In summary, 2 µL of a solution containing 0.1 M HEPES and 3.3 M sodium
formate, pH 7.00, was mixed with 2 µL of the protein solution (9.5 mg/mL, T205), containing
0.6 mM NAD+. After growing for 2 weeks at 18°C, appropriated crystals were exposed for a
time span of 1 min up to 20 hours to the soaking solution containing 0.2M NaCl, 0.1M
HEPES set at pH 7.00, 17.5% PEG3350, 100-50 mM fragment with a final DMSO
concentration of 10% and 25.0% PEG 400 as cryo-protectant. The crystals obtained were
subsequently flash frozen in liquid nitrogen.
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Co-crystallization of the protein with inhibitors
The co-crystallization of 17β-HSD14 in complex with the different types of inhibitors was
performed following the already described procedure [126, 127]. The final inhibitor
concentration of 4 mM was incubated with the protein solution (9.5 mg/mL) containing 0.6
mM NAD+ and 5% DMSO for 30 minutes. The mixture was then centrifuged at 10000 g for
20 minutes in order to separate the precipitates. Afterwards, 2 µL of the supernatant was
mixed with 2 µL of mother liquor composed of 0.1 M HEPES, 20% (w/v) PEG6000 and 5%
(v/v) DMSO and adjusted to pH 7.0. Crystals of sufficient quality for data collection were
grown at a temperature of 18°C for 10 days and then exposed for a few seconds to a cryo
buffer solution obtained by the combination of mother liquor with the addition of 20%
glucose and then flash-frozen in liquid nitrogen.
Data collection and processing
The data collection of crystals exposed to soaking trials with the 96 probe fragments and of
the two co-crystalized inhibitor complexes was achieved at beamlines , Elettra beamline
XRD1 in Trieste, Italy at a wavelength of 1Å and a temperature of 100 K on a Pilatus 2M
pixel detector,  ID23-1 beamline at the European Synchrotron Radiation Facility (ESRF)
[140] in Grenoble, France at a wavelength of 0.97242 Å and a temperature of 100K on a
silicon Pilatus 6M pixel detector, BL 14.1 operated by the Helmholtz-Zentrum Berlin (HZB)
at the BESSY II electron storage ring (Berlin-Adlershof, Germany) [141] at a wavelength of
0.9184 Å and at a temperature of 100 K on a Pilatus 6M pixel detector and at beamline P13 at
PETRA III (EMBL/DESY) in Hamburg, Germany, on a silicon Pilatus 6M pixel detector at a
temperature of 100K. All datasets were indexed, processed and scaled with XDS [142].
Structure determination and refinement
All structures were determined by molecular replacement with the program PHASER MR
[143] from the CCP4 suite [132]. The structure 5JS6 was used as a search model. In the
refinement, a subset corresponding to 5% of all reflections were omitted during refinement
and used for the calculation of Rfree. Model building was achieved in COOT [144] and
refinement using the PHENIX.refine version 1.10.1-2829 [145]. Ligand SMILE codes were
created with Molinspiration v2014.11[146] and built as 3D-models with the Grade Web
Server [147], which was also used for energetically minimization and restraint generation.
Cartesian simulated annealing, applying default parameters, was used as a first refinement
step. Subsequently, refinement of XYZ coordinates, occupancies and individual B-factors
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were alternated with structural adaption in COOT [144] until the model was readily built and
gave the best possible explanation of the electron density.
Inhibition of 17β-HSD14
Inhibitory activities were evaluated with a fluorimetric assay as previously described [126,
127]. Briefly, the potential inhibitor was added in DMSO (final DMSO concentration in
assay: 1%) to a mixture of NAD+ (1.2 mM) and estradiol (32 µM) in 100 mM phosphate
buffer pH 8, and the enzymatic reaction was started with the addition of the purified enzyme
(1 mg/ml). The production of the fluorescent NADH formed was measured continuously for
15 min on a Saphir Tecan2. A linear relationship between product formation and reaction
time was obtained and the slope of the progress curves was determined by linear regression.
The Ki values were calculated by means of the Morrison equation using the procedure
detailed by Copeland [167] as previously described.[127] The fitting and data analysis were
performed using GraphPad Prism 7.
MOE models
The inhibitors 6.2-6.7 and 6.9-6.10 were modeled inside the crystal structure of the protein
in complex with J15 and minimized with MOE [173]. During minimization, the AMBER12
force field was applied. The heavy atoms of the protein and the oxygen atom of the carboxylic
acid group of the inhibitors involved in H-bond to Tyr154 were kept fix. In order to give to
the ligand sufficient freedom to move also the residues His93, Gln148 and Met199 were
allowed to move unrestrictedly during minimization.
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17β-Hydroxysteroid dehydrogenase type 14 (17β-HSD14, retSDR3 or SDR47C1) is the latest
subtype of 17β-HSD (belonging to the SDR family) that has been identified [32]. This
enzyme oxidizes the hydroxyl group at position 17 of estradiol (E2) and 5-androstenediol (5-
diol) under the presence of NAD+ as cofactor in vitro. The cDNA of the corresponding gene,
called DHRS10, was originally isolated from retina epithelium. Two variants of this cytosolic
protein exist: S205 and S205T. So far, the protein has not been thoroughly investigated in
detail and its physiological role remains unknown.
Prior to this thesis, the 17β-HSD14 apoenzyme (S205) had already been crystallized by
Lukacik et al. [32]. The determined structure revealed a very broad and open active site, a
cofactor binding domain for NAD+, and, characteristic for the SDR family, the conserved
catalytic triad and the Rossmann-fold motif. Unfortunately, several amino acids from the
flexible loops of some chains were not defined in the electron density, and none of the C-
termini of the chains could be detected. It is impossible to derive information regarding a
potential substrate from this crystal structure. Furthermore, due to the various
conformations of the flexible loops, this crystal structure is poorly suited for docking studies.
Therefore, the new structural determination of this protein alone as well as in complex with
its cofactor and substrate was of utmost importance.
Chapter 2 reports the successful establishment of the expression and purification protocols
to get high yield of pure recombinant 17β-HSD14 protein. The thermal shift assay (TSA) was
critical for the success of the protein purification, since it allowed the identification of a
buffer that enhances the stability of the protein. Subsequently, the two enzyme isoforms
(S205 and T205) were biochemically characterized. No difference between the catalytic
actions of the two isoform could be evidenced. Employing extensive crystallographic
screenings, it was possible to reproduce the structure of the apoenzyme with an even
improved resolution by 0.9 Å compared to the reported value. The asymmetric unit of the
determined apoenzyme structure is a homotetramer (the native form of the enzyme) and
exhibits only two conformations of the flexible loops (segments αFG1 and αFG2) found in an
either open (A2 dimer) or closed (B2 dimer) conformation. Next, the structures of the binary
complexes (in complex with cofactor NAD+) of both protein isoforms (S205 and T205) were
elucidated. No structural difference between the two isoforms could be recorded. However,
these structures are different from the apoenzyme with respect to the flexible loop which
adopts a unique closed conformation in the presence of NAD+. Binding of the cofactor
appears to induce a shift of the flexible loop, which reduces the size of the active site and
thereby produces the active conformation of the enzyme. The ternary complex of the enzyme
with E1 (estrone) and NAD+ was also elucidated. The overall structure and the active-site
geometry of the ternary and binary complex are very similar. Both have the flexible loop in
the same closed conformation and the size of their active site is reduced by the C-terminal
chain of the adjacent monomer (Tyr253’). E1, the product of the catalytic reaction, is found
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to be bound to the active site in an atypical fashion with its A-ring positioned within van der
Waals interaction distance to the nicotinamide moiety of the cofactor, whereas the carbonyl
group of E1 in position 17 does not establish any interactions. In conclusion, a structural
characterization of the protein in different binding state could be successfully achieved.
Enzyme inhibitors are useful tool compound to study the consequences of full enzyme
inhibition in vivo. This could help to clarify whether this enzyme might be interesting as a
new drug target for a certain disease. In addition, potent and selective inhibitors are also
useful to address the selectivity issue with other 17β-HSDs. As no inhibitor of 17β-HSD14
has been reported prior to this study, the goal was to identify and optimize 17β-HSD14
nonsteroidal inhibitors as well as to disclose their structure-activity relationship (SAR).
Chapter 3 describes the initially performed screen of a 17β-HSD1 and 17β-HSD2 inhibitors
library against 17β-HSD14, selected with respect to scaffold diversity. The most promising hit
with respect to 17β-HSD14 activity and selectivity toward 17β-HSD1 and 17β-HSD2 was
taken as starting point for further chemical modification applying a ligand-based approach.
Newly designed compounds were synthesized and subsequently tested for their 17β-HSD14
inhibitory activity. The two best inhibitors identified in this study (3.1 and 3.9) had a very
high affinity toward the enzyme with a Ki equal to 7 nM. Prior to this thesis, no human
17β-HSD structures have been reported in complex with a nonsteroidal compound.
Nevertheless, after an extensive crystallographic screening, the crystallizion and structure
determination of five crystal structures of the protein in ternary complex with its cofactor
and different nonsteroidal inhibitors could be accomplished. The 3D-structures confirmed
that the inhibitors bind to the substrate binding site. It was possible to rationalize the strong
affinity of these inhibitors toward the enzyme by analysis of the molecular interactions
stabilizing the inhibitor, especially the H-bond contact with catalytic Tyr154. In addition, the
important role of an extended H-bond network in the stabilization process could be
highlighted (Figure 7.1). The selectivity of the most potent compounds with respect to 17β-
HSD1 and 17β-HSD2 could be addressed and 3.9 demonstrated to have also a good
selectivity discrimination with respect to both related enzymes 17β-HSD1 and 17β-HSD2
(23% and 43% at 1 μM, respectively). Taken together, the first potent nonsteroidal inhibitors
with a good in vitro selectivity profile could be identified, and their structures in complex
with the protein could be obtained. In the following, these results enabled a strong basis to
pursue a structure-based optimization approach for the discovery of new class of 17β-HSD14
inhibitors.
Chapter 4 describes two different structure-based strategies to optimized ligand 3.9 (Figure
7.2). The first structure-based modifications of the initial pyridine-based scaffold led to the
ten-fold more potent compound 4.4 (Ki = 1.5 nM) compared to the initial 3.9 (Ki = 13 nM).
However, even though all the newly synthesized pyridine-based inhibitors showed a high
selectivity toward 17β-HSD10, a less satisfactory selectivity profile toward 17β-HSD1 and
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17β-HSD2 was observed. The optimization of the cocrystallization conditions resulted in the
determination of three new crystal structures of the inhibitor-enzyme complex. The analysis
of the crystal structure of 4.4 in complex with the protein revealed how this ligand achieves
its high affinity through a complementary geometry with the enzyme.
The goal of the second structure-based optimization strategy was to extend the central
pyridine core to interact with the empty binding pocket adjacent to the A and B-ring. The
designed quinoline-based inhibitors were first modelled into the crystal structure and, as the
simulation suggested a good fit to the active site of the protein, they were subsequently
synthesized. The predicted binding mode of 4.8 was confirmed by the co-crystal structure
and, as anticipated, the very high potency (Ki = 12 nM) was subsequently determined by
Figure 7.1: Schematic summary of Chapter 3. On the left, the preliminary screening of known
17β-HSD14 inhibitors is shown leading to the first optimization candidates. On the right, the H-
bond network stabilizes the inhibitor bound to the active site of 17β-HSD14. Carbon atoms of the
inhibitor are colored in gray and displayed as sticks. Protein residues involved in establishing the
H-bonding network and the cofactor NAD+ (beige) are shown as thin sticks. H-bond interactions
are depicted as dotted lines. Water molecules are shown as red spheres.
Figure 7.2: Schematic summary of Chapter 4. On the left and on the right, synthetic modifications
scheme starting from the 2,6-pyridine ketone 3.9 are indicated. The image in the center shows a
close-up view of the binding pocket of 17β-HSD14 in complex with 3.9. The inhibitor is shown as
stick model with carbon atoms colored in yellow. Protein residues (white) and the cofactor NAD+
(beige) are shown as thin sticks. H-bond interactions are depicted as dotted lines. The Fo-Fc
difference electron density is shown as green mesh at a contour level of 3σ.
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biophysical characterization. Four co-crystal structures were obtained of the enzyme in
complex with the quinoline-based inhibitors. Crystal structures of the protein-ligand
complexes were prerequisite for understanding the inhibitor’s SAR and for their further
optimization. The determined crystal structures revealed how small chemical modifications
of the inhibitor’s substituents can affect the adopted binding mode. In fact, the deviating
binding mode of 4.10 (that differs from 4.8 by only a single methyl group) did not result in a
significant change of the binding affinity compared to 4.8 (Ki = 6 nM vs Ki = 13 nM,
respectively). Surprisingly, the 3-OH group of the C-ring did not form a direct H-bond
interaction with Tyr154 of the catalytic triad. Instead, it establishes an H-bond only with
Ser141. Nevertheless, Tyr154 establishes an H-bonding contact through a bridging water
molecule (W6) with the ligand’s carbonyl linker. The fact that this water molecule is found in
close proximity to the catalytic triad and that so far its position was found conserved in four
structures, raises the question about a possible involvement in the catalytic mechanism.
The selectivity profile of three compounds (4.12, 4.13 and 4.15) between 17β-HSD14 and the
three other proteins (17β-HSD1, 17β-HSD2, and 17β-HSD10) was comparable to the
selectivity profile of 3.9. Thus, these four compounds exhibit the most favorable selectivity
profile as well as the highest potency. In addition, 3.9, 4.12, 4.13 and 4.15 showed a very low
cytotoxicity (IG50 > 100 µM) and were not appointed either as substrates or as inhibitors of
the multi-drug resistance protein Pgp, indicating that these compounds might not be efflux
from the brain and at the same time the risk of potential side effects would be reduced. This
suggests them as potent tool compounds for the further investigation of a putative in vivo
administration to get insights into the physiological role of 17β-HSD14.
In Chapter 5, a structural comparison with the aim to rationally explain the selectivity
profiles of the ligands between 17β-HSD14 and other 17β-HSDs was conducted. The
superimposition based on the Cα coordinates of the crystal structures of 17β-HSD1 reveals
how the adopted conformation of the flexible loop drastically deviates depending on the
bound state of the enzyme. Furthermore, the comparison revealed that different inhibitor
classes induce different conformational geometries for this protein region. The variable
character of the flexible loop is also observed for 17β-HSD14. As only one crystal structure
for 17β-HSD8 and 17β-HSD10 has been published yet, it is difficult to perform the same
analysis of the flexible loop for the latter two enzymes. The typical V-like shape of the
binding pocket of 17β-HSD14 is determined by the two amino acids His93 and Gln148,
which are not present in 17β-HSD1, 17β-HSD8 and 17β-HSD10. In addition, the latter three
enzymes also exhibit a rather flat binding pocket. In conclusion, it has to be expected that the
design of inhibitors that match with the characteristically three-dimensional requirements of
17β-HSD14 (and optionally address His93 and/or Gln148) should increase the selectivity
toward the latter target. A docking study with the program GOLD (Genetic Optimization for
Ligand Docking) [196] was performed with the aim to rationally select ligands for an initial
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in vitro screening from a library of about 400 17β-HSD1 and 17β-HSD2 compounds. Despite
a properly validated docking protocol and several attempts to dock ligands into 17β-HSD14,
the predicted binding modes of the ligands were in poor agreement with the later
crystallographically determined binding modes due to the large flexibility of the binding
pocket.
Chapter 6 describes a large fragment screening campaign by X-ray crystallography with the
aim to discover new inhibitor scaffolds. The fragment screening library, developed by the
Klebe group in collaboration with the structural biology group at the HZB, Berlin and
consisting 96 different fragments was subjected to crystals of 17β-HSD14. The fragment
screening resulted in the identification of two fragments that could be clearly identified in the
electron density (J6 and J15). However, no significant inhibitory activity against 17β-HSD14
could be detected for these two fragments, likely due to very weak binding. Thus, besides
examples already reported in literature, this result again proves that crystallographic
fragment screening is a superior approach to identify binders compared to other biophysical
screening method. This is especially the case when the binding affinity of the fragment is very
low. In addition to hit identification, crystallographic screening provides essential structural
information about the binding mode of the ligand, which is an utmost prerequisite for their
further structure-based optimization. Furthermore, the possibility of false positives can
certainly be excluded when a clear electron density could be obtained. In order to enhance
the affinity against the target of the two identified fragment hits, two strategies (fragment
growing and fragment linking) have been applied. The new compounds were designed by
computational modelling applying the crystallographically determined binding modes of the
fragments as a basis, and subsequently synthesized, tested for their 17β-HSD14 activity, and
finally crystallized. This approach resulted in two newly designed ligands exhibiting a better
affinity than the starting fragments.
In summary, both isoforms, S205 and T205, of 17β-HSD14 were biochemically and
structurally characterized and it resulted in four new crystal structures. The first two classes
of inhibitor for this enzyme were discovered and the ligands were thoroughly profiled. In
addition, the structures of 12 nonsteroidal inhibitors in complex with the protein were
elucidated for the first time for this protein family. The fragment screening, after the
determination of 96 structures, resulted in two fragment hits that were successfully optimize
and it culminated in two more active inhibitors compared their starting point.
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